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1. ABBREVIATIONS 
αKG  α-Ketoglutarate 
6PGL  6-Phosphogluconate   
   Dehydrogenase  
6PG  6-Phosphogluconolactone 
ACC  Acetyl-CoA Carboxylase 
ACLY  ATP Citrate Lyase 
ACoA  Acetyl-CoA 
Cit   Citrate  
DCA  Dichloroacetate    
DHAP  Dihydroxyacetone    
   phosphate 
E4P  Erytrose-4-phosphate  
ELOLV Very Long Chain Fatty Acid 
F16BP  Fructose-1,6-biphosphate 
F26BP  Fructose -2,6-biphosphate 
F6P  Fructose-6-phosphate 
FASN  Fatty Acid Synthase 
G6P  Glucose-6-phosphate  
G6PD  Glucose-6-phosphate   
   Dehydrogenase  
GAP  Glyceraldehyde-3-   
   phosphate  Dehydrogenase 
GAPDH Glyceraldehyde-3-   
   phosphate Dehydrogenase 
GLDH  Glutamate dehydrogenase 
GLS  Glutaminase 
HexP  Hexose phosphate pool 
HIF1  Hypoxia-Inducible Factor 1 
HK   Hexokinase  
IDH  Isocitrate Dehydrogenase  
IDH1  Isocitrate Dehydrogenase 
   isoform 1 
KEAP1 Kelch-like ECH-associated 
   protein 1 
LDH  Lactate Dehydrogenase 
Mal  Malate  
MDH  Malate Dehydrogenase 
ME  Malic Enzyme  
ME1  Malic Enzyme isoform 1 
NRF2  Nuclear factor erythroid 2-
   Related Factor 2 
Oaa  Oxaloacetate 
PC   Pyruvate Carboxylase  
PDH  Pyruvate Dehydrogenase 
PDK  Pyruvate Dehydrogenase 
PenP  Pentose phosphate pool 
PEP  Phosphoenolpyruvate  
PFK1  Phosphofructokinase 1 
PFK2  Phosphofructokinase 2 
PK   Pyruvate Kinase  
PGLS  6-phosphoglucolactonase  
PPP  Pentose Phosphate Pathway 
Pyr  Pyruvate 
R5P  Ribose-5-phosphate 
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RPE  Ribose phosphate 3-  
   epimerase  
RPIA  Ribose-5-phosphate   
   isomerase 
ROS  Reactive Oxygen Species  
S7P  Sedoheptulose-7-   
   phosphate 
SCDs  Stearoyl-CoA Desaturase  
SRBPs  Sterol Regulatory Binding 
   Proteins 
SucCoA Succinil-CoA 
TALDO Transaldolase 
TALDO1 Transaldolase 1 
TCA  Tricarboxylic Acid  
TKT  Transketolase 
TKTL1  Transketolase-like 1  
TrisP  Triose phosphate pool 
X5P  Xilulose-5-phosphate 
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2. INTRODUCTION 
2.1 A GENERAL OVERVIEW OF CANCER FUNDAMENTALS 
Cancer is a generic term that includes a large group of diseases in which abnormal cells 
divide without control and are able to invade other tissues resulting in metastasis 
formation (www.cancer.gov). In 2008, more than 12.6 millions of new cases of cancer 
were diagnosed and around 7.5 millions of cancer deaths were registered worldwide, 
being lung and breast cancer the most frequent among men and women respectively 
(Ferlay et al., 2010). 
The development and progression of cancer requires that malignant cells acquire 
certain capabilities along the carcinogenic process. Since there are more than 100 types 
of cancer, a high degree of both inter- and intratumor heterogeneity exists. However, 
some similarities common to the majority of cancers have been outlined (Hanahan and 
Weinberg, 2011). Figure 2.1 highlights these capabilities, also commonly known as the 
hallmarks of cancer.  
Healthy tissues carefully regulate proliferative stimuli, which are transmitted by 
signaling pathways and govern cell growth and division signals. On the contrary, in 
cancer cells these signaling pathways are often altered, rendering cancer cells to 
proliferate autonomously (Davies and Samuels, 2010; Hynes and MacDonald, 2009). As 
an example, activating mutations in the RAS signaling pathway controlling proliferative 
signals are frequently found in a variety of cancers (Malumbres and Barbacid, 2003). 
However, uncontrolled proliferation requires not only the existence of enhanced 
proliferative signals but also inactivation of the mechanisms that restrict cell 
proliferation. In this regard, cancer cells must also bypass powerful programs aimed to 
negatively control cell proliferation, which are mainly regulated through the action of 
tumor suppressor genes, such as TP53 or RB (Burkhart and Sage, 2008; Sherr and 
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Figure 2.1  The hallmarks of cancer 
The required capabilities for tumor growth and progression are shown.  
Reprinted from Cell, 144(5), Hallmarks of cancer: the next generation, 646-674, Copyright © 2011, with permission
from Elsevier. 
 
  
 
 
 
 
 
 
 
 
 
McCormick, 2002). In the same sense, cancer cells must also circumvent the inherent cell 
death program of apoptosis, which serves as a natural barrier to cancer development. 
Thus, tumor cells adopt a variety of strategies to evade this process, such as loss of 
TP53 tumor suppressor function, induction of antiapoptotic regulators (BCL-2, BCL-xL) 
or downregulation of proapoptotic factors (BAX, BIM, PUMA) (Adams and Cory, 2007; 
Junttila and Evan, 2009; Lowe et al., 2004).  
The above-mentioned traits do not suffice to guarantee the progression of the tumor. It 
is generally accepted that cancer cells require unlimited replicative potential in order to 
generate macroscopic tumors. In healthy tissues, the replicative capacity is limited by 
two main mechanisms: senescence, which maintains cells in a resting but viable state, 
and crisis, which involves cell death. The ability of cancer cells to overcome these 
limitative processes has been called immortalization and is considered a pivotal 
hallmark in cancer progression. The enzyme telomerase plays an essential role in this 
process and is correlated with a resistance to induction of both senescence and crisis, 
conferring cancer cells the capability for unlimited replicative capacity (Blasco, 2005).  
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Despite of the capability to proliferate uncontrollably and limitlessly, no proliferation is 
feasible without a properly sustenance in the form of nutrients and oxygen as well as an 
ability to evacuate metabolic wastes and carbon dioxide efficiently. As tumor grows, a 
new and more extensive local vasculature must be created to fulfill these requirements 
in a process called angiogenesis. Then, an angiogenic switch takes place during 
tumorigenesis and remains almost always activated, causing normally quiescent 
vasculature to continually sprout new vessels that help sustain expanding neoplasic 
growth (Hanahan and Folkman, 1996). This angiogenic process is the result of a balance 
between pro- and anti-angiogenic signals. In this sense, tumor cells display a variety of 
strategies to enhance neovasculature formation, such as upregulation of VEGF, the gene 
encoding the main ligand involved in orchestrating new blood vessel formation (Ferrara, 
2009). 
Although the described hallmarks are essential to cancer progression, the mortality of 
cancer lies in the capability of cancer cells for spreading to other parts of the body in a 
multistep process of invasion and metastasis. This process consist of a succession of cell 
changes, beginning with local invasion, then intravasation into nearby blood and 
lymphatic vessels, transit of cancer cells through the lymphatic and hematogenous 
system, followed by extravasation, the formation of micrometastasis and finally the 
growth of micrometastasis lesions into macroscopic tumors in a process called 
colonization (Talmadge and Fidler, 2010). Over this process, cancer cells develop 
alterations in their shape as well as in their attachment to other cells and to the 
extracellular matrix. A pivotal role in this process is played by E-cadherin, a protein 
involved in adherent junctions with adjacent epithelial cells that has been documented 
to be frequently downregulated and mutated in human carcinomas (Berx and van Roy, 
2009). 
Over the last years, the intensive research in cancer has prompted the appearance of 
two emergent new hallmarks of cancer (Hanahan and Weinberg, 2011). First, the 
capacity of cancer cells to evade the immune system, which is responsible for detecting 
and eliminating the vast majority of incipient cancer cells and nascent tumors. It is still 
unclear how cancer cells evade the immune system, but some studies indicate they can 
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do so by secreting TGF-β or other immunosuppressive factors (Yang et al., 2010b). The 
second emergent hallmark corresponds to the reprogramming of cancer metabolism. In 
order to achieve all the above-mentioned hallmarks, cancer cells must reorganize the 
metabolic network at the service of an increased demand of energy and 
macromolecules to sustain cell proliferation and tumorigenesis (Ward and Thompson, 
2012). The study of the cited tumor metabolic reprogramming that takes place in 
cancer, mainly focused on oncogene-induced metabolic reprogramming,  and the 
identification of key players in the metabolic network constitutes the main topic of this 
thesis. Aiming to provide a general knowledge of this emergent hallmark, the essential 
traits of cancer cell metabolic reprogramming are presented throughout the next pages. 
2.2 TUMOR METABOLIC REPROGRAMMING 
Metabolism is the set of life-sustaining chemical transformations within the cells of 
living organisms. These enzyme-catalyzed reactions allow organisms to grow and 
reproduce, maintain their structures, and respond to their environments. All the cells in 
our body require certain amounts of nutrients and oxygen to perform their cellular 
functions. Nutrients can either be burned to produce energy (catabolism) or used to 
produce building blocks to sustain proliferation (anabolism). Accordingly, the 
requirements of nutrients are particularly high in proliferating cells, since they need not 
only to preserve their integrity and perform their physiological functions but also to 
generate a new daughter cell. Then, as cancer is a tissue-proliferation disorder, it is 
expected that cancer cells rewire metabolism at the service of proliferation. 
Furthermore, all the above-mentioned hallmarks of cancer are also intimately related to 
certain aspects of cellular metabolism, extending the role of metabolism beyond growth 
and proliferation (Kroemer and Pouyssegur, 2008). 
In the 1920s, Otto Warburg showed that tumor slices displayed increased rates of 
glucose uptake compared with normal tissues and that, even in the presence of oxygen, 
tumors metabolized glucose via oxygen-independent aerobic glycolysis rather than via 
oxidative phosphorylation (Jones and Schulze, 2011; Warburg et al., 1927). Today, this 
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phenomenon is widely called the “Warburg effect”. It has been long stated that altered 
metabolism in cancer cells is merely an indirect phenomenon in cancer, a secondary 
effect that pales into insignificance beside the activation of primary proliferative and 
survival signals. The majority of oncogenes and tumor suppressor genes encode 
proteins involved in signal transduction pathways, whose roles in carcinogenesis have 
been attributed to their ability to trigger proliferative, survival and anti-apoptotic 
processes. However, over the last years, a new paradigm has emerged (Ward and 
Thompson, 2012). The pivotal role of activated oncogenes and deactivated tumor 
suppressor genes well might be to reprogram cellular metabolism. Classical view of 
metabolism supports the idea that metabolic fluxes are governed by allosteric effects of 
metabolites on rate-limiting steps of the metabolic pathways, giving them self-
regulatory capacity. Nevertheless, although these mechanisms exist in proliferating cells, 
the efforts to elucidate the consequences of signal transduction on cell proliferation 
have revealed a variety of signaling effects directed at metabolic fluxes.  For instance, 
during proliferation of tumor cells and lymphocytes, growth-factor signaling suppresses 
β-oxidation of fatty acids, minimizing futile cycling and promoting lipid synthesis 
(Deberardinis et al., 2006). Therefore, growth-factor signaling can reorganize metabolic 
fluxes independently of traditional allosteric mechanisms of pathway regulation. 
Proliferating and non-proliferating cells display an opposite metabolic behavior. Non-
proliferating differentiated cells are surrounded by an abundance of nutrients, but they 
are not autonomous for nutrient uptake. Instead, they compete for limiting levels of 
growth factors that direct this process. To survive in such conditions, they adopt a 
catabolic metabolism focused on maximizing the efficiency of ATP production. In 
contrast, when growth factors are abundant and proliferation and signaling pathways 
are activated, cells increase their nutrient uptake and adopt an anabolic status.  
The components of signaling pathways controlling both proliferation and survival and 
metabolic network are largely conserved between tumor and normal cells.  The main 
differences arise from the fact that in normal cells initiation of signaling requires 
extracellular stimulation, whereas cancer cells often harbor mutations that trigger a 
sustained activation of the signaling processes (Kan et al., 2010). These signaling 
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pathways activate proliferative and survival programs in which metabolism must be 
reorganized to fulfill the energetic and biosynthetic requirements. As an example, 
mutations in PI3K, a key player in PI3K/AKT/mTOR signaling pathway involved in cell 
proliferation and survival, is mutated in approximately 20-30% of breast, brain and 
gastric tumor analyzed by Samuels and collaborators (Samuels et al., 2004). PI3K 
stimulates a plethora of downstream effects regulating the metabolic network, from 
enhancing glucose uptake and glycolysis to fatty acids synthesis, which are required for 
the tumorigenic process (Bauer et al., 2005) Thus, increasing evidence support that 
metabolic reprogramming is not a merely bystander in tumorigenesis, but an essential 
requirement. 
2.2.1  Obtaining ATP: cancer cell bioenergetics and the Warburg 
effect. 
2.2.1.1 Glucose catabolism, ATP production and the Warburg effect 
As it has been mentioned before, cancer cells display an enhanced glycolysis even in the 
presence of oxygen. The so-called Warburg effect has been demonstrated in different 
cancer types and has turned into a very valuable clinical tool for detection of tumors by 
18F-deoxyglucose positron emission tomography (FDG-PET)(Som et al., 1980). 
Metabolizing glucose by glycolysis to produce lactate is energetically inefficient, since 
most of the ATP generated by glucose catabolism (34 out of 36 ATP molecules per 
molecule of glucose) occurs not in glycolysis but during the TCA (Tricarboxilic Acid) 
cycle. Then, this increased glycolysis displayed in tumors presented a paradox that 
today still remains unclear. In order to understand the potential benefits of this 
phenotype, a number of explanations have been proposed.  
One of these explanations postulates that an increased glycolysis allows cells to use 
glucose (the most abundant extracellular nutrient) to produce ATP, and although the 
yield of ATP per molecule of glucose is low, the percentage of cellular ATP produced 
from glycolysis can exceed that produced from oxidative phosphorylation (Guppy et al., 
1993). Nonetheless, Kilburn and collaborators documented that the amount of 
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additional energy (assuming that glucose is the main substrate) to produce a new cell is 
50% above the baseline required to maintain cellular homeostasis. Hence, it is surmised 
that the amount of ATP in a proliferating cell is not dramatically different from a resting 
cell, but the proliferative cell must accumulate biomass, replicate DNA and divide 
(Kilburn et al., 1969). A second explanation proposes that the Warburg effect can 
provide cells with an adaptive advantage under circumstances of low glucose 
availability, since it confers the capability of synthesizing ATP at high rate, what is 
particularly important when a competition for glucose exists (Pfeiffer et al., 2001). A 
third is that a heightened glycolysis provides proliferating cells with metabolic 
intermediates needed for biosynthetic pathways including ribose for nucleotides, 
glycerol and citrate for lipids, and aminoacids. Thus, it seems fairly clear that the 
Warburg effect might contribute to meet both energetic and biosynthetic needs. A 
fourth idea to explain the observed Warburg effect is that a decreased dependence on 
aerobic respiration becomes advantageous within the unique tumor microenvironment. 
As early tumor expands it outgrows the diffusion limits of its local blood supply and 
oxygen becomes scarce. Low and fluctuating levels of oxygen led to the stabilization of 
HIF1α, thus contributing to the Warburg effect (Denko, 2008; Stubbs and Griffiths, 
2009). Additionally, glycolytic cancer cells generate high amounts of lactate with the 
subsequent acidification of the extracellular milieu, which favors tumor invasion due to 
the pH-dependent activation of cathepsines and metalloproteinases that degrade 
extracellular matrixes and basements membranes (Kroemer and Pouyssegur, 2008; 
Swietach et al., 2007). Finally, the Warburg effect could positively influence the evasion 
of apoptosis, one of the hallmarks of cancer, since highly glycolytic cells under-use the 
mitochondria, which is the main source of apoptotic stimuli. This idea is fully supported 
by the fact that activation of PDH complex by pyruvate dehydrogenase kinase (PDK) 
inhibitor dichloroacetate (DCA) in highly glycolytic cancer cells activates oxidative 
phosphorylation and promotes apoptosis (Bonnet et al., 2007).  
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2.2.1.2 The Warburg effect, oncogenes and tumor suppressor genes 
Accumulating evidence indicate that oncogenes and tumor suppressor genes affect 
metabolic regulation. Then it is not surprising that the Warburg effect is regulated by 
many signaling pathways at different levels (Bensinger and Christofk, 2012; Soga, 2013). 
Elevated expression of glucose transporters and glycolytic enzymes are found in 
numerous cancers and may contribute to tumor progression (Adekola et al., 2012; 
Palaskas et al., 2011). This metabolic phenotype can be due to the action of HIF1α 
(Hypoxia-Inducible Factor 1α), which is activated in many tumors by a variety of 
mechanisms, some of them triggered by the action of oncogenes (Stubbs and Griffiths, 
2009). MYC is an important regulator of the metabolic phenotype in cancers. Among 
the thousands of genes upregulated by MYC are several glucose transporters and 
glycolytic enzymes`, as well as PDK1 and LDH-A (Dang et al.; Shim et al., 1997). 
Moreover, MYC can collaborate with hypoxia-inducible transcription factor (HIF), 
considered one of the main regulators of glycolysis, to activate many target genes 
involved in this metabolic pathway (Gordan et al., 2007). The tumor suppressor TP53 is 
another important transcription factor that regulates metabolism by decreasing the 
glycolytic flux through inhibiting glucose transporters, decreasing expression of 
glycolytic enzymes and increasing the expression of TIGAR, a negative regulator of 
glycolysis (Kondoh et al., 2005; Pilkis et al., 1981; Schwartzenberg-Bar-Yoseph et al., 
2004; Vousden and Ryan, 2009).  
2.2.1.2.1 RAS oncogene 
A very illustrative example of oncogene-induced metabolic reprogramming is the case 
of RAS. In humans, RAS gene encodes four distinct but highly homologous 21 kDa RAS 
proteins: HRAS, NRAS, KRAS4A and KRAS4B (these last two proteins are alternative 
splice variants of the KRAS gene). RAS gene is mutated in approximately 30% of human 
tumors (Fernandez-Medarde and Santos, 2011; Takashima and Faller, 2013) and K-RAS 
isoform is the most frequently mutated among the three isoforms in malignancies; with 
a  mutation rate in all tumors estimated to be 25-30%. In contrast, mutations in NRAS 
and HRAS are less common (8 and 3% mutation rate, respectively) (Fernandez-Medarde 
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Figure 2.2  RAS signaling pathway 
RAS protein activates several major signaling pathway involved in a wide range of cellular functions. Two of the main
pathways activated by RAS are RAF-MEK-MAPK pathway and PI3K/AKT pathway, which in addition to the processes
shown in the figure, also regulate cellular metabolism. BAD, BCL-2 antagonist of cell death; CDC42, cell division
cycle 42; DAG, diacylglycerol; FOX, forkhead transcription factor; GAP, GTPase-activating protein; GEF, guanine
nucleotide exchange factor; IKK, IκB kinase; IP3, inositol-1,4,5-trisphosphate; mTORC, mTOR complex; NF-κB,
nuclear factor-κB; PDK1, phosphoinositide-dependent kinase 1; PKC, protein kinase C; PLA, phospholipase A; PLCɛ,
phospholipase Cɛ; PLD, phospholipase D; RALGDS, RAL guanine nucleotide dissociation stimulator; RHEB, RAS
homologue enriched in brain; RIN1, RAS and RAB interactor 1; TSC1/2, tuberous sclerosis 1/2; TIAM1, T cell
lymphoma invasion and metastasis 1. Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews
Cancer. Berndt, N., A. D. Hamilton, et al. (2011). Targeting protein prenylation for cancer therapy. Nat Rev Cancer
11(11): 775-791, Copyright © 2011. 
and Santos, 2011; Takashima and Faller, 2013).  RAS proteins act as transducer that 
couple cell surface receptors to intracellular effectors and alternate between on and off 
conformation that are conferred by binding of GTP or GDP respectively (Figure 2.2). 
Under physiological conditions, the transitions between these two states is regulated by 
guanine nucleotide exchange factors (GEFs), which promote the activation of RAS by 
stimulating GDP for GTP exchange, and by GTPase activating proteins (GAPs), which 
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 accelerate RAS-mediated GTP hydrolysis (Pylayeva-Gupta et al., 2011). This inactivation 
of RAS activity by GAPs is the predominant target of the most common somatic 
mutations that are found in the oncogenic variants of RAS alleles. Oncogenic 
substitutions in residues G12 and G13 of RAS prevent the formation of Van der Waals 
bonds between RAS and the GAP through esteric hindrance, perturbing the proper 
orientation of the catalytic glutamine Q61 in RAS, which results in the pronounced 
attenuation of GTP hydrolysis (Scheffzek et al., 1997). The outcome of these 
substitutions is the persistence of the GTP-bound state of RAS and, as a consequence, 
the permanent activation of a multitude of RAS dependent downstream effectors 
pathways, involved in many aspects of the tumor phenotype such as promotion of 
proliferation, suppression of apoptosis, metabolic reprogramming, remodeling of the 
microenvironment, evasion of the immune response and metastasis (Pylayeva-Gupta et 
al., 2011). As it is the case for PI3K, RAS also promotes a remodeling of the metabolic 
network.  
Although RAS modulates different metabolic processes in the cell, regulation of 
glycolysis is one of the most important metabolic effects (Figure 2.3). Its main effect on 
metabolism is targeted to glycolysis by upregulating HIF1α, considered one of the main 
regulators of glycolysis, and glucose transporter expression (Blum et al., 2005; Chen et 
al., 2001; Chun et al., 2010; Kikuchi et al., 2009). Additionally, RAS family proteins act 
upstream PI3K/AKT/mTOR pathway, which is a regulatory axis with deep effects on 
aerobic glycolysis and cellular biosynthesis. This pathway has been shown to stimulate 
cell growth and ATP production by regulating the activity and expression of key 
glycolytic enzymes and nutrient transporters, enabling increased uptake of glucose, 
aminoacids and other nutrients (Barata et al., 2004; Edinger and Thompson, 2002; Roos 
et al., 2007; Wieman et al., 2007). In addition, AKT activation is sufficient to increase 
glycolysis and lactate production to induce a Warburg effect in either transformed cells 
or cancer cells (Elstrom et al., 2004; Plas et al., 2001; Rathmell et al., 2003). RAS also 
induces the Warburg effect partly through increasing the activity of MYC in an example 
of a cooperative mechanism between oncogenes to regulate metabolism (Sears et al., 
1999). 
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Figure 2.3  RAS effects on metabolism 
RAS exerts most of its metabolic effects by activating hypoxia inducible factor 1α (HIF1α), either directly or via
activation of PI3K/AKT or ERK, both converging in the activation of mTOR (mammalian target of rapamycin), which
subsequently activates HIF1α. The activation of HIF1α leads to an overexpression of some glycolytic enzymes such
as hexokinase (HK), phosphofructokinase (PFK) or lactate dehydrogenase (LDH). The activation of glycolysis
promotes an increase of metabolic precursors available for synthesis of macromolecules such as lipids, aminoacids
and proteins, and nucleotides. Also, part of the RAS-induced metabolic effects can be carried out by AKT or mTOR
activation through a HIF1α-independent process. TSC2, tuberin or tuberous sclerosis 2; LKB1, liver kinase B1; RSK,
ribosomal protein S6 kinase. Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Cancer.
Pylayeva-Gupta, Y., E. Grabocka, et al. (2011). RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 11(11):
761-774, Copyright  © 2011. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.1.3  Glutamine catabolism and ATP production 
Although glucose is the major energetic substrate, other nutrients can be processed 
with energetic purposes. One of the nutrients most largely available to tumors is 
glutamine, the most abundant aminoacid in the plasma. Tumor cells consume 
glutamine in a larger amount than normal cells both in vitro and in vivo. (Eagle, 1955; 
Sauer and Dauchy, 1983; Sauer et al., 1982). These observations led to the notion that 
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glutamine metabolism stood with the Warburg effect as a major component of the 
general metabolic phenotype of tumor cells.  
Glutamine takes part in many different physiological processes in the cells, being 
involved in both ATP and NADPH production as well as in biosynthetic and anaplerotic 
reactions. These processes can roughly be divided into reactions that use glutamine for 
its γ-nitrogen (nucleotide and hexosamine synthesis) and those that use either the α-
nitrogen or the carbon skeleton directly from glutamine or from glutamine-derived 
glutamate or α-ketoglutarate (transamination, synthesis of aminoacids, lipids, or 
glutathione, ATP and NADPH production) (DeBerardinis and Cheng, 2010). Oxidation of 
glutamine carbon skeleton in the mitochondria with energetic purposes is an important 
metabolic fate of glutamine. The complete oxidation of glutamine requires α-
ketoglutarate to progress along the TCA cycle and the exit as malate, its conversion first 
to pyruvate by malic enzyme and next to acetyl-CoA (ACoA) to finally reentry into TCA 
cycle with the subsequent ATP production. Alternatively, cells can partially oxidize 
glutamine and the formed pyruvate can be converted to lactate in a process known as 
glutaminolysis (DeBerardinis et al., 2007). In both complete and partial oxidation of 
glutamine, this aminoacid contributes to the synthesis of not only ATP through 
oxidative phosphorylation (OXPHOS) but also NADPH.  
2.2.2  Building a new cell: biosynthetic processes in cancer cell 
metabolism 
The Warburg effect provides proliferating cells with a rapid and oxygen-independent 
source of ATP, as well as metabolic intermediates for biosynthesis of macromolecules. 
The latter aspect is critical to provide cells with enough nucleotides, proteins, and lipids 
for a cell to double their total biomass and then divide to produce two daughter cells. 
This process requires a profound remodeling of metabolism, which involves the major 
metabolic pathways shown in Figure 2.4. 
 In contrast to the catabolic metabolism of differentiated cells, the anabolic metabolism, 
essential to cell growth and proliferation, is not focused on maximizing ATP yield.  
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Figure 2.4  Main metabolic pathways involved in tumor metabolic reprogramming 
The picture shows an overview of the major metabolic pathways involved in the synthesis of macromolecules:
nucleotide synthesis, the pentose phosphate pathway, serine synthesis, glutaminolysis, cholesterol synthesis, fatty-
acid synthesis and elongation desaturation. The enzymes involved in these pathways are shown in bold and those
induced in response to hypoxia are marked with an asterisk. Reductive carboxylation of α-KG by IDH1 and IDH2
produces citrate for lipid synthesis in hypoxic cells (black dashed arrow). ACC, acetyl-CoA carboxylase; ACLY, ATP
citrate lyase; ACO, aconitase; CA9, carbonic anhydrase 9; CoA, coenzyme A; CS, citrate synthase; FASN, fatty-acid
synthase; F1,6BP, fructose-1,6-bisphosphate; F2,6BP, fructose-2,6-bisphosphate; F6P, fructose-6-phosphate; FH,
fumarate hydratase; GLS, glutaminase; GLUD, glutamate dehydrogenase 1; GOT, glutamic-oxaloacetic transaminase;
GSH, glutathione; G1P, glucose-1-phosphate; G6P, glucose-6-phosphate; G6PD, G6P dehydrogenase; HIF, hypoxia
inducible factor; HMGCR, 3-hydroxy-3-methylglutaryl-CoA reductase; KEAP, kelch-like ECH-associated protein 1;
LDHA, lactate dehydrogenase A; MCT, monocarboxylate transporters; MDH, malate dehydrogenase; ME1, malic
enzyme 1; NHE1, Na+/H+ exchange protein 1; NRF2, nuclear factor (erythroid-derived 2)-like 2; PDH, pyruvate
dehydrogenase; PDHK1, pyruvate dehydrogenase kinase; PEP, phosphoenolpyruvate; PFK, phosphofructokinase;
PHD, prolyl hydroxylases; PHGDH, phosphoglycerate dehydrogenase; PKM2, pyruvate kinase M2; PL, phospholipids;
ROS, reactive oxygen species; SCD, stearoyl-CoA desaturase; SDH, succinate dehydrogenase; TAG, triacylglycerides.
Modified by permission from Macmillan Publishers Ltd: Nature. Schulze, A. and A. L. Harris (2012). How cancer
metabolism is tuned for proliferation and vulnerable to disruption. Nature 491(7424): 364-373, Copyright © 2012. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rather than ATP, proliferating cells have a greater requirement of carbon and nitrogen, 
as well as cytosolic NADPH for reductive biosynthetic reactions. The recognition that 
proliferating cells do not maximize ATP production through mitochondrial oxidative 
phosphorylation has contributed to the misconception that proliferating cells, 
particularly cancer cells, do not utilize mitochondria. In fact, most cancer cells and 
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proliferating normal cells still derive a fraction of their ATP through OXPHOS. However, 
in proliferating cells, in contrast to quiescent cells, this OXPHOS-dependent production 
of ATP appears secondary to the use of mitochondrial enzymes in the synthesis of 
anabolic precursors (Ward and Thompson, 2012). Therefore, a pivotal role of the TCA 
cycle in proliferating cells might be to act as a hub for biosynthesis, resulting in a 
continuous efflux of TCA cycle intermediates, in a process named cataplerosis (Owen et 
al., 2002). A very illustrative example of this process is the synthesis of lipids or 
lipogenesis. However, a continuous efflux of TCA cycle intermediates from the 
mitochondria might end up in a depletion of intermediates. This process is 
compensated by the activation of metabolic routes that contribute to the influx of 
carbons into TCA cycle in a process called anaplerosis. A paradigmatic example of 
anaplerosis is the metabolism of glutamine. 
2.2.2.1 The synthesis of lipids or lipogenesis 
Although most cells in the adult body rely on lipids from the bloodstream, many cancer 
cells show reactivation of de novo fatty acid synthesis (Santos and Schulze, 2012). The 
high proliferation of cancer cells requires large amount of lipids as building blocks for 
biological membranes. This enhanced lipid demand is fulfilled through the export of 
mitochondrial citrate to the cytosol, where it is converted to oxaloacetate and the 
lipogenic precursor ACoA by the enzyme ATP-citrate lyase (ACLY). Then, oxaloacetate 
can be converted into pyruvate by the malic enzyme (ME), generating NADPH for lipid 
synthesis. Fatty acids biosynthesis requires the activation of ACoA to malonyl-CoA, 
catalyzed by the enzyme acetyl-CoA carboxylase (ACC). The acetyl and malonyl groups 
are then coupled to the enzyme fatty acid synthase (FASN). Further elongation and 
desaturation of newly synthesized fatty acids are obtained through the action of a 
family of enzymes named elongation of very long chain fatty acids (ELOVL) proteins that 
add two carbons to the end of the chain in each cycle of reaction. Next, desaturation is 
catalyzed by fatty acyl-CoA desaturases, which include stearoyl-CoA desaturases (SCDs).  
In the 60s, it was noted that neoplasic tissues were able to synthesize lipids. Since then, 
several studies have documented that cancer cells reactivate de novo lipid synthesis. 
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Some cancers show increased expression of FASN (Swinnen et al., 2000; Yoon et al., 
2007). Moreover, ACLY has been shown to be required for cell transformation in vitro 
and for tumor formation in vivo (Bauer et al., 2005; Hatzivassiliou et al., 2005), and 
chemical inhibition of ACC induces growth arrest and apoptosis in prostate cancer cells 
(Beckers et al., 2007). These studies demonstrate that lipogenesis is essential in 
tumorigenesis. 
Furthermore, lipogenesis is controlled by many signaling pathways often deregulated in 
cancer. Expression of the enzymes involved in the synthesis of fatty acids and 
cholesterol is regulated by the sterol regulatory binging proteins family (SREBPs), which 
are in turn partially regulated by PI3K/AKT/mTOR, and have been found overexpressed 
in a number of cancers (Menendez and Lupu, 2007). AKT can also phosphorylate ACLY 
(Berwick et al., 2002) and activate the expression of several genes involved in 
cholesterol and fatty-acid biosynthesis (Porstmann et al., 2005). Moreover, lipogenesis is 
also controlled by RAS oncogene through the action of HIF1, which induces the 
expression of FASN in human breast cancer cell lines, (Furuta et al., 2008).  In this 
regard, the activity of stearoyl-CoA desaturase 1 (SCD1) has been demonstrated to be 
essential for RAS-mediated transformation (Fritz et al.). 
2.2.2.2 Mitochondrial metabolism and glutamine as biosynthetic precursor  
Mitochondrial metabolism roughly consist of the metabolic reactions that make up TCA 
cycle, where reduced coenzymes are generated, and the process termed oxidative 
phosphorilation, where the coenzymes are oxidized back in a process placed in the 
electron transport chain that involves oxygen consumption and ATP production. 
The export of citrate for lipid synthesis impacts over the function of the TCA cycle, 
resulting in what has been called a “truncated” cycle due to the relative decrease in the 
fraction of citrate that is oxidized (Hatzivassiliou et al., 2005; Parlo and Coleman, 1986). 
To sustain TCA cycle function and compensate for cataplerotic processes, cells must 
activate an influx of carbons through anaplerotic reactions to resupply mitochondrial 
intermediates. This essential feature of proliferating metabolism is known as anaplerosis 
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provides cells with the ability to use TCA cycle as a hub of macromolecules precursors. 
Several mechanisms exist to produce anaplerotic activity within the cell. The main of 
them uses pyruvate carboxylase (PC), which transforms pyruvate into OAA that 
replenish TCA cycle to keep on cycling.  
An alternative source of anaplerosis is through metabolism of aminoacids, particularly 
glutamine. Proliferating cells metabolize glutamine in multiple processes for 
bioenergetics and biosynthesis. As mentioned earlier, these processes can roughly be 
divided into reactions that use glutamine for its γ-nitrogen and those that use either the 
α-nitrogen or the carbon skeleton (DeBerardinis and Cheng, 2010). The processes in the 
second group are tightly related to anaplerotic reactions, since they supply carbon 
atoms to TCA cycle.  
The role of glutamine anabolism in cancer cell proliferation and survival has been 
demonstrated to be essential in certain types of cancer (Wise et al., 2008; Yuneva et al., 
2007) and it has even been suggested that some tumors are glutamine addicted (Wise 
et al., 2008). Furthermore, this aminoacid also contributes importantly to the synthesis 
of lipids, not only by oxidative metabolism of its carbons but also by reductive 
carboxylation via its conversion to α-ketoglutarate and subsequently to isocitrate by 
IDH reversible reaction. This process is particularly important in hypoxia, VHL-deficient 
cells (cells with mutation or suppression of the von Hippel Lindau protein) and tumor 
cells with defective mitochondria, since it has been demonstrated to sustain cell growth 
and proliferation under these circumstances (Gameiro et al., 2013; Holleran et al., 1995; 
Metallo et al., 2012; Mullen et al., 2012; Wise et al., 2011). 
Mitochondrial metabolism is the main source of metabolic precursors for anabolic 
reactions that allow cells to proliferate. Then, it is expected that the master signaling 
pathways that drive proliferation control directly or indirectly mitochondrial metabolism. 
In particular, the PI3K/AKT/mTOR pathway, as it has been described previously, 
regulates lipid metabolism and, unbreakably, mitochondrial metabolism. Also some of 
the most relevant oncogenes trigger important effects on mitochondrial and glutamine 
metabolism (Li et al., 2005). For instance, MYC oncogene promotes mitochondrial and 
glutamine metabolism and cells overexpressing this oncogene are glutamine addicted, 
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since glutamine metabolism inhibition leads to cell death in vitro and inhibition of the 
tumor growth in vivo (Gao et al., 2009b; Li et al., 2005; Wise et al., 2008) (Dang et al., 
2009).  
RAS oncogene also modulates mitochondrial metabolism, although the metabolic 
consequences of this modulation are not fully understood. Some studies performed 
using human KRasV12-transfected cells (Hu et al., 2012) and mouse HRasV12-
transfected cells (Yang et al., 2010a) describe that RAS oncogenic activation leads to an 
impairment of mitochondrial respiration combined with a gradually acquisition of the 
Warburg effect. Also, an impairment of mitochondrial respiration has been reported in 
mouse fibroblast transfected with oncogenic H-RasQ61L (de Groof et al., 2009). On the 
contrary, human HRasV12-expressing cells have been reported to increase 
mitochondrial metabolism (Telang et al., 2007). Despite of these opposed conclusions 
on the regulation of mitochondrial metabolism by RAS, it is widely accepted that 
glutamine and mitochondrial metabolism are essential for cell cycle progression (Gaglio 
et al., 2009) and in vivo tumorigenesis in KRAS-driven tumors (Son et al., 2013; 
Weinberg et al., 2010). Moreover, it has been documented that K-RAS regulates a 
specific pathway for glutamine mitochondrial metabolization where glutamine-derived 
glutamate can be converted into oxaloacetate by aspartate transaminase and this 
oxaloacetate is subsequently converted into malate and then pyruvate by malic enzyme, 
increasing the NADPH/NADP ratio (Son et al., 2013).  
2.2.2.3 The pentose phosphate pathway  
An increased proliferation requires the fulfillment of an enhanced demand of DNA and 
RNA synthesis. DNA and RNA are polymers of nucleotides, which consist of a 
nucleobase, a five-carbon sugar (ribose or deoxyribose), and a phosphate group. The 
five-carbon sugar or pentose is mainly synthesized through the pentose phosphate 
pathway (PPP), being then this pathway essential to nucleotide production. 
On the other hand, the increased biosynthetic activity of cancer cells requires not only 
synthesis of precursors of macromolecules, but also an increase in the production of 
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reduced equivalents such as NADPH (Ward and Thompson, 2012). This cofactor is 
involved in many essential processes in the cell, such as lipids, nucleotides and 
aminoacids synthesis. Moreover, NADPH is used in the maintenance of the reduced 
glutathione pool to counteract oxidative stress. At least five sources of NADPH exist in 
the cell: ME, IDH, aldehyde dehydrogenase (ALDH), NAD kinase (NADK) and the 
enzymes of the PPP glucose-6-phosphate dehydrogenase (G6PD) and 6-
phosphogluconate dehydrogenase (6PGD). The role that each reaction plays in 
providing cells with NADPH remains to be examined in deeper detail and it is probable 
that cells do not rely on a single NADPH generating system (Pollak et al., 2007; 
Wamelink et al., 2008). 
Then, the PPP is committed to both the production of macromolecules and to the 
supply of reduced equivalents. It provides an alternative pathway for glucose oxidation 
and the percentage of glucose metabolized through PPP may vary from 5 to 30% in a 
tissue dependent-manner.  
PPP is classically divided into the oxidative and the nonoxidative branch (Figure 2.5). The 
oxidative branch is a non-reversible metabolic pathway. There, glucose-6-phosphate is 
transformed into 6-phosphoglucono-δ-lactone by G6PD, which is hydrolyzed to 6-
phosphogluconate by 6-phosphoglucolactonase (PGLS) and subsequently transformed 
into ribulose-5-phosphate 6PGL with the subsequent production of NADPH and CO2. 
The resulting ribulose-5-phosphate can be then converted into ribose-5-phosphate and 
used for the synthesis of nucleotides. Proliferating cells require high amounts of 
pentoses phosphate, and this demand is particularly high in cancer cells. There are two 
main conditions that regulate the activity of PPP. The first one is the cell proliferation 
rate: the greater is the proliferation, the greater is the requirement for ribose-5-
phosphate and NADPH. The second condition is the requirement of NADPH. The 
enzyme of the oxidative branch of the PPP G6PD, can be active in human cells as a 
dimer or tetramer (formed by the association of two dimers), each inactive monomer 
being composed of 515 aminoacids (Au et al., 2000; Riganti et al., 2012). The NADP+ 
amount is critical for the activity of this enzyme. G6PD activity is directly related to the 
NADP+/NADPH ratio, since NADP+ is necessary for stabilizing the dimer (Au et al., 2000).  
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Figure 2.5 Metabolic scheme of the pentose phosphate pathway 
The oxidative and nonoxidative branches of the pentose phosphate pathway are depicted. The irreversible oxidative
pathway is catalyzed by G6PD (glucose-6-phosphate dehydrogenase), 6-phosphogluconolactonase (not shown)
and 6PGD (6-phosphogluconate dehydrogenase). This branch produces NADPH, used to convert the oxidized form
of glutathione into the reduced form and to synthesize fatty acids. The reversible nonoxidative pathway carries out a
carbon exchange between PPP and glycolysis, either recycling the excess of pentoses or synthesizing ribose from
glycolytic intermediates. The main enzymes involved in this branch are TKT (transketolase) and TALDO
(transaldolase). 
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When NADPH raises, some NADPH molecules might bind G6PD instead of NADP+, but 
NADPH lacks stabilizing effects (Kotaka et al., 2005) and reduces G6PD activity. It is 
worth noting that G6PD usually works at 1-2% of its maximal potential in healthy 
subjects, because of the high concentration of NADPH in resting conditions. Upon 
NADPH oxidation, NADP+/NADPH ratio increases and G6PD shifts to the most active 
state, increasing oxidative PPP flux (Eggleston and Krebs, 1974). Consistent with the role 
of G6PD in the synthesis of NADPH for lipogenesis, a negative regulation of this enzyme 
by the lipid intermediate palmitoyl-CoA has also been described (Asensio et al., 2007). 
The nonoxidative branch of the PPP, on the contrary to the oxidative one, consists of a 
set of reversible reactions. In this branch, ribose-5-phosphate and xilulose-5-phosphate 
generated from glucose-6-phosphate undergo the exchange of two carbon units 
operated by tranketolase enzyme (TKT), to yield glyceraldehyde-3-phosphate and 
sedoheptulose-7-phosphate. These two products generate fructose-6-phosphate and 
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erytrose-4-phosphate via a three carbon exchange reaction catalyzed by transaldolase 
(TALDO). Next, TKT catalyzes again the exchange of two carbon units between a second 
xylulose-5-phosphate and erytrose-4-phosphate, finally producing fructose-6-
phosphate and glyceraldehyde-3-phosphate, which can be either metabolized in the 
glycolytic pathway or reintroduced in the PPP.   
Since PPP provides essential substrates required for proliferation and also regulates 
oxidative through the synthesis of NADPH, changes in the PPP activity usually occur 
during cancer development and progression. PPP plays a role in many aspects of tumor 
biology, such as proliferation and survival, tumor invasion, angiogenesis, and response 
to chemo- and radiotherapy, and it has been proposed that the regulated activation of 
the entire PPP could be regarded as a hallmark of cell transformation (Riganti et al., 
2012). Because intracellular nucleotides reservoir is unable to meet the requirements for 
cell duplication, the metabolic routes that provide the cell with precursors of these 
nucleotides are needed to be upregulated in proliferating tissues. Accordingly, an 
overexpression of the main PPP genes has been shown in certain tumor types including 
gastric, colorectal and kidney (Kekec et al., 2009; Langbein et al., 2008). Furthermore, 
G6PD and TKT are both increased in human colon cancer cells and their maximal activity 
is found during late G1 and S phases, suggesting that changes in PPP mediate in cell 
cycle progression (Vizan et al., 2009).  
In particular, the role of the oxidative PPP branch in tumor biology has been studied in 
the context of cell proliferation and transformation. Although G6PD works at a low basal 
rate in nontransformed cells, it can exert a strong proliferative role when it becomes 
deregulated. The key role of G6PD in tumorigenesis is also supported by the fact that 
G6PD gene overexpression transforms NIH3T3 cells and induces tumors in nude mice 
(Kuo et al., 2000). In accordance, cells overexpressing G6PD proliferate more than wild-
type cells (Leopold et al., 2003; Tian et al., 1998).  
On the other hand, also the nonoxidative branch has been described to contribute 
importantly to ribose-5-phosphate synthesis in tumors (Boros et al., 1998; Cascante et 
al., 2000). Given the reversibility of the reactions involved in the nonoxidative branch, an 
increased glycolysis (Warburg effect) can enhance the use of this branch (Pelicano et al., 
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2006). In experiments in vitro using pancreatic adenocarcinoma cells, around 85% of the 
ribose has been reported to be synthesized through the nonoxidative pathway and the 
inhibition of TKT by oxythiamine led to a decrease of 90% in final tumor mass in mice 
hosting Ehrlich's ascitic tumor (Boros et al., 1997). Furthermore, in pancreatic ductal 
adenocarcinoma mouse model ribose biogenesis is mainly carried out through the 
nonoxidative PPP branch and it is essential for tumor progression in vivo (Ying et al., 
2012).  
The enzyme TKT belongs to a family that includes genes encoding TKT and two other 
TKT-like proteins (TKTL1 and TKTL2)(Coy et al., 2005). Given the important role of TKT 
described in some tumors , the presence and state of all three isoforms has been 
examined in cancer cells (Coy et al., 2005) and overexpression of TKTL1 has been found 
in some tumors (Krockenberger et al., 2007; Langbein et al., 2006; Staiger et al., 2006). 
Moreover, TKTL1 contributes significantly to the total TKT activity in human hepatoma 
and colon cancer cells (Hu et al., 2007; Xu et al., 2009; Zhang et al., 2007). It has also 
been demonstrated that the specific inhibition of TKTL1 expression by shRNA triggers 
apoptosis and suppresses tumor growth in HCT116 colon cancer cells (Xu et al., 2009). 
Finally, although more efforts are required to elucidate the role of TKTL1 in cancer, it 
has been hypothesized that this isoform could generate ACoA, which would link 
glycolysis and lipogenesis through the non-oxidative PPP (Coy et al., 2005). 
In the context of anabolic tumor metabolism, PPP is regulated by some of the most 
important oncogenes and tumor suppressor genes. It has been described that 
oncogenic transformation by K-RAS is accompanied by an increase in PPP and 
glycolysis because of the simultaneous upregulation of G6PD, pyruvate kinase (PK) and 
lactate dehydrogenase (LDH) (de Atauri et al., 2011). Moreover, it has been 
demonstrated that K-RAS drives glycolysis intermediates into the nonoxidative PPP for 
ribose biogenesis in pancreatic ductal adenocarcinoma cells (Ying et al., 2012). Also, 
PI3K/AKT signaling promotes anabolic metabolism through PPP by activating NRF2, a 
transcription factor involved in response to cellular stress that activates G6PD among 
other enzymes. Under activation of PI3K signaling, TKT and G6PD are essential to NRF2-
driven tumor proliferation and their simultaneous inhibition impaired tumor growth in 
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vivo (Mitsuishi et al., 2012b). On the other hand, tumor suppressor genes also regulate 
PPP. A very illustrative example is the case of p53, which modulates PPP activity by 
regulating G6PD dimer formation (Jiang et al., 2011).  
2.2.3  Maintenance of redox homeostasis: ROS detoxification 
As a result of the oxidative metabolism carried out mainly in the mitochondria, not only 
many essential compounds are produced, but also waste by-products that must be 
either excreted or neutralized. Part of these compounds are known collectively as 
reactive species and can be toxic if the concentration increases, producing what is 
commonly known as oxidative stress. Reactive species can be classified into four groups 
based on the main atom involved: reactive oxygen species (ROS), reactive nitrogen 
species (RNS), reactive sulfur species (RSS) and reactive chloride species (RCS). Among 
all the compounds derived from oxidative metabolism, ROS are the most abundantly 
produced. ROS are essential for many biological functions such as cell growth and 
differentiation, enzyme regulation or inflammation, and they regulate many signal 
transduction pathways involved in these processes. They can be produced either inside 
the cells (internal sources) or by environmental agents (external sources). Sources of 
internal oxidative stress include peroxisomes and enzymes, particularly the detoxifying 
enzymes from the p450 complex, xanthine oxidase complexes, and the NADPH oxidase 
complexes. Most of these enzymes operate in the mitochondria, which is the main 
source of oxidative stress. With regard to the external sources of oxidative stress, they 
include UV radiation, chemical compounds and exercise (Sosa et al., 2013). 
2.2.3.1 ROS, cancer and oncogenes 
Oxidative stress is important from the biomedical point of view because it is related to a 
wide variety of illnesses, such as cancer. A moderate increase in ROS can promote cell 
proliferation and differentiation, whereas excessive amount of ROS can damage many 
molecules, including DNA, RNA, lipids and proteins, inducing senescence and/or cell 
death (Figure 2.6) (Perry et al., 2000). Then, levels of ROS need to be finely regulated  
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Figure 2.6 ROS levels and cancer 
Cancer cells deal with increased levels of ROS as a consequence of intrinsic or extrinsic factors. A slight increase in
ROS levels can promote proliferation and cell survival. However, a great increase results in cell death and
senescence. Then cancer cells must keep a balance between processes producing and removing ROS. This is
achieved by activating a serie of genes involved in ROS detoxification, such as NRF2-KEAP1 system, which lead to
the synthesis of antioxidants that allow cells to counter the excess of ROS, but also increases the chance that the cell
experience additional ROS-mediated mutagenic events and stress responses that promote tumorigenesis. Reprinted
by permission from Macmillan Publishers Ltd: Nature Reviews Cancer. Cairns, R. A., I. S. Harris, et al. (2011).
Regulation of cancer cell metabolism. Nat Rev Cancer 11(2): 85-95, Copyright © 2011.
 
 
 
 
 
 
 
 
 
 
(Boonstra and Post, 2004) and this regulation is achieved through modulating the ROS 
generation and elimination by scavenging systems, such as superoxide dismutases, 
glutathione peroxidase, peroxiredoxins, glutaredoxins, thioredoxins or catalase.  
Abnormal cancer cell growth is associated with increase in ROS and reflects a disruption 
of redox homeostasis, due to either an elevation of ROS production or to a decrease of 
ROS-scavenging capacity, resulting in a condition known as oxidative stress. Oxidative 
stress mediated signaling events have been reported to affect all features of cancer cell 
behavior, including cell cycle progression and proliferation, cell survival and apoptosis, 
energy metabolism, cell morphology, motility and adhesion, angiogenesis, and tumor 
stemness (Sosa et al., 2013). This regulation is performed by modulating several 
signaling pathways profoundly involved in cancer, such as MAPK pathway or PI3K/AKT 
pathway (Liou and Storz, 2010). In fact, the requirement of ROS in tumorigenesis is 
clearly demonstrated by the mechanisms developed by cancer cells to avoid ROS 
activation of p38α, a negative regulator in the process of transformation induced by H-
RAS (Dolado et al., 2007). Because the increase in ROS may play an important role in 
cancer initiation and progression, such oxidative stress is often viewed as an adverse 
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event. Nevertheless, as excessive levels of ROS stress can be toxic, cancer cells with 
increased oxidative stress are likely to be more vulnerable to damage by further ROS 
insults induced by exogenous agents, opening new avenues for therapeutic intervention 
(Trachootham et al., 2009). 
Compared to normal cells, malignant cells display higher levels of endogenous oxidative 
stress in vitro and in vivo (Kawanishi et al., 2006; Szatrowski and Nathan, 1991). Breast 
tumors are a paradigmatic example, since they are characterized by persistent ROS 
generation (Brown and Bicknell, 2001; Kang, 2002). Also, markers of constitutive 
oxidative stress have been detected in samples from in vivo breast carcinomas 
(Toyokuni et al., 1995; Portakal et al., 2000). In the same line, 8-hydroxy-2'-
deoxyguanosine, one of the major oxidatively modified DNA base products, is almost 
ten-fold more prevalent in invasive ductal breast carcinoma cells than in normal control 
samples from the same patient (Toyokuni et al., 1995). 
Despite the clear implications of ROS in tumorigenesis, the precise mechanisms leading 
to oxidative stress in cancer cells remain unclear. However, some intrinsic and extrinsic 
mechanisms are demonstrated to cause oxidative stress during cancer development 
and disease progression. Oncogene activation, aberrant metabolism, mitochondrial 
dysfunction, and loss of p53 are intrinsic factors known to cause increased ROS 
production in cancer cells. Moreover, the expression of genes associated with tumor 
transformation, such as RAS, BCR-ABL and c-MYC, were found to induce ROS 
production (Trachootham et al., 2006; Weinberg et al., 2010). In HRasV12-transformed 
NIH3T3 fibroblasts, a large amount of superoxide was generated through the activation 
of the membrane associated ROS-producing enzyme NADPH oxidase (NOX) (Irani et al., 
1997).  
In addition to the intrinsic mechanisms, extrinsic ones such as inflammatory cytokines, 
imbalance of nutrients, and a hypoxic environment could also affect intracellular redox 
homeostasis (Cook et al., 2004). As cancer cells actively produce high levels of ROS and 
are continuously exposed to oxidants, it is reasonable that oxidative stress may exert 
selective pressure to enrich the population of cells that are capable of adapting to 
oxidative stress. Those cells that survive under oxidative stress are likely to have 
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acquired adaptive mechanisms to counteract the potential toxic effects of elevated ROS 
and promote cell survival pathways. For instance, oncogenic HRas-transformed cells, 
which exhibited increased superoxide and hydrogen peroxide levels, were shown to 
express higher levels of antioxidant enzymes such as peroxiredoxin-3 and thioredoxin 
peroxidase compared with their non-tumorigenic parental cells (Young et al., 2004). 
Their enhanced antioxidant capability is likely to serve as a key mechanism to evade 
ROS-induced apoptosis as evidenced by the resistance to hydrogen peroxide-induced 
cell death that was observed in the HRas-transformed cells (Young et al., 2004). In the 
same line, RAS-transformed cells were also found to be more sensitive to depletion of 
glutathione, leading to ROS accumulation and cell death (Trachootham et al., 2006). 
Also, an increase  of the flux through the oxidative branch of PPP (Vizan et al., 2005) as 
well as the overexpression of the NADPH producing enzyme G6PD has been reported in 
KRas-transfected NIH3T3 cells (de Atauri et al., 2011; Vizan et al., 2005). Then, it is 
possible that along tumorigenesis, oncogenic signals stimulate both the formation of 
ROS to enhance proliferation and the promotion of antioxidant mechanisms to 
minimize oxidative damage. The mechanisms of redox regulation involve multiple 
signaling pathways which employs several antioxidant-sensitive transcription factors 
such as nuclear factor-κB (NF-κB), nuclear factor (erythroid-derived 2)-like 2 (NRF2), c-
JUN, and HIF1, which led to the increased expression of antioxidant molecules such as 
superoxide dismutase (SOD), catalase, thioredoxin and reduced glutathione.  
2.2.3.2 The NRF2 detoxification system  
Of particular interest in redox homeostasis maintenance is the role of NRF2 
transcription factor. It is a potent transcriptional activator that plays a pivotal role in the 
inducible expression of many cytoprotective genes in response to oxidative stress. The 
main regulator of NRF2 is the protein Kelch-like ECH-associated protein 1 (KEAP1). 
Under normal conditions, NRF2 is constantly ubiquitinated through KEAP1 in the 
cytoplasm, and degraded in the proteasome (Figure 2.7). KEAP1 is a thiol-rich protein 
that possesses multiple highly reactive cysteine residues. Upon exposure to ROS, these 
cysteine residues are modified, leading to the inactivation of KEAP1 and the stabilization  
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Figure 2.7 KEAP1-NRF2 system 
Under normal conditions, NRF2 is constantly ubiquitinated through Keap1 and degraded in the proteasome.
Following exposure to electrophiles or oxidative stress, KEAP1 is inactivated. Stabilized NRF2 accumulates in the
nucleus and activates many cytoprotective genes. Ub, ubiquitin.  Original work from Mitsuishi, Y., H. Motohashi, et al.
(2012). The Keap1-Nrf2 system in cancers: stress response and anabolic metabolism.  Front Oncol 2: 200 doi:
10.3389/fonc.2012.00200. Copyright © 2012 Mitsuishi, Motohashi and Yamamoto. This is an open-access article
distributed under the terms of the Creative Commons Attribution License.  
(http://creativecommons.org/licenses/by/3.0/) 
 
 
 
 
 
 
 
 
 
 
 
 
of NRF2. Consequently, NRF2 translocates into the nucleus and activates the 
transcription of many cytoprotective genes that encode detoxifying enzymes and 
antioxidant proteins. NRF2 target genes are mainly involved in glutathione synthesis, 
the elimination of ROS, xenobiotic metabolism, and drug transport (Mitsuishi et al., 
2012a).  
Interestingly, an increase in NRF2 levels has been frequently detected in various types of 
human cancers, resulting in an overactivation of its target genes that provide cells with 
additional capabilities of malignance (Kim et al., 2010; Singh et al., 2006; Solis et al., 
2010; Tsai et al., 2008). Also, highly activated NRF2 target genes confer a great 
advantage to cancer cells for survival against anticancer drugs and irradiation (Singh et 
al., 2010; Zhang et al., 2010). Moreover, NRF2 knockdown in constitutively NRF2-
activated lung cancer cells suppresses tumor growth, and results in increased sensitivity 
to chemotherapeutic drug–induced cell death in vitro and in vivo. (Singh et al., 2008). 
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Several mechanisms have been reported to explain the increased activity of NRF2-
KEAP1 system in cancer cells: somatic mutation in KEAP1 or NRF2, DNA hyperventilation 
at the promoter region, the aberrant accumulation of proteins that disrupt the KEAP1-
NRF2 interaction, transcriptional upregulation of NRF2 gene through oncogene-
dependent signaling, and the modification of KEAP1 protein through oncometabolites 
(Mitsuishi et al., 2012a). The regulation of NRF2 by oncogene-dependent signaling is 
particularly interesting (Ganan-Gomez et al., 2013). In a recent study, this type of 
regulation has been described to be determinant in NRF2 activity (DeNicola et al., 2011). 
Therein, it is reported that K-RAS activates NRF2 transcription through the MEK-ERK-
JUN signaling pathway and reduces ROS levels in primary fibroblasts. Furthermore, the 
activation of this transcription factor by oncogenic signals is demonstrated to play a 
pivotal role in ROS detoxification and tumorigenesis (DeNicola et al., 2011).  
A significant portion of the genes regulated by NRF2 are metabolic genes involved in 
PPP and NADPH production, such as G6PD, PGD (phosphoglycerate dehydrogenase), 
TKT, TALDO1 (transaldolase 1), ME1 (malic enzyme 1) and IDH1 (isocitrate 
dehydrogenase 1), all of them containing antioxidant response element sequences in 
their promoters. These genes are not only involved in maintenance of redox 
homeostasis but also in anabolic reactions for synthesis of macromolecules. Indeed, PPP 
enzymes G6PD and TKT are reported to be essential to NRF2-induced tumor growth in 
vitro (Mitsuishi et al., 2012b). NRF2 also promote glutamine consumption through 
enhancing glutaminolysis and glutathione synthesis. Then, these results place NRF2 as 
the cornerstone in the interface between redox homeostasis maintenance and anabolic 
metabolism, pointing out the intimate collaboration between carbon metabolism and 
ROS detoxification systems. 
2.2.3.3 The metabolic network in the maintenance of redox homeostasis 
The metabolic network plays a fundamental role in redox homeostasis. Some metabolic 
reactions produce reduced coenzymes, such as NADPH, which are essential to the 
maintenance of the reduced antioxidants pool. On the other hand, the use of some 
metabolic routes, such as TCA cycle, can increase the concentration of ROS. In this 
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regard, the Warburg effect has often been considered as an adaptive mechanism not 
only to produce high amounts of glycolytic intermediates required for proliferation of 
cells but also to avoid ROS generation proceeding from oxidative metabolism in the 
mitochondria (Sosa et al., 2013). Besides, this high glycolytic rate also provides 
substrates for PPP that contribute to ROS homeostasis via NADPH production, as 
described earlier.  In this sense, the essential role of the enzyme G6PD in protection 
against oxidative stress is sturdily documented (Cheng et al., 2004; Gao et al., 2009a; Ho 
et al., 2000). The shunting of glycolytic intermediates towards PPP is finely regulated by 
the enzyme PKM2. This enzyme oscillates between an active tetrameric form and an 
almost inactive dimeric form. The tetrameric form displays high affinity to its substrate, 
phosphoenolpyruvate (PEP), then promoting conversion of glucose to lactate. The 
dimeric form displays low affinity by PEP, promoting the accumulation of glycolytic 
intermediates and its use in different biosynthetic processes (Mazurek, 2011). It has 
been shown that PKM2 oxidation on C358 in high ROS concentrations reduces PKM2 
activity by impairing tetramer association. (Anastasiou et al., 2011). This ROS-dependent 
inhibition of PKM2 leads to an enhanced flux of glucose-6-phosphate into the PPP 
which provides NADPH required for glutathione reductase to generate reduced 
glutathione (GSH) for ROS detoxification. The impairment of this mechanism has been 
demonstrated to result in sensitization to oxidative stress and increased apoptosis 
(Brimacombe et al., 2010). Moreover, PKM2 activity is also regulated by growth-factor 
signaling pathways. In particular, PKM2 is regulated by RAS oncogene, which induces its 
tetramerization and subsequently the Warburg effect (Mazurek, 2011; Mazurek et al., 
2001). Then, many of the oncogenes that induce both the Warburg effect and ROS 
generation simultaneously, such as RAS, are indeed inducing a dual metabolic program 
aimed to provide cancer cells with metabolic precursors and ROS protection, fulfilling 
two essential requirements for tumor progression. 
Glycolysis is not the unique metabolic pathway involved in redox homeostasis. Also 
glutaminolysis participates in redox regulation by providing carbons for NAPDH-
producing reactions catalyzed by ME and IDH (DeBerardinis et al., 2007). In an 
analogous manner to glycolysis, this pathway is regulated by oncogenes that produce 
ROS deregulation such as RAS (Son et al., 2013). In KRas-mutated pancreatic tumors, 
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glutamine supports tumor growth by fueling a KRas-regulated metabolic pathway. It 
leads to an increased NADP/NADPH ratio by enhancing a serie of reactions involving 
transaminases and malic enzyme (Son et al., 2013). 
2.3 THE STUDY OF TUMOR METABOLISM 
With the emergence of modern molecular biology, research on cancer metabolism has 
been mainly focused on the role of oncogenes and tumor suppressor genes and how 
some of these proteins regulate a particular metabolic pathway, reaction or enzyme 
(Jones and Thompson, 2009; Levine and Puzio-Kuter, 2010). Although this approach has 
contributed notably to the current knowledge in cancer metabolism, it often does not 
suffice to describe the metabolism in great detail. This approach has been traditionally 
focused on analyzing transcriptomic or proteomic data rather than metabolic 
information. For instance, transcriptomics data cannot provide information about the 
directionality or activity of biochemical pathways. Additionally many reactions compete 
for common substrates what can result in misleading conclusions on the biochemical 
status of a reaction if only a single reaction or a small portion of the metabolic network 
is considered. As a consequence, metabolism of tumor cells cannot be studied by using 
transcriptomics or proteomics data exclusively, and the inclusion of biochemical 
information will more completely characterize the metabolic phenotype of cancer cells. 
Therefore, the study of metabolism is commonly addressed from an integrated 
perspective that aims to consider the metabolic network in its entirety. To this end, 
experimental and computational approaches are joined in the framework of 
Computational Systems Biology, an emerging discipline described as the integration of 
experimental and computational approaches in order to explain and predict complex 
cellular behavior of biological systems (Borodina and Nielsen, 2005; Cascante and 
Marin, 2008; Hiller and Metallo, 2012).  
Although transcriptomics data can provide very relevant information, metabolic data is 
still required to reliably study metabolic networks. Metabolomics or “metabolome 
analysis” addresses the identification and quantification of all the metabolites of an 
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organism (Fiehn, 2002). Recent advances in mass spectrometry and NMR have allowed 
for quantification of large amount of metabolites simultaneously (Denkert et al., 2008; 
Mal et al., 2012). However, while metabolomics provides invaluable information of the 
metabolic status of a system, it only provides a picture of the metabolic status of the 
cell in a particular moment. Insights into the performance of the metabolic network 
cannot be obtained by solely analyzing the concentration of metabolites. Metabolites 
form part of the metabolic processes that occur within the living cell. The complete 
metabolic picture is a consequence of the transformation and transport of metabolites 
throughout metabolic reactions and transport processes, which are finely regulated at 
different levels, including transcription. To overcome these limitations, the analysis of 
flux distributions and the changes associated to them are explored at cellular level in 
the emergent field called fluxomics (Cascante and Marin, 2008; Winter and Kromer, 
2013). The fluxome, or the total set of fluxes in the metabolic network of a cell, 
represents an additional layer of information in Computational Systems Biology. Thus, 
metabolomics and fluxomics complement each other and allow the study of the 
metabolism in different contexts, such as tumor cell metabolism (Cascante and Marin, 
2008). 
2.3.1  Fluxomics: the study of metabolic fluxes 
2.3.1.1 Flux Balance Analysis  
Metabolic fluxes can be studied at various levels in biological systems, ranging from in 
silico constraint-based models that estimate what is stoichiometrically possible, to 
experiments that analyze individual metabolic reactions in detail.  
A traditional technique employed in the study of metabolic networks is flux balance 
analysis (FBA). It involves the computational profiling of metabolic flux distributions 
across all known biochemical reactions based on their stoichiometry (Orth et al., 2010). 
These techniques can employ annotated genome-scale metabolic networks that are 
usually pared down using gene expression data. In order to constraint the flux map 
distribution in in vitro metabolic experiments, measurements of metabolite exchanges 
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with cell culture media are needed. However, due to the complexity of these metabolic 
networks and depending on the available experimental data, there is usually an 
important level of uncertainty affecting unmeasured exchanges and internal reactions 
(ramifications, cycles, etc). The range of possible flux values for each reaction can be 
determined using linear programming techniques where each reaction flux is 
maximized or minimized while leaving all other reaction fluxes free, as applied by 
Llaneras and Pico (Llaneras and Pico, 2007) in the flux spectrum approach. In FBA, the 
usually large solution space of possible metabolic flux distributions for a particular 
network is constrained by optimizing particular objective functions (e.g., biomass 
production). However, in complex biological systems such as tumor cells, a clear 
objective function to be optimized does not exist. (Hiller and Metallo, 2012). 
2.3.1.2 13C-Metabolic Flux Analysis  
2.3.1.2.1 13C-assisted metabolomics experiments 
The use of stable isotope-labeled precursors of metabolic pathways, mainly 13C-labeled 
substrates, provides a valuable additional source of constraints for reducing the space 
of possible flux distributions together with those used in FBA mentioned above (Boren 
et al., 2001; Hellerstein and Neese, 1992). The use of 13C-labeled substrates for flux 
estimation is commonly known as 13C metabolic flux analysis (13C-MFA) (Antoniewicz, 
2013). In these methods, cells are fed with 13C-labeled substrates (also called tracers), 
resulting in 13C-labeled metabolites downstream of the tracer. Depending on the 
metabolic pathway driven by the tracer, 13C atoms are incorporated into the newly 
formed metabolites in distinct numbers and at different positions, producing 
metabolites with a particular mass isotopomer distribution. In the context of 13C 
labeling, mass isotopomer (or isotopologue) refers to isomers with specific number of 
13C substitutions and positional isotopomer (or isotopomer) to isotopes with 13C 
substitution in a specific carbon position (Paul Lee et al., 2010). Thus, mass isotopomer 
accounts for those reaction products with zero, one, two, etc. 13C substitutions, which 
are denoted as m0, m1, m2, etc. respectively. For a specific metabolite, the number of 
possible mass isotopomers, n+1, depends on the number, n, of carbons of each  
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Figure 2.8  13C-assisted metabolomics experiment using [1,2-13C2]-glucose 
The use of [1,2-13C2]-glucose allows estimating the performance of several major metabolic pathways such as
pentose phosphate pathway (PPP), glycolysis or TCA (tricarboxylic acid) cycle. The contribution of the oxidative and
the nonoxidative PPP branches to R5P (ribose-5-phosphate) production, required for the synthesis of nucleotides,
can be estimated by determining the mass isotopomer distribution of RNA ribose through quantifying the
percentage of R5P molecules containing one 13C (m1 ribose, mainly [1-13C]-R5P) or two 13C (m2 ribose, mainly [1,2-
13C2]-R5P). Also, the mass isotopomer distribution of Lac (lactate) gives information of the pathway used for glucose
metabolization, since [2,3-13C2]-Lac (m2 lactate) is produced by glycolysis whereas [3-13C]-Lac (m1 lactate) is
produced by metabolization of glucose by PPP, where [1-13C-R5P] is reintroduced into glycolysis through the
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metabolite, whereas the positional isotopomers are 2n.  For instance, three-carbon 
molecules such as lactate can potentially give 3+1=4 mass isotopomers and 23=8 
positional isotopomers. Thus, a lactate molecule denoted as m2 can correspond to three 
possible positional isotopomers (13C1-13C2-12C3, 13C1-12C2-13C3 and 12C1-13C2-13C3).  
When performing a 13C-assisted metabolomics experiment, the selection of the 
appropriate tracers and labeled products to be analyzed is a major challenge that is 
conditioned by the intracellular fluxes to be quantified and strongly influences the 
quality of the estimated fluxes (Metallo et al., 2009). Depending on the fluxes under 
study, a wide range of tracers exists. Among them, 13C-glucose and 13C-glutamine are 
the most widely used. Traditionally, 13C tracers have been employed in the study of 
microbial metabolism, where microorganisms are generally fed with single carbon 
source (Al Zaid Siddiquee et al., 2004). The issue of tracer choice is more complex in 
mammalian cell systems, which are cultured with multiple carbon sources and are 
grown in complex media containing all amino acids and often additional compounds 
such as nucleotides or lipids. Researchers have used a variety of tracers in order to 
study particular metabolic pathways, including labeled glucose, glutamine, acetate and 
atypical substrates such as propionate (Burgess et al., 2007; Collins et al., 2011; Gaglio et 
al., 2011; Rodriguez-Prados et al., 2010).  
Among 13C-glucose tracers, [1,2-13C2]-glucose is one of the most informative and widely 
used, because it allows the reliable metabolic assessment of glycolysis, pentose 
phosphate pathway, pyruvate oxidation versus carboxylation or de novo synthesis of 
lipids (Figure 2.8) (Boren et al., 2003; Marin et al., 2003; Vizan et al., 2009). However, in 
 
 
 
 
 
 
nonoxidative PPP giving m1 labeled glycolytic intermediates (for simplicity, glycolytic intermediates corresponding to
this process are not shown in the figure). Glucose entrance into the mitochondria can also be estimated by
analyzing the mass isotopomer distribution of Glu (glutamate). According to the pathway employed to shunt
pyruvate into the TCA cycle, the positional isotopomer distribution of glutamate will vary. Entrance of glucose via
PDH (pyruvate dehydrogenase) yields [4,5-13C2]-Glu, whereas entrance via PC yields [2,3-13C2]-Glu. Details about the
procedures used to determinate the mass isotopomer distribution of all these metabolites are described in Section
4.10. G6P, glucose-6-phosphate; G6PD, glucose-6-phosphate dehydrogenase; 6PG, 6-phosphogluconate; 6PGD, 6-
phosphogluconate dehydrogenase; Ri5P, ribulose-5-phosphate; X5P, xilulose-5-phosphate; TKT, transketolase;
TALDO, transaldolase; F6P, fructose-6-phosphate; F16BP, fructose-1-6-biphosphate; G3P, glyceraldehyde-3-
phosphate; Pyr, pyruvate; Cit, citrate; αKG, α-Ketoglutarate. 
2. Introduction 
 
46 
 
cancer cells, 13C-glucose does not allow for assessing the TCA cycle fluxes reliably, since, 
most 13C atoms can be excreted in the form of lactate and alanine. In this case, 13C-
glutamine tracers can be used to better resolve the activity of the TCA cycle. One of the 
most extensively used 13C-glutamine tracer is [U-13C]-glutamine (Metallo et al., 2012)  
According to the number of tracers employed in 13C-assisted metabolomics 
experiments, these can be divided in single labeling experiments and parallel labeling 
experiments. For a single 13C-assisted metabolomics experiment design, only one 
experiment is conducted, which can involve the use of a single labeled substrate (e.g 
[1,2-13C2]-glucose), a mixture of tracers of the same substrate (e.g a mixture of [1,2-
13C2]-glucose and [U-13C]-glucose) or multiple labeled substrates (e.g. [U-13C]-glucose 
and [U-13C]-glutamine). For a parallel labeling experiment design, two or more tracer 
experiments are conducted in parallel. In each experiment a different tracer set is used 
(e.g. [1,2-13C2]-glucose in one experiment and [U-13C]-glutamine in the other 
experiment). Typically, parallel experiments are started from the same seed culture to 
minimize biological variability (Ahn and Antoniewicz, 2013; Antoniewicz et al., 2006; 
Crown and Antoniewicz, 2013). Parallel experiments offer several advantages that 
include tailoring to resolve specific fluxes with high precision, reducing the length of 
labeling experiments by introducing multiple entry points of tracers, validating 
biochemical network models, and improving the performance of 13C-MFA in systems 
where the number of measurements is limited (Crown and Antoniewicz, 2013). 
2.3.1.2.2 Mass Isotopomer Distribution Analysis 
The mass isotopomer distribution of specific 13C-labeled metabolites downstream the 
tracer, in combination with measurements of the extracellular fluxes involving the tracer 
and/or other substrates, can be used to determine either some intracellular fluxes or the 
ratio among some of them. This is achieved by using simple analytical formulas based 
on the previous knowledge of the reactions that compose the metabolic network. This 
13C-MFA approach is known as Mass Isotopomer Distribution Analysis (MIDA). As an 
example, 13C tracer propagation from [1,2-13C2]-glucose to ribose can be analyzed to 
determine the approximate ratio of fluxes through the oxidative and nonoxidative 
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branches of PPP (Figure 2.8)(Alcarraz-Vizan et al., 2010; Ramos-Montoya et al., 2006). 
Glycolytic intermediate glucose-6-phosphate loses carbon 1 when metabolized through 
the oxidative PPP branch, yielding m1 ribose ([2-13C]-ribose). On the contrary, if ribose is 
synthesized trough the nonoxidative PPP branch, [1,2-13C]-glucose is converted into 
[1,2-13C]-fructose, which in turn yields m2 ribose ([1,2-13C]-ribose) through the 
nonoxidative PPP branch reactions. Likewise mass isotopomer distribution of lactate in 
combination with produced amount of lactate can be used to determine the 
approximate glucose to lactate flux via PPP and via direct glycolysis, as described in 
Section 4.11.1. In addition, 13C tracer propagation from [1,2-13C2]-glucose to glutamate 
can be analyzed to estimate the approximate relative contributions of PC and PDH to 
TCA cycle (Marin et al., 2003). Hence, MIDA provides a simple and fast way to quantify 
some metabolic fluxes and the relative use of some metabolic pathways. 
2.3.1.2.3 Fluxomics 
13C-labeled substrates can facilitate the estimation of intracellular fluxes by 
incorporating labeling data into detailed computational atom-transition metabolic 
network models. According to the mass isotopomer distribution of the downstream 
metabolites, this labeling data can correspond to isotopic or nonisotopic steady state. 
Under isotopic steady state, the isotopomer distribution of a particular metabolite 
remains stable over time, while it is changing under nonisotopic steady state. In the first 
case, mass isotopomer distributions can be predicted by analogous methods to those 
employed in FBA under steady state (Antoniewicz et al., 2006; Antoniewicz et al., 2007). 
However, isotopic steady state in extracellular metabolites can take too long to reach, 
thus limiting the application of isotopic analysis to long incubation times. To overcome 
this limitation, nonisotopic or dynamic flux analysis should be performed. This is carried 
out by combining the kinetic information of the enzymes involved in the metabolic 
network under study as well as the concentrations and isotopomer distributions of 
intermediary metabolites. Estimation of fluxes by this method requires alternative 
mathematical approaches and may offer improved resolution over isotopic steady-state 
methods (Baxter et al., 2007; Noh et al., 2006; Selivanov et al., 2006; Selivanov et al., 
2005; Selivanov et al., 2010). 
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Regardless of using isotopic or nonisotopic approaches to estimate the metabolic 
fluxes, the computational models simulate all the rearrangements of labeled carbon 
isotopes in the reaction network contributing to the obtained pattern of isotopomer 
distribution. The computed isotopomer distribution is obtained as a result of simulation 
of metabolic fluxes; the best fit of all experimental data obtained from 13C-assisted 
metabolomics experiment 
2.3.2  Metabolic control analysis: the identification of controlling 
enzymes 
When analyzing metabolic networks, questions regarding the existence of rate-limiting 
reactions often arise. The detection of the rate-limiting step in a particular metabolic 
pathway is of special relevance since variations in its activity change the flux through 
the metabolic pathway. However, some evidences show that in many cases there is not 
a unique step controlling the flux of the metabolic pathway, but the control is shared 
among various steps. (Fell, 1997). Metabolic Control Analysis (MCA) is a powerful 
approach applied to study the genetic-, enzymatic- and substrate-level regulatory 
mechanisms in metabolic networks (Fell, 1997; Kacser and Burns, 1973). In the 
framework of MCA, sensitivity coefficients are estimated to measure in what extent a 
perturbation of a system parameter (e.g. Km, Vmax or enzyme concentration) affects the 
steady state value of a system variable (e.g. metabolite concentration or flux through a 
metabolic route), when the whole system is allowed to relax to a new steady state. 
Among these sensitivity coefficients, the control coefficients are the most important.  
(Fell, 1997; Kacser and Burns, 1973). System properties of the whole metabolic network 
are described as a function of the local properties of individual enzymes (or blocks of 
enzymes). Steady state fluxes through the metabolic network, metabolite 
concentrations and control coefficients are system properties. Individual enzyme 
activities and elasticities, by contrast, are local properties, and depend on the specific 
mechanism and parameters governing the enzyme kinetics. In the framework of MCA, 
an elasticity εqk is the parameter sensitivity of the rate vq (enzyme activity) of an isolated 
reaction (at the same conditions as in the whole and system at the steady state of 
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interest) to changes in the concentration xk of one of its substrates, an inhibitor or any 
other kinetic effector of the isolated reaction (Cornish-Bowden, 2000; Fell, 1997):  
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∂
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Similarly, a concentration or flux control coefficient is a system property defined as the 
sensitivity of a steady state metabolite concentration xg or a steady state flux Jq to 
changes in some parameter p, usually the enzyme concentration that will in principle be 
proportional to the individual activity of the enzyme vk (Cornish-Bowden, 2000; Fell, 
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Therefore, the greater the control coefficient of an enzyme, the greater is its 
contribution to pathway control and regulation, being the flux or the metabolite 
concentration more sensitive to changes in the activity of this enzyme. 
Different approaches have been proposed for deriving control coefficients from 
elasticities, including methods based on matrix equations (Cascante et al., 1989a; 
Cascante et al., 1989b; Fell and Sauro, 1985; Reder, 1988; Westerhoff and Kell, 1987). 
These methods allow the derivation of large expressions describing the control 
coefficients, whose sign and magnitude are a function of the pathway stoichiometry, the 
elasticities, and the ratios of fluxes in branched pathways. In systems with moiety 
conservations, concentrations are also required (Reder, 1988). 
However, the sign of a control coefficient (positive or negative) is sufficient to predict 
whether a flux or concentration will increase or decrease when an enzyme activity is 
changed. From equations 2 and 3, a positive control coefficient indicates that changes 
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in xg or Jq will follow the same pattern as changes in enzyme activity vk. This means that 
an increase of vk will induce an increase of xg or Jq, while a decrease of vk will also 
decrease the value of xg or Jq. A negative control coefficient, on the contrary, indicates 
that changes in vk will induce an inverse effect on xg or Jq.  
Given a particular network structure and when the magnitude of elasticities are 
unknown, but not their signs, some control coefficients have fixed signs, irrespective of 
the magnitudes of the elasticities and fluxes, and they are either always positive or 
always negative (Baldazzi et al., 2010; Sen, 1996). Moreover, some control coefficients 
are always zero, and other control coefficients are sign-indeterminate, meaning they 
can be positive or negative depending on the unknown magnitude of the elasticities 
and fluxes. The classification of control coefficients according to their signs, in general 
requires only the knowledge of the metabolic network structure and direction of the 
regulatory dependencies of the network, which basically refer to the positive or 
negative sign of the elasticities: i) elasticities with respect to substrates or activators are 
always positive; ii) elasticities with respect to inhibitors (or products in reversible 
reactions) are always negative. As previously defined (Eqs. 2 and 3), each control 
coefficient predicts changes in fluxes and concentrations resulting from the change of 
one enzyme activity. The predictive value of this sensitivity coefficient is defined for 
infinitesimal changes of the enzyme activity and decays for larger changes. The positive 
or negative sign of a fixed-sign control coefficient will be maintained for larger changes 
as long as the sign of elasticities are maintained. These control coefficients with fixed 
signs can be used in order to evaluate if observed increases or decreases in fluxes and 
concentrations can be explained by observed increases or decreases in particular 
enzyme activities.  
MCA has had a considerable impact on the study of regulatory processes in central 
carbon metabolism because of the relevant information it has provided. The estimation 
of control coefficients has facilitated the correlation between changes at the molecular 
level and pathological alterations at the physiological level (Agius, 1998). Furthermore, 
what is of greater interest is the potential application of MCA to the rational design of 
drug therapies in the treatment of complexes diseases such as cancer (Cascante et al., 
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2002; Hornberg et al., 2007). According to MCA, the enzymes with the highest control 
coefficients in a given metabolic process are the most suitable sites to target drugs at 
(Boren et al., 2002). Thus, although each enzyme is essential for the existence of the 
metabolic process, the effects on the metabolic fluxes are likely to be obtained by 
modulating an enzyme with high control coefficient (Salter et al., 1994). 
2.4 TARGETING TUMOR METABOLISM 
2.4.1  Exploiting oncogene-induced metabolic dependencies 
Over the previous pages it has been described how tumor cells rewire carbon 
metabolism to fulfill metabolic requirements. This metabolic reprogramming renders 
cancer cells highly dependent on specific metabolic enzymes or pathways, thus 
providing a set of attractive therapeutic targets. Many cancer-causing genetic 
alterations converge in a single metabolic phenotype, which is characterized by cell 
autonomous nutrient uptake and reorganization of metabolic pathways to support 
biosynthesis. For instance, a vast array of mutations in PI3K and RAS induce Warburg 
effect, suggesting that glycolysis activation is a common adaptive metabolic strategy 
regardless of the genetic origin of the tumor. As it has been stated before, proliferation 
signaling pathways frequently altered in tumors promote metabolic reprogramming. In 
spite of the great progress carried out over the last decades, effective agents targeting 
many of the common driver mutations located in these signaling pathways are not 
available. Mutations in RAS or deregulated expression of MYC are frequent events in 
human cancer, but no specific therapies exist to treat cancers based on either genetic 
event, and many RAS-driven cancers are refractory to existing therapies (Linardou et al., 
2009). The presence of mutations in oncogenes and tumor suppressor genes rewire 
metabolism in such a profound way that renders cells dependent on particular 
metabolic pathways. For instance, enzymes that are involved in metabolism appear to 
be key effectors in RAS- and MYC-dependant tumorigenesis.  While RAS-mutant cells 
are dependent on glycolysis (Clem et al., 2008), MYC-dependent cells have particular 
reliance on glutamine metabolism (Dang et al., 2009; Wise et al., 2008; Yuneva et al.,  
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Figure 2.9  Rational design of potential therapies targeted to tumor metabolism. 
Each tumor adopts a proliferative metabolic solution according to a set of intrinsic or extrinsic factors that dictates
and compromises its progression and viability, resulting in a defined metabolic reprogramming profile. This profile
implies the acquisition of a set of metabolic dependencies, which can include the activation or inhibition of particular
metabolic reactions, pathways, isoforms of enzymes, etc. These metabolic dependencies represent potential
vulnerabilities in the tumor survival strategies that might be targeted by delineating an optimal therapeutic
intervention strategy. Reprinted from Cancer Discovery, Copyright © 2012, Cancer Discov 2(10): 881-898, Cantor, J.
R. and D. M. Sabatini (2012). Cancer cell metabolism: one hallmark, many faces, with permission from AACR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2007). But not only genetic alterations define a potential therapeutic intervention point 
within the metabolic network. A non-genetic component in the form of tumor 
microenvironment must additionally be considered as a component of metabolic 
reprogramming strategy. As an example, solid tumors are poorly vascularized, and 
therefore their surrounding environment can subject distinct regions of the tumor to 
spatial and temporal gradients of oxygenation, pH and nutrient availability (Tredan et 
al., 2007). All these conditions have also to be taken into consideration when 
delineating a therapeutic intervention based on tumor metabolism. Hence, genetic and 
non-genetic elements define a metabolic strategy for each tumor that implies the 
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acquisition of a set of metabolic dependencies, providing specific metabolic targets for 
an optimal therapeutic intervention (Figure 2.9) (Cantor and Sabatini, 2012). 
The metabolic network has been targeted with therapeutic purposes in a number of 
tumors (Caro et al., 2012; Possemato et al., 2011; Wang et al., 2010) and many metabolic 
pathways and enzymes have been proposed as potential therapeutic intervention points 
(Butler et al., 2013). Targeting metabolic enzymes has been shown to be effective in the 
treatment of KRAS-mutant tumors in vivo (Clem et al., 2008). Since RAS-mutated tumors 
display a high glycolytic flux, inhibition of glycolysis by small-molecule inhibitors has 
been proposed. The enzyme 6-phosphofructokinase/fructose-2,6-biphosphatase 2 
(PFK/FBPase 2 or PFKFB2) activates 6-phosphofructokinase (PKF1) by generating the 
allosteric activator fructose-2,6-biphosphate (F26BP), increasing flux through this step 
(Telang et al., 2006). Most isoforms of PFK/FBPase are bifunctional enzymes with both 
kinase and phosphatase activity, and can catalyze the destruction of the PFK/FBPase 
product reaction F26BP and decrease PFK1 activity (Yalcin et al., 2009b). The isoform 
PFK/FBPase 3 or PFKFB3 is expressed in many cancers and its expression has been 
documented to be regulated by some oncogenes such as RAS. Contrary to other 
PFK/FBPase isoforms, PFKFB3 has almost no phosphatase activity, enhancing the 
production of F26BP and promoting the Warburg effect. In addition, it has been shown 
to stimulate proliferation and to be required for anchorage-independent growth of 
RAS-driven tumors (Telang et al., 2006; Yalcin et al., 2009a). Small-molecule inhibitors of 
PFKFB3 have been reported to decrease levels of F26BP, to have cytostatic effect on 
RAS-transformed cancer cells and to impair the growth of xenograft tumors (Clem et al., 
2008). 
2.4.2  The PPP as potential cancer therapeutic target 
Warburg effect is a metabolic trait widely displayed by most cancer cells. Therefore, 
glycolysis has been a very attractive pathway to be targeted in cancer treatment and 
has been explored as a potential therapeutic target (Pelicano et al., 2006). Likewise, 
other metabolic pathways with a pivotal role in tumor metabolic reprogramming have 
been proposed to be suitable targets (Butler et al., 2013; Vander Heiden, 2011). Among 
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them, the PPP has been considered a rational therapeutic target, since it meets two 
essential requirements of cancer cells: ribose synthesis for nucleotides production and 
NADPH synthesis for ROS protection lipogenesis. The main enzymes of the PPP, G6PD 
and TKT have been proposed as potential therapeutic targets (Boros et al., 1997; de 
Atauri et al., 2011; Rais et al., 1999; Ramos-Montoya et al., 2006).  
A deficiency in G6PD is found in approximately 400 million people worldwide, with 
patients suffering mild anemia but no other serious health issues, which opens a 
potential therapeutic window for inhibition of this enzyme in cancer treatment. The 
reduction of G6PD levels seems to exert different effects on proliferation. In cancer cells, 
inhibition of G6PD leads to a clear decrease in proliferation (Li et al., 2009). 
Nevertheless, the complete absence of the enzyme in G6PD-deleted embryonic stem 
cells does not reduce proliferation, but makes cells more sensitive to strong 
antioxidants (Fico et al., 2004). On the other hand, G6PD inhibition in human foreskin 
fibroblast reduces cell growth and induces cellular senescence (Ho et al., 2000) 
 Also, the TKT enzyme has been explored as a potential therapeutic target.  It has been 
observed that inhibition of the nonoxidative PPP pathway provokes a greater decrease 
in tumor proliferation than the inhibition of the oxidative branch. In vivo testing of the 
TKT inhibitor oxythiamine and the G6PD inhibitor dehydroepiandrosterone in C57BL/6 
mice hosting Ehrlich's ascitic tumor cells revealed a 90.4 and a 46% decrease in the final 
tumor mass respectively after 3 days of treatment (Boros et al., 1997).  Likewise, the 
inhibition of TKT or G6PD by oxythiamine and dehydroepiandrosterone respectively 
results in a cell cycle arrest in Ehrlich’s ascites tumor in vivo, and the combined 
administration of both drugs resulted in a synergic effect (Rais et al., 1999). Moreover, it 
has been also reported that the ratio between oxidative and non-oxidative branches is 
critical in maintaining the metabolic efficiency in tumor cells (Ramos-Montoya et al., 
2006).  
In addition to G6PD and TKT, other enzymes of the PPP have been also described to be 
potential targets. Knockdown of 6-phosphogluconate dehydrogenase (6PGD) inhibits 
growth of lung cancer cells by senescence induction (Sukhatme and Chan, 2012). Also, 
inhibition of the nonoxidative-branch enzymes ribose-5-phosphate isomerase (RPIA) 
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and ribulose-phosphate 3-epimerase (RPE) decreases tumor growth in xenograft model 
of KRAS-induced pancreatic ductal adenocarcinoma (Ying et al., 2012). Taken together, 
these results indicate that inhibition of the PPP can be a potential therapeutic strategy 
to combat tumor progression in different cancer models. 
The inhibition of the PPP, particularly the inhibition of the oxidative branch, is especially 
attractive since it also targets the ROS protection system of cancer cells. Targeting 
cancer cells with ROS mediated mechanism has been proposed as an interesting 
therapeutic approach. As mentioned earlier, cancer cells usually work with increased 
levels of ROS and acquire protective and compensating mechanisms by activation of 
ROS detoxification mechanisms. Moderate levels of ROS can promote many aspects of 
tumor biology. However, a delicate balance exists between ROS-producing and 
removing reactions. Since this equilibrium is forced in cancer cells, they are more 
sensitive to further external insults affecting this balance, promoting ROS formation, 
inhibiting ROS removal reactions or both actions simultaneously (Trachootham et al., 
2009). Thus, given the role of G6PD in ROS detoxification, inhibition of this enzyme is 
likely to break this equilibrium, dismantling the ROS adaptive response and causing cell 
death. This hypothesis is fully supported by the fact that G6PD-deficient cells show 
enhanced oxidative stress and increased sensitivity to oxidative damage, indicating that 
G6PD plays a fundamental role controlling ROS levels, and that it might be a potential 
target in a ROS-based cancer therapy approach (Cheng et al., 2004; Gao et al., 2009a; 
Ho et al., 2000). 
2.4.3  The tumor metabolism as therapeutic opportunity in cancer 
One essential consideration when designing therapeutic strategies is in what extent a 
drug can perform its therapeutic function without affecting or damaging other healthy 
cells and tissues. This fact, commonly known as therapeutic window, is specially 
challenging when targeting cancer metabolic adaptations, since most of the cancer cells 
and normal proliferating cells rely on the same metabolic pathways. Although this is the 
case for some metabolic targets, the success of cytotoxic agents that target folate 
metabolism and DNA synthesis illustrates that a therapeutic window can exist for 
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anticancer drugs that target metabolic pathways. Most of the current therapeutic 
approaches are targeted to key proteins involved in signaling pathways and, with 
exception of gain-of-function mutations, no target is unique to cancer cells. Successful 
targeted therapies take advantage of the dependence of cancer cells on specific 
pathways. Similarly, metabolic dependencies of cancer cells can also be exploited for 
cancer treatment. To this end, a detailed and reliable knowledge of the metabolic 
phenotype of tumors both in vitro and in vivo is required. This ambitious goal can be 
achieved by an integrative approach, combining different omics targeted to reliably 
unveil the metabolic dependencies of tumors not only in vitro but also in vivo to 
establish a potential therapeutic window. 
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3. OBJECTIVES 
Over the last years, it has emerged a renewed interest in the field of metabolism, 
particularly in cancer metabolism. Great efforts have been focused on the association 
between mutated oncogenes or tumor suppressor genes and tumor metabolic profiles, 
in the search of metabolic dependencies that offer new potential venues for cancer 
treatment. The pursuit of discovering tumor metabolic alterations in which cancer cells 
rely on has represented the cornerstone of this interesting discipline. Thus, this thesis is 
part of this recent and promising scientific current and is intended to shed light on the 
metabolic alterations accompanying oncogene mutation and on potential metabolic 
pathways that might be of therapeutic interest in the future. Hence, the objectives of 
this thesis can be divided into two specific aims:   
1. Analysis of the metabolic reprogramming of RAS oncogenic activation using stable 
transfected cell lines with mutated copies of K-RAS and H-RAS. 
 
2. Validation of the pentose phosphate pathway as a potential therapeutic target and 
exploration of its role within tumor metabolism in colon and breast cancer cell models. 
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4. MATERIALS AND METHODS 
4.1  Cell Culture  
Breast cancer cell line MCF7 was purchased from ATCC and cultured in MEM media 
without phenol red (Ref. 51200, Gibco) containing 10% Fetal Bovine Serum (FBS) (Ref. 
7524, Sigma-Aldrich), 10 mM glucose (Sigma-Aldrich), 1 mM pyruvate (Biological 
Industries), 2 mM glutamine (Gibco), 0.1% antibiotic (Penicillin 10 Units/mL-
Streptomycin 10 µg/mL, Gibco), 0.01 mg/mL insulin (Sigma-Aldrich) and 1% non-
essential aminoacids (Biological Industries). HT29 and Caco-2 cell lines were cultured in 
DMEM (Ref. A14430, Gibco) containing 10% FBS (Ref. A15-151, PAA Laboratories), 10 
mM glucose, 2 mM glutamine and 0.1% antibiotic. Cell lines SW620 and SW480 were 
kindly provided by Dr. G. Capellà (Bellvitge Biomedical Research Institute, Spain) and 
cultured in RPMI 1640 media (Ref. R0883, Sigma-Aldrich) supplemented with 10% FBS 
(Ref. A15-151, PAA Laboratories) and 0.1% antibiotic. Human colonocytes cell line 
NCM460 was provided by INCELL and cultured in M3Base media (Ref. M300A, INCELL) 
supplemented with 10% FBS (Ref. A15-151, PAA Laboratories) and 10 mM glucose. 
Human fibroblasts BJ and BJ-HRasV12 were kindly provided by Dr. R. Schäfer (Charité 
Universitätsmedizin Berlin, Germany). Both cell lines were immortalized and H-RasG12V 
cassette was expressed for BJ-HRasV12 cell line generation as described in Hahn et al 
1999(Hahn et al., 1999). They were cultured in media consisted of DMEM (Ref. 11966, 
Gibco) and Medium 199 (Ref. M7653, Sigma-Aldrich) in 4:1 proportion containing 10% 
FBS (Ref. S0115, AG Biochrom), 10 mM glucose, 3 mM glutamine, 1 mM pyruvate, 0.085 
mg/mL hygromycin B (Roche), 0.4 mg/mL puromycin (Sigma-Aldrich) and 1% antibiotic. 
BJ-HRasV12 cell line was routinely cultured in presence of 0.4 mg/mL of the selection 
antibiotic geneticin (Gibco). NIH3T3, K12- and K13- transfected cells were kindly 
provided by Dr. R. Mangues (Sant Pau Biomedical Research Institute, Spain) and 
cultured in DMEM (Ref. 5796, Sigma-Aldrich) in the presence of 10% FBS (Ref. A15-151, 
PAA Laboratories), 25 mM glucose and 4 mM glutamine. K12 and K13 cells were 
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cultured in the presence of 0.25 mg/mL of the selection antibiotic geneticin (Gibco). The 
transfectants contained a K-RAS minigene with a G:C to A:T mutation at the first 
position of codon 12 (K12 cells) and a G:C to A:T mutation at the second position of 
codon 13 (K13). All FBS used in this section were held at 56 °C for 30 min for 
inactivation before use. Also, all cell lines described in this section were cultured in 
humidified atmosphere at 37 °C and 5% CO2. 
4.2 Proliferation, viability and cell cycle analysis 
Proliferation and viability assays were performed by flow citometry combining direct cell 
counting and propidium iodide (PI) staining. At the end of the experiment or as 
indicated elsewhere cells were tripsinized and resuspended in 500 µL of solution 
consisted of 450 µL of complete media, 45 µL of Flow-Count Fluorospheres (Beckman 
Coulter) and 5 µL of 1 mg/mL propidium iodide. Flow cytometer was adjusted to 1x104 
fluorospheres cut-off and total cell number was registered, allowing discrimination 
between dead and alive cells.  
Viability was also assessed by MTT assay (Mosmann, 1983), which is based upon the 
principle of reduction of MTT ((3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) into blue formazan pigments by viable mitochondria in healthy cells. Cells 
were seeded in a 96-well flat-bottom plate as indicated elsewhere and 24h later, media 
was replaced by fresh media containing the drug under study. At the end of the 
experiment, media was replaced by 0.5 mg/mL MTT solution and cells were incubated 
at 37 °C for 1h. Over this period, MTT was reduced to blue formazan. Then, media was 
removed and the formazan precipitate was dissolved in DMSO. Absorbance values were 
measured in an ELISA plate reader at 550 nm wavelength. Values were normalized to 
the absorbance of cells cultured in media without the drug under study (the 
proportional amount of drug vehicle was added to these wells). 
For cell cycle analysis by flow citometry, cells were collected at the indicated time points 
and fixed with 70% cold ethanol prior to centrifugation and resuspension in buffer 
consisted of PBS, 0.01% (v/v) Triton X-100, 1 mg/mL propidium iodide, and 0.2 mg/mL 
4. Materials and Methods 
65 
 
RNAse A (REAL Laboratories). For cell cycle phase distribution analysis the software 
FlowJo® was used, and the percentage of cells in G1, S and G2 was obtained. 
4.3  siRNA transfection 
MCF7 cell line was transfected using Metafectene (Biontex) according to the 
manufacturer’s instructions. Briefly, 1x105 cells were seeded in 6-well plates and after 
24h, 60 nM of either control siRNA (siNEG) or siRNAs against TKT (siTKT) or G6PD 
(siG6PD) were transfected. RNAi sequences employed for each gene were purchased 
from Dharmacon and are listed as follows: siNEG, ON-TARGETplus Non-targeting siRNA 
D-001810-03-20 (sequence not provided by the manufacturer); siTKT, ON-TARGETplus 
J-004734-06-0010, GGAACUAGCCGCCAAUACA; siG6PD, ON-TARGETplus J-008181-06-
0010, GAGAGUGGGUUUCCAGUAU.  
HT29 cell line was transfected using RNAi/MAX (Invitrogen) following the 
manufacturer’s instructions. Briefly, 5x104 cells were seeded in 6-well plates and after 
24h, 50 nM of G6PD siRNA pool (siG6PD, ON-TARGETplus SMARTpool, L-008181-02-
0010) or control siRNA pool (siNEG, ON-TARGETplus Non-Targeting pool, D-001810-
10-20) were transfected. The siG6PD pool includes the next sequences: 
ACAGAUACAAGAACGUGAA; CCGUGUACACCAACAUGAU; CAGAUAGGCUGGAACCGCA; 
AUUCACGAGUCCUGCAUGA. The sequences contained in the siNEG pool are not 
detailed by the manufacturer. 
4.4 RNA isolation and gene expression analysis 
RNA isolation was performed from fresh or frozen pellets or cultured plates using 
Trizol® reagent (Invitrogen) following manufacturer’s instructions. Briefly, Trizol was 
added to samples and cell homogenates were mixed with chloroform and centrifuged, 
resulting in an upper aqueous phase, an interphase, and a lower organic phase. RNA 
was precipitated from the aqueous phase by adding cold isopropanol and centrifuging 
at 12000xg for 15 min at 4 °C. Next, supernatant was removed and pellet was washed 
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three times with cold 75% ethanol. After ethanol evaporation at room temperature, 
RNA was resuspended in RNAse-free water for subsequent quantification by Nanodrop. 
Next, cDNA was obtained using 1 µg of RNA, random primers (Roche) and M-MLV 
reverse transcriptase (Invitrogen) according to the manufacturer’s indications. Gene 
expression analysis was performed by qPCR (ABI Prism 7700 Sequence Detector System, 
Applied Biosystems) in standard conditions provided by the manufacturer, employing 
Taqman® (Applied Biosystems) specific sequences for each gene (G6PD: 
Hs00166169_m1; TKT: Hs00169074_m1; NFE2L2: Hs00975961_g1; HMDX1: 
Hs01110250_m1; NQO1: Hs01045994_m1). Subsequently, expression was quantified by 
∆∆Ct method using PPIA (Hs99999904_m1) as reference gene. 
4.5 Western Blot 
Cell extracts were obtained from either fresh cells or frozen plates using lysis buffer 
consisted of 50 mM Tris-HCl pH 7.5, 1 mM EDTA, 1 mM DTT, 0.2% (v/v) Triton X-100, 0.2 
mg/mL sodium deoxycolate and 1x protease inhibitor cocktail (Sigma-Aldrich). Protein 
concentration was determined by bicinchoninic acid assay (BCA). 10-30 µg of protein 
were separated by 10% SDS-PAGE and proteins were transferred to PVDF membrane. 
After 1h blocking in PBS containing 5% non-fat dried milk and 0.1% (v/v) Tween 20, 
membranes were incubated with primary antibodies according to the conditions 
indicated below. Then the membranes were rinsed with 0.1% (v/v) PBS-Tween followed 
by exposure to the appropriate horseradish peroxidase-conjugated secondary antibody 
visualized on Fujifilm X-ray film using chemiluminescence detection system (Millipore). 
The following antibodies were used: α-G6PD (Ref. ab993, Abcam, 1/10000), α-Actin (Ref. 
691001, Millipore, 1/50000) and α-NRF2 (Ref. sc-365949, Santa Cruz, 1/100). α-G6PD 
and α-NRF2 were incubated O/N at 4 °C and α-Actin was incubated for 45 min at room 
temperature. 
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4.6 ROS levels measurement 
Total intracellular ROS levels were determined by means of flow citometry using 
H2DCFA probe (Invitrogen). Cells were incubated with 5 µM H2DCFA in PBS for 30 min. 
After that, PBS was replaced by specific cell culture media, as appropriately described 
for each case in Section 5, and cells were incubated for 15 min at 37 °C and 5% CO2. 
Next, cells were tripsinized and resuspended in a solution consisted of 50 µM H2DCFA 
and 20 µg/mL propidium iodide. Internalized probe reacts with ROS and emits 
fluorescence when excited at 492 nm. Emitted fluorescence was recorded by flow 
citometry at 520 nm wavelength. For ROS analysis, only negative PI cells were 
considered. 
4.7 Glutathione content 
Total glutathione content was determined by glutathione reductase enzymatic method. 
Fresh cells were lysed with 5% SSA (5-sulfosalicylic acid) solution, vortexed and 
disrupted by two freezing/defreezing cycles in liquid N2 and 37 °C water bath. 50 µL of 
this solution was separated for subsequent protein quantification by BCA assay. Cell 
extracts were held at 4 °C for 10 min and centrifuged at 10000xg for 10 min. For 
glutathione quantification, working solution consisted of 15 U/mL of glutathione 
reductase and 40 µg/mL of DTNB (5,5′-Dithiobis(2-nitrobenzoic acid)) dissolved in 100 
mM K2HPO4/KH2PO4, 1 mM EDTA, pH 7  was prepared. Reaction was initiated by mixing 
150 µL of working solution with up to 10 µL of cell extract or 10 µL of standard. Next, 
150 µL of 40 mg/mL NADPH solution was added and the increase in absorbance was 
recorded at 340 nm wavelength. Total glutathione concentration was normalized by 
protein content determined by BCA method. 
4.8 ATP/ADP ratio 
Nucleotides were extracted from freshly cultured cells by addition of 10% HClO4 to the 
plates, scrapping on ice and centrifugation for 5 min at 10000xg at 4 °C. Next, pH of 
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supernatant was neutralized with 5M K2CO3 and filtered using Microcon Centrifugal 
Filter Devices YM-10 10000 MWCO (Millipore) at 10000xg for 10 min. ATP and ADP 
detection and quantification were carried out by HPLC employing a Waters Acquity 
UPLC instrument equipped with a Kinetex Phenomenex column (2.6 µm C18 100 x 4.6 
mm) coupled to a DAD detector at 260 nm wavelength. Sample separation was 
performed by applying a binary gradient at a flow rate of 0.5 mL/min at 35 °C. Solvent B 
consisted of 4 mM tetrabutylammonium hydrogensulphate in 0.05 M KH2PO4, pH 6.0. 
Solvent A consisted of methanol:solvent B mixture in proportion 30:70 (v/v). The table 
below shows the gradient used:  
Time (min) % A % B
0 0 100
2.5 0 100
5 30 70
10 40 60
17 100 0
21 100 0
23 0 100
33 0 100
  
Retention time (RT) for ATP and ADP were 20.1 and 17.2 min respectively. ATP/ADP 
ratio was calculated by dividing ATP peak area by the corresponding one for ADP. 
4.9 Oxygen consumption rate 
Oxygen consumption rate was determined using Seahorse XF24 Extracellular Flux 
Analyzer instrument. 4x104 cells were seeded in XF24 plates in complete media 
described in Section 4.1 and maintained at 37 °C and 5% CO2. After 24h, media was 
replaced with non-buffered DMEM media supplemented exclusively with the carbon 
source indicated in each case for 30 min prior to oxygen consumption measurement. 
Over this period, cells were maintained in humidified atmosphere at 37 °C in non-CO2 
conditions. Oxygen measurements were carried out over 90 minutes divided into four 
periods. Within the first period, basal oxygen consumption was determined. The second 
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period begun with the injection of 1.5 µM solution of complex-V inhibitor oligomycin to 
determine the portion of oxygen consumption coupled to ATP production. It was 
calculated by subtracting oligomycin-insensitive oxygen consumption to basal oxygen 
consumption (see figure below). The third period started after addition of                    
0.5 µM solution of the uncoupler agent FCCP (Carbonyl cyanide                    
4-(trifluoromethoxy)phenylhydrazone) and finally, at the beginning of the fourth   
period, 0.5 µM solution of complex-I inhibitor rotenone was injected. The difference 
between basal and rotenone-insensitive oxygen consumption allowed for the 
calculation of basal mitochondrial oxygen consumption.  
4.10 Biochemical assays 
Glucose, lactate, glutamate and glutamine were determined by spectrophotometry 
(COBAS Mira Plus, Horiba ABX) from cell culture media by monitoring the production of 
NAD(P)H in specific reactions for each metabolite at 340 nm wavelength (de Atauri et 
al., 2011).  Glucose concentration was measured using HK and G6PD coupled enzymatic 
reactions (commercial enzymatic kit). Lactate concentration was determined by LDH 
reaction, which was carried out at 37 °C by adding media sample to a cuvette 
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containing 1.55 mg/mL NAD and 87.7 U/mL LDH in 0.2M hydrazine 12 mM EDTA buffer, 
pH 9. Determination of glutamate concentration was done by its conversion to            
α-ketoglutarate through glutamate dehydrogenase (GLDH) reaction in the presence of 
ADP. This reaction was performed at 37 °C by adding media sample to a cuvette 
containing 2.41 mM ADP, 3.9 mM NAD and 39 U/mL of GLDH in 0.5M glycine/0.5M 
hydrazine buffer, pH 9. Glutamine was determined by its conversion first to glutamate 
through glutaminase (GLS) reaction and subsequently quantification of glutamate 
concentration as described above. GLS reaction was performed by adding media 
sample to a cuvette containing a mixture consisted of 90 mU/mL GLS in 111 mM 
acetate buffer, pH 5. Reaction was carried out for 90 min at 37 °C in agitation. 
In order to calculate the consumption/production rate of each metabolite, media 
samples at the beginning and at the end of the experiment were taken and frozen for 
subsequent analysis. From the same plates, or parallel plates when required, cell 
numbers were determined through the procedure described in Section 4.2 for 
normalization. 
4.11 13C-assisted metabolomics  
13C-assited metabolomics experiments were carried out as indicated in each case in 
Section 5. In general, at the beginning of the experiment culture media was replaced by 
fresh media containing either 50% [1,2-13C2]-glucose (Sigma-Aldrich) or 100% [U-13C]-
glutamine (Sigma-Aldrich) and after the incubation period indicated in each case, 
media, pellets and cultured plates were collected. Media samples were frozen at -20 °C 
for ulterior determination of glucose, lactate, glutamate and glutamine concentrations 
as described in Section 4.10. Also, mass isotopomer distributions of glucose, lactate and 
glutamate were determined from media samples. Pellets were obtained by 
trypsinization and kept at -20 °C until used for analysis of mass isotopomer distribution 
of ribose and fatty acids. Cultured plates were frozen in liquid nitrogen and stored at     
–80 °C for mass isotopomer distribution analysis of TCA cycle intermediates. As stated 
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in Section 4.10, cell number was determined at each time point of the experiment 
following the procedure described in Section 4.2.  
Analysis of 13C-labeled intracellular and extracellular metabolites for mass isotopomer 
distribution analysis was done by gas chromatography coupled to mass spectrometry 
(GC-MS). GC-MS was performed using an Agilent 7890A GC equipped with a HP5 
capillary column connected to an Agilent 5975C MS. Fatty acids GC-MS analysis was 
performed employing a GCMS-QP 2012 Shimadzu equipped with a bpx70 (SGE) 
column. In all cases, one microliter of sample was injected at 250 °C using helium as a 
carrier gas at a flow rate of 1 mL/min. Different procedures for metabolite isolation, 
derivatization and detection were used for each metabolite as described below.  
4.11.1 Glucose 
Glucose was isolated from cell culture media using a tandem set of Dowex-1X8/ Dowex-
50WX8 ion-exchange columns, being glucose eluted with water. After that, water was 
evaporated to dryness under airflow and isolated glucose was held at 100 °C for 30 min 
with 2% (v/v) hydroxylamine hydrochloride in pyridine for derivatization. Then acetic 
anhydride was added for 1h more.  Excess of reagent and solvent were removed by 
evaporation with N2, and glucose derivative was dissolved in ethyl acetate for GC-MS 
analysis. GC-MS analysis was performed under chemical ionization mode. Sample 
injection was done at 250 °C and oven temperature was held at 230 °C for 2 min after 
injection and increased to 260 °C at 10 °C/min. Detector was run in SIM, recording ion 
abundance of C1-C6 molecule in the range of 327-336 m/z. RT was 3.8 min. 
4.11.2 Lactate 
Sample media was acidified by addition of HCl and shortly after ethyl acetate was 
added for lactate extraction and evaporated to dryness under N2. Dried lactate was 
incubated at 75 °C for 1h in presence of dimethoxypropane and methanolic chloride. 
Next, n-propilamine was added to the reaction mixture, held at 100 °C for 1h and 
evaporated to dryness under N2. Precipitate was then resuspended in dichloromethane 
and heptafluorobutyric anhydride at room temperature for 10 min. After that, sample 
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was evaporated to dryness under N2 and resuspended in dichloromethane for GC-MS 
analysis. GC-MS analysis was performed under chemical ionization mode. Sample 
injection was done at 200 °C and oven temperature was held at 100 °C for 3 min after 
injection and increased to 160 °C at 20 °C/min. Detector was run in SIM recording ion 
abundance of C1-C3 molecule in the range of 327-332 m/z. RT was 5.4 min. 
4.11.3 Glutamate 
Sample media was passed through a 3-ml Dowex-50WX8 (H+) column. Aminoacids 
were eluted from the column with 2N NH4OH, and the solution was evaporated to 
dryness by airflow. To further separate glutamate from glutamine, the aminoacid 
mixture was passed through a 3-ml Dowex-1X8 (acetate) column.  Glutamine was 
washed with water, and glutamate was collected with 0.5N acetic acid. The acid-fraction 
containing glutamate was evaporated to dryness. Dried glutamate was therefore held at 
100 °C for 1h in butanolic HCl. The excess of reagents was removed under N2 and the 
precipitate was dissolved in methylene chloride. Reaction was completed with the 
addition of trifluoroacetic anhydride. Then, samples were dried under N2, and the 
derivative was dissolved in methylene chloride for injection into GC-MS equipment. GC-
MS analysis was performed under electron impact mode to yield two fragments 
corresponding to C2-C4 and C2-C5 glutamate fragments. Sample injection was done at 
250 °C and oven temperature was held at 215 °C for 2 min after injection and increased 
to 225 °C at 9 °C/min and then to 233 °C at 3 °C/min. Detector was run in SIM mode 
recording ion abundance in the range of 151-157 m/z for C2-C4 and 197-203 m/z for 
C2-C5. RT was 3.9 min.  
4.11.4 Ribose 
Ribose from RNA was isolated from cultured cells using the aqueous phase after 
addition of Trizol® (Invitrogen) as described in Section 4.4. Purified RNA was hydrolyzed 
in 2N HCl for 2h at 100 °C and solvent was evaporated to dryness under airflow. RNA 
ribose was derivatized as previously described for glucose (see Section 4.10.1).  GC-MS 
analysis was performed under chemical ionization mode. Sample injection was done at 
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250 °C and oven temperature was held at 150 °C for 1 min after injection, increased to 
275 °C at 15 °C/min and finally to 300 °C at 40 °C/min. Detection was run in SIM 
recording ion abundance of C1-C5 molecule in the range of 256-261 m/z. RT was 5.3 
min. 
4.11.5 Palmitate 
Fatty acids from cultured cells were extracted from the inter- and lower phase of Trizol 
extract as described above (Section 4.4) by adding 100% ethanol and 30% KOH. After 
that, samples were incubated at 70 °C overnight. Then, free fatty acids were extracted 
with petroleum ether, which was subsequently evaporated to dryness under N2. Fatty 
acids were then derivatized adding 0.5N methanolic-HCl and held at 70 °C for 1h. GC-
MS analysis was performed under chemical ionization mode. Sample injection was done 
at 250 °C and oven temperature was held for 1 min at 120 °C after injection and 
increased to 220 °C at 5 °C/min. Detector was run in SIM recording ion abundance in 
the range of 269-278 m/z. RT was 9.2 min. 
4.11.6 TCA cycle intermediates  
TCA cycle intermediates from cultured cells were extracted from liquid nitrogen frozen 
cultured plates by scrapping on ice with addition of 100% methanol:H2O (1:1) mixture. 
Then, cell extracts were sonicated using a titanium probe (VibraCell, Sonics & Materials 
Inc., Tune: 50, Output: 30) and vortexed for 30 min at 4 °C. After that, samples were 
centrifuged and the upper aqueous phase was separated and evaporated to dryness 
under airflow at room temperature. TCA cycle intermediates were derivatized by 
addition of 2% (v/v) methoxyamine in pyridine and held at 37 °C for 90 min. Next, 
MBTSTFA + 1% TBDMCS was added and samples were incubated for 1h more at 55 °C 
and transferred to GC-MS vials. GC-MS analysis was under electron impact ionization. 
Sample injection was done at 270 °C and oven temperature was held at 100 °C for 3 
min, increased to 165 °C at 10 °C/min, then to 225 °C at 2.5 °C/min, to 265 °C at 25 
°C/min and finally to 300 °C at 7.5 °C/min. The following table shows the metabolites 
and m/z ranges monitored by SIM. 
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Metabolite Empirical Formula RT (min) m/z range 
Pyruvate C6H12O3NSi 8.2 173-177 
Fumarate C12H23O4Si2 18.17 286-292 
a-Ketoglutarate C14H28O5NSi2 24.56 345-352 
Malate C18H39O5Si3 27.58 418-424 
Aspartate C18H40O4NSi3 28.90 417-423 
Citrate C20H39O6Si3 37.67 458-466 
 
4.12 GC-MS data reduction  
Spectral data obtained from a mass spectrometer simply represent the distribution of 
ions of a compound or its fragments with different molecular weights. The value for 
each observed m/z is the sum of experimental isotope incorporation, the presence of 
isotopes in heteroatoms, the presence of natural abundance of 13C in the background, 
and, when corresponds, the 12C isotope impurity in the 13C-labeled precursor.  
Furthermore, the derivatizing reagents often contain isotopes which contribute to the 
mass isotopomer distribution of the derivatized compound as well.  Correction for all 
such contributions is necessary before the amount of isotope incorporation and its 
distribution in the compound of interest can be determined. This correction was 
performed by using regression analysis employing in-house developed software.  The 
algorithm used by Lee et al. corrects all the previous detailed contributions over the 
observed spectral intensities of each ion cluster, giving us the distribution of mass 
isotopomers in the metabolite of study due to incorporation of 13C atoms from the 
tracer precursor. Results of the mass isotopomers in any of the ion clusters were 
reported as fractional enrichments of molecule isotopomers. These fractional 
enrichments are defined as the fraction of molecules having a certain number of 
isotope substitutions.  They are designated as m0, m1, m2, etc., where the number 
indicates the number of labeled carbons in the molecule (see Section 2.3.1.2.1) corrected 
as described above.  Note that the sum of all mass isotopomers of the ion clusters, 
∑ ݉௜௜ୀ଴௜ୀ௡  (n = number of carbons in the molecule or fragment), is equal to 1 or 100 %. 
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4.13 Mass isotopomer distribution analysis  
4.13.1 Calculation of pathway-specific produced lactate  
The amount of lactate produced from glucose, via glycolysis or PPP, and produced from 
other substrates, can be estimated by combining the concentration and the mass 
isotopomer distribution of lactate in cell culture media from cells cultured in the 
presence of 50% [1,2-13C2]-glucose. In order to calculate these fluxes, we assumed that 
BJ and MCF7 cells do not consume lactate, so this metabolite is only produced. Thus, as 
lactate present in the media at the beginning of the incubation period does not contain 
13C coming from the tracer, it will contribute to m0 pool of total lactate at the end of 
the incubation. Taking this into account, we have first estimated the mass isotopomer 
distribution of produced lactate (total lact-initial lac). To do this, first mass isotopomer 
distribution of lactate (LacTot(m0,m1,m2,m3)t=f (%)) was multiplied per final 
concentration of lactate ([Lac]t=f) to obtain the absolute mass isotopomer distribution of 
total lactate in mM ([LacTot(m0,m1,m2,m3)]t=f (mM)) at the end of the incubation period  
(t=f) (Eq. 4):  
[LacTot(m0,m1,m2,m3)]t=f (mM) = LacTot(m0,m1,m2,m3)t=f (%) * [Lac]t=f       (4) 
Next, initial lactate concentration ([Lac]t=i) was subtracted to the concentration of total 
lactate m0 [LacTot(m0)]t=f (mM) to obtain the produced lactate in mM that does not 
contain 13C ([LacProd(m0)] (mM)) (Eq. 5). The value of produced lactate in mM that 
contains one, two o three 13C ([LacProd(m1,m2,m3)] (mM)) coincides with the  measured 
values of m1, m2 and m3 in mM in total lactate ([LacTot(m1,m2,m3)]t=f (mM)). 
 [LacProd(m0)] (mM) = [LacTot(m0)]t=f (mM) – [Lac]t=i            (5) 
Next, relative mass isotopomer distribution of produced lactate (LacProd(m0,m1,m2,m3) 
(%)) was recalculated by dividing [LacTot(m0,m1,m2,m3)]t=f (mM) values by total 
produced lactate ([LacProd] (mM)) (Eq. 6). Total produced lactate was estimated by 
subtracting initial lactate concentration to final lactate concentration (Eq. 7).  
LacProd(m0,m1,m2,m3)t=f (%) = [LacProd(m0,m1,m2,m3)]t=f (mM) / [LacProd] (mM)   (6) 
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[LacProd] (mM) = [LacTot]t=f-[LacTot]t=i                (7) 
Following, glycolytic tax (GT), which is the percentage of produced lactate that comes 
from glucose through direct glycolysis, was calculated as follows: 
GT = LacProd(m2)t=f (%) * 2/ Glc(m2)t=i (%)              (8) 
where Glc(m2)t=i is the percentage of [1,2-13C2]-glucose in the cell culture media at the 
beginning of the experiment. Next, maximum feasible amount of lactate coming from 
glycolysis ([LacProdGlyc]) was obtained by multiplying the GT per produced lactate 
([LacProd] (mM)) (Eq. 9). 
[LacProdGlyc] (mM) = GT * [LacProd] (mM)               (9) 
In order to calculate the amount of lactate from glucose coming through the PPP, first, 
Pentose Cycle (PC) parameter was calculated following the next expression (Eq. 10) 
using values of mass isotopomer distribution of total lactate. 
PC = {LacTot(m1) t=f /LacTot(m2)t=f}/{3+ LacTot(m1) t=f /LacTot(m2)t=f}        (10) 
PC parameter is defined as the relative amount of glucose metabolized through 
glycolysis related to the glucose metabolized through PPP. A detailed description of this 
parameter and the deduction of the formula employed can be found in Lee et al 1998 
(Lee et al., 1998). 
Following, lactate from glucose coming through PPP was obtained by multiplying PC 
value per the maximum feasible amount of lactate coming from glycolysis [LacProdGlyc] 
(Eq 11). 
[LacProdPPP] (mM) = PC *  [LacProdGlyc] (mM)              (11) 
In order to calculate the amount of lactate coming from other sources different of 
glucose ([LacProdOS]), the lactate produced from glycolysis ([LacProdGlyc] (mM)) and lactate 
coming from glucose through PPP ([LacProdPPP] (mM)) were subtracted to produced 
lactate ([LacProd] (mM)) (Eq 12). 
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[LacProdOS] (mM) = [LacProd] (mM) - [LacProdGlyc] (mM) - [LacProdPPP] (mM)      (12) 
4.13.2 Calculation of PC and PDH contribution to glucose entrance into the 
mitochondria  
Glucose can enter into the TCA cycle via two major enzymes: PDH, which converts 
pyruvate into acetyl-CoA, or PC, which transforms pyruvate into oxaloacetate. Acetyl-
CoA and oxaloacetate are combined in a reaction catalyzed by the enzyme citrate 
synthase that yields citrate, which is subsequently transformed into α-ketoglutarate, 
which is in equilibrium with glutamate. If a molecule of [1,2-13C2]-glucose enters into 
TCA cycle through PDH enzyme, it will yield [1,2-13C]-acetyl-CoA, which will be 
eventually transformed into [4,5-13C2]-glutamate. On the other hand, if a molecule of 
[1,2-13C2]-glucose enters into TCA cycle through PC, it will yield [2,3-13C2]-glutamate. 
The pathway employed to enter glucose into TCA cycle can be assessed by analyzing 
the mass isotopomer distribution of glutamate molecule fragments C2-C4 and C2-C5 
from cells cultured in the presence of [1,2-13C2]-glucose, as it is described in the table 
below: 
Then, the relative contribution (%) of each pathway to glucose entrance into the TCA 
cycle was calculated as follows (Sanchez-Tena et al., 2013): 
% PC = GluC2-C4(m2) / GluC2-C5(m2)                (13) 
% PDH = (GluC2-C5(m2)- GluC2-C4(m2))/ GluC2-C5(m2)            (14) 
PDH PC
[4,5-13C2]-Glutamate [2,3-13C2]-Glutamate
C2-C5 fragment m2 m2
C2-C4 fragment m1 m2
C
2-C
4
C
2-
C
5
C
2-C
4
C
2-
C
5
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4.13.3 Calculation of the glucose and glutamine contribution to synthesis of 
palmitate  
The relative contribution of glucose or glutamine to palmitate synthesis was analyzed 
by firstly calculating the fraction of 13C-acetyl-CoA (q) in total acetyl-CoA pool in cells 
cultured in the presence of 50% [1,2-13C2]-glucose or 100% [U-13C]-glutamine (Boren et 
al., 2003; Lee et al., 1995). Fraction of 13C-acetyl-CoA (q) was determined from the 
m4/m2 ratio of palmitate as follows: 
Pal(m4)t=f/Pal(m2)t=f = (n – 1)/2 * (p/q)                (15) 
where n is the number of acetyl units in the fatty acid under analysis (in our case, 
palmitate n=8), q is the labeled fraction, and p is the unlabeled fraction (p + q = 1). 
In order to estimate the glucose or glutamine contribution to synthesis of palmitate, the 
theoretical fraction of 13C-acetyl-CoA of cells cultured in the presence of the tracer must 
be estimated. 
When cells were cultured in the presence of 50% [1,2-13C2]-glucose, this theoretical 
fraction of 13C-acetyl-CoA was estimated using the next expression: 
Theoretical fraction of 13C-acetyl-CoA = Glc(m2)t=i (%)/2          (16) 
where Glc(m2)t=i is the percentage of [1,2-13C2]-glucose at the beginning of the 13C-
assisted metabolomics experiment. Since a molecule of glucose yields one 13C-acetyl-
CoA and one non-labeled acetyl-CoA, this theoretical fraction corresponds to the value 
of Glc(m2)t=i divided by 2.  
The calculation of the theoretical fraction of 13C-acetyl-CoA when using 100% [U-13C]-
glutamine is more complex. In this situation, acetyl-CoA can be produced via glutamine 
oxidative metabolism (GOM), which yields m0 acetyl-CoA, glutamine reductive 
metabolism (GRM), yielding m2 labeled acetyl-CoA, and malate dehydrogenase (MDH) -
ME reactions, which can produce m2 labeled 13C-acetyl-CoA (see Figure 4.1). Then, the 
theoretical fraction of 13C-acetyl-CoA was assumed to be as follows: 
4. Materials and Methods 
79 
 
Theoretical fraction of 13C-acetyl-CoA = (GRM + ME) / (GRM + GOM + ME)    (17) 
In the conducted experiments culturing cells in the presence of 100% [U-13C]-glutamine, 
less than 1% of 13C incorporation in pyruvate was observed (see data shown in Annex 
10.1, Table 10.1). Thus, the contribution of MDH and ME to total acetyl-CoA synthesis 
was neglected and the theoretical fraction of 13C-acetyl-CoA was assumed to be as 
follows: 
Theoretical fraction of 13C-acetyl-CoA = GRM / (GRM + GOM)        (18) 
Glutamine oxidative
metabolism (GOM)
Glutamine reductive
metabolism (GRM)
Glu
α-KG
Gln
m4 Cit
Oaa
ACoA
Pyr
Oaa
Fatty acids
Glc
Pyr
ME
m0 ACoA
MDH
Glu
α-KG
Gln
m5 Cit
Oaa
ACoA
Pyr
Oaa
Fatty acids
Glc
Pyr
ME MDH
Mal Mal m2 ACoA
Figure 4.1  Glutamine contribution to acetyl-CoA synthesis 
[U-13C]-glutamine oxidative and reductive metabolism contribute differently to acetyl-CoA synthesis, yielding m0
and m2 labeled acetyl-CoA respectively. Black arrows indicate the pathway followed by glutamine carbons, while
grey arrows denote inactive or non-used pathways. Note that malic enzyme (ME) reaction is shown as inactive in
both cases, as described in Section 4.13.3, reducing therefore the contribution of malate dehydrogenase (MDH) and
ME reactions to acetyl-CoA synthesis. Glc, glucose; Pyr, pyruvate; ACoA, acetyl-CoA; Mal, malate; Oaa, oxaloacetate;
Cit, citrate; α-KG, α-ketoglutarate; Glu, glutamate; Gln, glutamine. 
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In parallel, oxidative and reductive glutamine metabolism yield m4 and m5 labeled 
citrate respectively (Figure 4.1). Then, the relation between the fluxes through the 
oxidative and the reductive glutamine metabolism can be expressed as relation 
between m4 and m5 labeled citrate: 
GOM/GRM = Cit(m4)t=f / Cit(m5)t=f                (19) 
Thus equations 18 and 19 can be combined in order to obtain the theoretical fraction of 
13C-acetyl-CoA from 100% [U-13C]-glutamine, resulting in the next expression: 
Theoretical fraction of 13C-acetyl-CoA = Cit(m5)t=f / ((Cit(m5)t=f + Cit(m4)t=f))    (20) 
Once the theoretical enrichment was calculated, the percentage or either glucose or 
glutamine used for palmitate synthesis was determined by using the expression: 
% of contribution = q/ Theoretical fraction of 13C-acetyl-CoA         (21) 
4.14 Sugar phosphates determination  
Hexose, pentose and triose phosphates were determined in cultured plates frozen in 
liquid nitrogen by LC-MS-MS using addition curve method as described in Vizan et al 
2007 (Vizan et al., 2007). Briefly, frozen cultured plates at 80−90% of confluence were 
scraped at 4 °C by adding 2×1 mL of 100 mM acetic acid (extraction buffer) and 1 mL of 
100 mM acetic acid containing 100 ng/µL of D-ribose as internal standard. From the cell 
homogenate, 50 μL was split for protein determination by the BCA protein assay. Cell 
extract was then centrifuged at 400xg for 10 min at 4 °C. The pellet was discarded, and 
supernatant was filtered through 0.22 μm filter and frozen at −80 °C until injection. In 
parallel, calibrators (F16BP, G6P, F6P, R5P, X5P, E4P, GAP, DHAP, PEP) were diluted in 
extraction buffer and added in increasing concentrations to extra plates following the 
same procedure used for samples to generate the addition curve. HPLC 
chromatography was performed using an Agilent 1100 quaternary pump equipped with 
a refrigerated autosampler. A Nucleodex β-OH HPLC column, 200 × 4 mm i.d. (Panreac) 
was used with a binary gradient at a flow rate of 0.75 mL/min. Solvent A consisted of 10 
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mM ammonium acetate, pH 4.0. Solvent B consisted of acetonitrile. MS and MS-MS 
experiments were carried out on an API 3000 triple quadrupole mass spectrometer. The 
MRM (multiple reaction monitoring) transitions were 339/97 for F16BP, 259/97 for G6P 
and F6P (hexose phosphates, HexP), 229/97 for R5P and X5P (pentose-phosphates, 
PenP), 169/97 for GAP and DHAP (triose phosphates, TrisP) and 167/79 for PEP. 
4.15 Enzyme activities 
Fresh cell culture plates were rinsed with PBS and scrapped in lysis buffer (20 mM Tris-
HCl, pH 7.5, 1 mM dithiothreitol, 1 mM EDTA, 0.02% (v/v) Triton X-100, 0.02% (v/v) 
sodium deoxycholate) supplemented with protease inhibition cocktail (Sigma-Aldrich). 
Cell lysates were disrupted by sonication using titanium probe (VibraCell, Sonics & 
Materials Inc., Tune: 50, Output: 30) and immediately centrifuged at 12000×g for 20 min 
at 4 °C. The supernatant was separated and used for the determination of specific 
enzyme activities using a COBAS Mira Plus chemistry analyzer. All enzymatic activities 
were determined by monitoring NAD(P)H increment or decrement at 340 nm 
wavelength.  
4.15.1 Glucose-6-phosphate dehydrogenase (G6PD, EC 1.1.1.49.)  
G6PD activity was measured by adding samples to a cuvette containing 0.5 mM NADP+ 
in 50 mM Tris-HCl, pH 7.6, at 37 °C. Reaction was initiated by the addition of G6P up to 
a final concentration of 2 mM. 
4.15.2 Hexokinase (HK, EC 2.7.1.1)  
HK specific activity was determined by coupling HK and G6PD reactions in the following 
conditions: 3.3 mM NADP+, 14.8 mM ATP, 14.8 mM MgCl2, 2.8 U/mL G6PD and 50 mM 
Tris-HCl, pH 7.6, at 37 °C. Reactions were initiated by the addition of glucose up to a 
final concentration of 10 mM. 
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4.15.3 Transketolase (TKT, EC 2.2.1.1.)  
TKT specific activity was determined by adding samples to a cuvette containing 5 mM 
MgCl2, 0.2 U/mL triose phosphate isomerase, 0.2 mM NADH, 0.1 mM thiamine 
pyrophosphate in 50 mM Tris-HCl, pH 7.6, at 37 °C. The reaction was initiated by the 
addition of a substrate mixture prepared by dissolving 50 mM R5P in 50 mM Tris-HCl, 
pH 7.6, in the presence of 0.1 U/mL ribulose-5-phosphate-3-epimerase and 1.7 mU/mL 
phosphoriboisomerase. The substrate mixture was continuously stirred and held at 37 
°C  for 1 h and then kept at -20 °C until use. 
4.15.4 Pyruvate kinase (PK, EC 2.7.1.40)  
PK specific activity was determined by coupling PK and LDH reactions in the following 
conditions: 0.8 mM NADH, 1.6 mM ADP, 12.1 mM MgCl2, 36.8 mM KCl and 5.2 U/mL 
LDH in 20 mM KH2PO4/K2HPO4 buffer, pH 7.2, at 37 °C. Reactions were initiated by the 
addition of PEP up to a final concentration of 3.5 mM.  
4.15.5 Lactate Dehydrogenase (LDH, EC 1.1.1.42)  
LDH specific activity was measured by adding sample extracts to a cuvette containing 
0.2 mM NADH in 100 mM KH2PO4/K2HPO4, pH 7.4, at 37 °C. Reaction was initiated by 
the addition of pyruvate up to a final concentration of 0.2 mM. 
4.16 Statistical analysis  
For statistical analysis parametric unpaired two-tailed independent sample Student’s t-
test was used. In figures, bars represent mean ± SD and number of replicates (n) is 
indicated in each case.  One asterisk (*) denotes p-value<0.05 and two asterisks (**) 
denotes p-value<0.01 except in Chapter 5.1, where one asterisk (*) denotes                  
p-value<0.1, two asterisks (**) denotes p-value<0.05 and three asterisks (***)                
p-value<0.01. 
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                   Chapter 5.1 
Carbon Metabolism and the Sign of Control 
Coefficients in Metabolic Adaptations 
Underlying K-RAS Transformation 
This chapter corresponds to the published article (see Appendix III): 
Benito A., de Atauri P., Vizán P., Zanuy M., Mangues R., Marín S., and Cascante M. 
(2011). Carbon metabolism and the sign of control coefficients in metabolic adaptations 
underlying K-RAS transformation. Biochimica et Biophysica Acta 6, 746-754. 
5.1.1  Brief introduction and scope 
As described in the previous pages, signaling pathways control and reorganize 
metabolism to fulfill the specific energetic and biosynthetic requirements of cells for 
growth and proliferation. These requirements are especially important in proliferative 
and cancer cells. Besides, most of the oncogenic mutations in cancer are found in 
signaling pathways that regulate these processes, such as RAS signaling pathway, being 
the metabolic network rewired to support tumorigenesis. So far, no successful therapies 
targeting RAS exist and RAS-mutated tumors targeted with current therapies are often 
refractory (Linardou et al., 2009; Normanno et al., 2009). Since metabolic 
reprogramming is an essential step in tumors to progress, we sought to explore the K-
RAS induced metabolic reprogramming and to identify the key enzymes that drive this 
metabolic transition.  
Approximately 30% of human tumors are estimated to harbor activating mutations in 
one of the RAS isoforms K-RAS, N-RAS and H-RAS (Fernandez-Medarde and Santos, 
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2011). K-RAS is the most frequently mutated among the three isoforms and its mutation 
rate in all tumors is estimated to be 25-30% (Fernandez-Medarde and Santos, 2011). 
Moreover, and the RAS oncogenic mutations most commonly occur in codons 12, 13 
and 61, all them located in the GTPase catalytic domain.  
In order to unveil the key enzymes responsible for K-RAS induced metabolic 
reprogramming we employed RAS-transformed NIH-3T3 cells stably transfected with 
constitutively active K-RAS mutated at codon 12 or codon 13 (K12- and K13-
transformed cells). NIH-3T3 cells have been used as a model system to explore 
characteristics associated with cell transformation, such as a higher aerobic glycolysis 
and changes of enzyme activities (Chiaradonna et al., 2006a; Chiaradonna et al., 2006b; 
Gaglio et al., 2009; Liu et al., 2010). Depending on the specific RAS mutation transfected, 
NIH-3T3 cells induce tumors with distinct survival strategies, associated with distinct 
transforming capabilities and aggressiveness (Guerrero et al., 2000; Guerrero et al., 
2002). 
In order to derive hypotheses about the driving enzymes that contribute to the 
reprogramming of carbon metabolism: i) metabolic adaptations were characterized in 
non-transformed and K12- and K13-transformed cells by means of experimentally 
measured external and internal metabolite concentrations; ii) the range of possible flux 
values was computed for each reaction using a flux spectrum approach and the data 
obtained from external metabolite variations; iii) control coefficients with fixed signs 
were identified by only a partial knowledge based on an established network structure, 
the flux distribution and the sign pattern of the regulatory dependences, which are 
described through the sign of elasticities and iv) control coefficients with fixed signs 
were used to identify the potential enzymes responsible for the observed increases and 
decreases in fluxes and concentrations that define KRAS-induced metabolic 
reprogramming in these cells. 
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5.1.2  Results 
5.1.2.1.  Metabolic adaptations in K12- and K13-transformed NIH-3T3 cells 
5.1.2.1.1 System description  
The scheme of the whole network under study is depicted in Figure 5.1.1. Fluxes are 
represented with letter J, where Ji refers to the steady state metabolic flux through the 
ith step; concentrations are represented with letter x, where xi refers to the 
concentration of the ith metabolic intermediary; and activities are represented with 
letter v, where vi refers to the rate of the isolated reaction of the ith step. Solid arrows 
(Figure 5.1.1) – reaction steps A to Z – refer to the principal carbon metabolism, 
including glycolysis, the PPP, the tricarboxylic 
acid (TCA) cycle  and the main inputs and 
outputs. Some reactions were neglected and 
grouped into blocks – e.g. reaction step F refers 
to the block from glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) to enolase – and 
others were assumed to be involved in rapid 
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Figure 5.1.1. Network scheme.  
Each arrow indicates a reversible or irreversible reaction step 
catalyzed by an enzyme (or transporter) or one block of 
enzymes. Grey dashed lines account for the regulatory circuits 
(inhibitions and activations). Acetyl-CoA – ACoA, citrate – Cit, 
dihydroxyacetone-phosphate – DHAP, erythrose-4-phosphate 
– E4P, fructose-1,6-bisphosphate – F16BP, fructose-6-
phosphate – F6P, glucose-6-phosphate – G6P, glucose-6-
phosphate dehydrogenase – G6PD, glyceraldehyde-3-
phosphate – GAP, glyceraldehyde-3-phosphate dehydrogenase 
– GAPDH, hexokinase – HK, hexose phosphates – HexP, α-
ketoglutarate – αKG, lactate dehydrogenase – LDH, malate – 
Mal,  oxaloacetate – Oaa, pentose phosphates – PenP, 
pentose-phosphate pathway – PPP, phosphoenol pyruvate – 
PEP, phosphofructokinase  – PFK, pyruvate – Pyr, pyruvate 
kinase – PK, ribose-5-phosphate – R5P, sedoheptulose-7-
phosphate – S7P, succinate-CoA – SucCoA, transketolase – 
TKT, triose phosphates – TrisP. 
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equilibriums – e.g. glucose-6-phosphate isomerase -. Metabolites were combined into 
different pools: the pool x1 for HexP refers to G6P and F6P; the pool x2 for PenP refers 
to R5P; ribulose-5-phosphate and xylulose-5-phosphate; the pool x4 for TrisP refers to 
dihydroxyacetone-phosphate (DHAP) and glyceraldehyde-3-phosphate dehydrogenase 
(GAP); and the pool x13 refers to oxaloacetate (Oaa) and malate (Mal). The rest of 
metabolic intermediates are F16BP (x3), sedoheptulose-7-phosphate (x6; S7P), 
erythrose-4-phosphate (x5; E4P), PEP (x7), Pyr (x8), acetyl-CoA (x9; ACoA), citrate (x10; Cit), 
α-ketoglutarate (x11; αKG) and succinate-CoA (x12; SucCoA). In our system, the main 
fluxes in or out of the defined metabolic network correspond to experimentally 
measured glucose consumption (JA), glutamate from glutamine consumption (JU), and 
lactate production (JT). Additional output exchanges connected to biosynthetic 
processes were not associated with a measured value (JD, JX, JY, JZ).  
5.1.2.1.2 Flux distributions  
Under steady-state conditions, the flux balance associated with the stoichiometry 
constrains the dependences among fluxes (Kauffman et al., 2003; Llaneras and Pico, 
2007; Schilling et al., 1999). In order to estimate the different flux distributions of non-
transformed, K12- and K13-transformed cells, the fluxes for internal reactions can be 
expressed as dependent on a subset of fluxes including all output and input fluxes, e.g.:  
 JC = JE  = JA – ⅓ ( JB + 2×JD ), 
 JF = JK = 2×JA – ⅓ ( JB + 5×JD ), 
 JGf = ⅓ ( JB – JD ) + JGb ,  
 JHf = ⅓ ( JB – JD ) + JHb , 
 JIf = ⅓ ( JB – JD ) + JIb ,  
 JL =  JM =  2×JA – ⅓ ( JB + 5×JD ) – JT  + JU  – JX  – JY  – JZ , 
 JN =  2×JA – ⅓ ( JB + 5×JD ) – JT  + JU  – JX  – 2×JY  –  JZ , 
 JO = JP = 2×JA – ⅓ ( JB + 5×JD ) – JT  + 2×JU  – JX  – 2×JY  – JZ ,  
 JR =  JU  – JY – JZ ,                 (1) 
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where JGf, JHf, JIf and JGb, JHb, JIb are the forward (Jif) and backward (Jib) fluxes through the 
reversible reactions JG = JGf - JGb,  JH = JHf - JHb, and JI = JIf - JIb. An additional constraint 
was imposed based in our previous isotopomer-based analysis of non-transformed 
NIH-3T3 cells and K12- and K13-transformed cells (Vizan et al., 2005): 
 JB = f1 × JA                   (2) 
where factor f1 relates the oxidative branch of PPP (JB) with the entry of glucose (JA). This 
factor was set according to the measured ratios (Vizan et al., 2005): 0.063 ± 0.004 for 
non-transformed cells; 0.076 ± 0.012 for K12-transformed cells; and 0.153 ± 0.016 for 
K13-transformed cells. Thus, the flux through the oxidative branch of PPP was 
significantly lower than that descending through the glycolysis, and there was a 
significant increase of the flux through the PPP in transformed cells compared to non-
transformed NIH-3T3 cells. Between transformed cells, K13 mutants routed more 
glucose to the oxidative branch of PPP than K12 mutants. 
All these assumptions and measures are constraints limiting the space of solutions for 
the internal metabolic fluxes. Unfortunately, the complete system cannot be 
determined with the available measurements. Uncertainty is associated with the 
measured exchange fluxes (JA, JT, JU) and, specially, with those not measured (JX, JY, JZ, 
JD). An interval constraint satisfaction approach was applied as suggested by Llaneras 
and Picó (Llaneras and Pico, 2007) for cases where available measurements are 
insufficient and the complete flux distribution cannot be uniquely calculated. The 
feasible range of solutions satisfying all constraints was estimated for each reaction 
step. Initial lower and upper bounds for intervals were assigned to the flux through all 
reaction steps: 1) lower and upper bounds were assigned as the mean value ± 1.5 × 
standard deviation for measured fluxes JA, JT, and JU,; 2) a lower bound of zero was 
assumed for the irreversible fluxes JB, JD, JK, JL, JM, JN, JO, JR, JS, JX, JY, JZ, which were 
assumed to have positive values (0 < Ji). For each cell type, the lower and upper bounds 
were constrained to satisfy the stoichiometric description of the system (Eq. 1) and the 
isotopomer-based constraint in (Eq. 2). These intervals of fluxes satisfying all constraints 
were calculated by two independent procedures: 1) iterative interval propagation, or 2) 
solving each minimum and maximum bound through linear programming, taking 
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advantage of the linear nature of the problem. The resulting flux distributions for non-
transformed cells, K12- and K13-transformed cells are shown in Figure 5.1.2, which 
graphically depicts the interval ranges of flux values which satisfy all the constraints. As 
an example, for non-transformed cells, the initial intervals were 2.04 < JA < 3.41, 0 < JB 
< ∞, -∞ < JC < ∞, 0 < JD < ∞, -∞ < JE < ∞, -∞ < JF < ∞, 0 < JG < ∞, …, 6.63 < JT < 9.56, 
0.20 <  JU  < 0.84,  …, and the final intervals satisfying all constraints (solution space) 
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Figure 5.1.2. Comparison of fluxes. 
Non-transformed NIH-3T3 cells (white); K12-transformed cells (light gray); and K13-transformed cells (dark gray). ▲)
Increased flux in transformed cells with respect to non-transformed cells; and ▼) Decreased flux in transformed cells
with respect to non-transformed cells. Some dependent fluxes are grouped together:  JC and JE (JC,E); JF and JK (JF,K);
JG, JH and JI (JG,H,I) ; JL, JM and JN (JL,M,N); and JO and JP (JO,P). 
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Figure 5.1.3. Comparison of measured concentrations. 
Values for concentrations are proportional to the bar height for each chemical specie and error bars correspond to
standard deviations. See legend of Figure 5.1.2 for meaning of colours and triangles. As a reference for sugar
phosphate concentrations, [F16BP] = 3.229 nmol·mg prot-1, [HexP] = 1.799 nmol·mg prot-1, [PenP] = 0.726 nmol·mg
prot-1, [TrisP] = 2.710 nmol·mg prot-1 and [PEP] = 0.457 nmol·mg prot-1 for non-transformed NIH-3T3 cells. p-values
using two-tailed Student’s t-test: *: p < 0.1, **: p < 0.05; ***: p < 0.01. 
computed with both iterative interval propagation and linear programming were 2.93 < 
JA < 3.41, 0.18 < JB < 0.21, 2.86 < JC < 3.34, 0 < JD < 0.57, 2.86 < JE < 3.34, 5.80 < JF < 
6.75, -0.11 < JG < 0.07, …, 6.63 < JT < 7.59, 0.20 <  JU  < 0.84,  …. Even with the 
propagated uncertainty, substantial changes in flux distribution are detected in 
transformed cells with respect non-transformed cells, in particular for the flux pattern in 
glycolysis and the oxidative branch of the PPP. 
5.1.2.1.3 Metabolite concentrations 
Changes in fluxes were coupled with additional experimental measurement of key sugar 
phosphate concentrations. Thus, the concentrations of HexP (x1), PenP (x2), F16BP (x3), 
TrisP (x4), and PEP (x7) were measured for non-transformed and transformed cells (K12 
and K13) and are compared in Figure 5.1.3. All concentrations were found to be slightly 
decreased in transformed cells.  
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5.1.2.2.  Predicted changes in fluxes and concentrations 
5.1.2.2.1 The sign of control coefficients 
In order to identify control coefficients with fixed signs, all regulatory dependences were 
considered. The matrix approach proposed by Cascante et al (Cascante et al., 1989a) 
was applied and is depicted in Figure 5.1.4. A matrix M-1 with all concentration control 
coefficients and all independent flux control coefficients can be derived from the 
inverse of a matrix M containing all elasticities and flux dependences. The sign of the 
elasticities is taken in order to derive the sign of the control coefficients. For example, 
the dependence of G6PD (reaction step B) on its substrate (HexP, x1) corresponds to a 
positive elasticity εB1. In Figure 5.1.1, grey dashed lines account for the regulatory 
circuits – i.e. product (G6P, x1) inhibition of HK (reaction step A) (Pelicano et al., 2006), 
inhibition of phosphofructokinase (PFK, reaction step C) by Cit (x10) (Nakajima et al., 
2002) and activation of PK (reaction step K)  by F16BP (x3) (Mazurek, 2011; Mazurek et 
al., 2007), which are associated with negative (εA1), negative (εC10) and positive (εK3) 
elasticities, respectively -. Reversibility is associated with negative elasticities with 
respect to products. Finally, reaction steps D, X, Y and Z describing the demand of 
synthetic processes were assumed to be saturated with respect to their respective 
substrates and then controlled by the demand; so, the elasticities εD2, εX8, εY10, and εZ13 
were set to be zero. he sign of each control coefficient was analyzed by checking the 
positivity or negativity of the determinant |M| and the adjoint matrix in Adj(M) used for 
the derivation of the inverse:  
( )( )TMAdj
M
1M 1 =−          (3)      
Since the determinant |M| was positive, the sign depended on the adjoint matrices. The 
matrix M-1 in Figure 5.1.4.B shows all control coefficients for independent fluxes and 
concentrations derived from this analysis. Control coefficients for the dependent fluxes 
can be derived by considering the dependences among fluxes in Eq. 1 and the control 
coefficients of independent fluxes (Cascante et al., 1989a; Cascante et al., 1989b), as  
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Figure 5.1.4. Matrix estimation of the sign of control coefficients. 
Elasticities with a magnitude of zero appear as 0, while those positives are represented with a letter α (αki = εki > 0), 
and those negatives with a letter β (βki = εki > 0); control coefficients with a magnitude of zero appear as 0, while 
these positives are represented with the letter A (Aki = Cki > 0) or a symbol "+", and these negatives with the letter B 
(Bki = Cki < 0)  or a symbol "-";  Those control coefficients with indeterminate signs are represented with a letter G 
                           .../...
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.../... 
(Gki = Cki > 0 or Cki < 0) or a symbol "±". A-B. A matrix M (A) with the information containing both the stoichiometry
and the regulatory properties of the analysed system (elasticities and ratios among fluxes), is inverted to obtain the
matrix of control coefficients M-1 (B) for independent fluxes and concentrations. C. An example of estimation of a
control coefficient of dependent fluxes from the previously estimated control coefficients of independent fluxes.
D. Table of dependences connecting changes in fluxes and concentrations with changes in enzyme activities for a
subset of analyzed control coefficients. Superscripts "f" and "b" refers to net direction of reversible reactions of the
non-oxidative branch of PPP (G,H,I) following the forward or the backward directions, respectively. The net fluxes for
the remaining reversible reactions are set to follow only the forward direction according to Figure 5.1.2. Symbols
("+","-","±") identified with a black circle refer to control coefficients of very low magnitude in comparison with the
other ones. 
demonstrated in the example provided in Figure 5.1.4.C. A subset of control coefficients 
signs are presented in Figure 5.1.4.D in a table of dependences between the fluxes and 
concentrations and the main enzyme activities. Positive and negative symbols 
correspond to control coefficients with positive and negative signs, respectively. The 
signs in Figure 5.1.4.D collectively give a complete systemic predictive tool which can be 
used to evaluate the expected impact of changes in enzyme activities. Thus, the specific 
pattern of observed changes in fluxes and concentrations can be associated with 
increases or decreases in enzyme activities through analysis of the signs of control 
coefficients. For example, the observed decrease in the concentration of PEP (x7) could 
correspond to an increase of PK activity (vK), but never to a decrease. 
5.1.2.2.2 The magnitude of the control coefficients 
Analysis of the signs of metabolic control coefficients is sufficient if the aim is to predict 
the direction of changes in concentrations and fluxes. However, this previous analysis 
does not suffice if the objectives are to predict the magnitudes of these changes, and 
then the magnitude of the control coefficients is required. Unknown elasticities can be 
randomly sampled in order to derive feasible magnitudes for control coefficients (Wang 
et al., 2004). We have applied sampling procedures based on those described by Wang 
et al (Wang et al., 2004) in order to have an additional independent evaluation of the 
sign and mean magnitude of the control coefficients (results exactly match the 
computed signs). This analysis identified a subset of control coefficients which are 
always associated with small magnitudes. In the system considered (Figure 5.4.1) the 
PPP is a sub-network characterized by a flux which is much smaller than the main fluxes 
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through the rest of the network (JB <<< JC). The effect of changes in the activity 
throughout this sub-network will have minimal effect on the rest of the system, but 
these changes can have a significant effect on the concentrations and reaction steps 
inside the sub-network. The dependence of control coefficients on particular fluxes, 
such as JB, can be easily identified by inspecting the adjoint matrices. Control 
coefficients identified with black circles in Figure 5.1.4.D are directly proportional to the 
value of JB, which implies very small magnitudes due to the small flux through the 
oxidative branch of the PPP. 
5.1.2.3. Testing and validation of hypotheses based on variations in enzyme 
activities 
5.1.2.3.1 Specific activities 
The specific activities of HK (vA), G6PD (vB), TKT (vG, vH), PK (vK), and LDH (vT) were 
measured for non-transformed and transformed (K12 and K13) cells and compared in 
Figure 5.1.5.A. Increases or decreases in specific activities observed during the metabolic 
adaptation associated with the K-RAS transformation were analysed. Clear changes 
were observed in G6PD and LDH in both K12- and K13-transformed cells and also in PK 
in K13-transformed cells. In addition, slight changes for TKT were detected in both K12- 
and K13-transformed cells and. There were no significant changes in the observed HK 
activities. 
5.1.2.3.1 Do changes in measured activities satisfy the predictions for concentrations and 
fluxes?   
The table of dependences in Figure 5.1.5.B identifies both satisfied and non-satisfied 
predictions of the sign of control coefficients for those activities with measured changes 
(vB, vG, vH, vK and vT). Satisfied predictions, which are those where the direction of the 
changes in a concentration or flux is explained by the direction of the change in an 
enzyme activity, are marked in green. Otherwise, if the prediction is not satisfied, the 
sign of the control coefficients is marked in red.  For example, the increase in LDH 
activity (vT) could help to explain the measured increase in JA, but not the increased in JB, 
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which is satisfied by the increased G6PD activity (vB). Predictions regarding TKT are more 
complicated because the slight decrease of TKT activity could contribute to a predicted 
decrease of PenP levels (x2), but only if the net flux through the non-oxidative branch of 
PPP is following the backward direction to PenP as is shown in Figure 5.1.5.B. 
Indeterminate signs (±) identify control coefficients that can be positive or negative, 
depending on the relative values of the elasticities and ratios between fluxes. For a set 
of such sign-indeterminate control coefficients, only a limited combination of positive 
and negative signs is possible. Indeterminate signs (±) marked in green were used in 
Figure 5.1.5.B to highlight that a specific and feasible combination of elasticities and 
fluxes can result in a combination of signs that satisfies the changes in fluxes and 
concentrations. For example, the measured decreases in x2, x4, and x7 can be predicted 
by an increase in vT activity, which is possible because the negative control coefficients 
for C2T, C4T, and C7T can be obtained by selecting the appropriate elasticities. 
5.1.3  Discussion 
The existence of control coefficients with fixed or indeterminate signs is dependent on 
the topology of the metabolic pathway and location of regulatory loops (feedback, 
feed-forward), branches, etc. (Sen, 1996). The signs of the control coefficients estimated 
above (Figure 5.1.4) were obtained by assuming a model adapted to the available data, 
where the relevant topology and regulation are considered. Analysis of the signs of 
control coefficients in Figure 5.1.5.B provides a complete picture of the potential effect 
that any change in enzyme activities would have on systemic properties such as fluxes 
and metabolite concentrations. This picture confirms that the increased fluxes from 
glucose to lactate (JA, JC, JE, JF, JK, JT) and through the oxidative part of the PPP (JB) 
(Figure 5.1.2), and the decreased concentrations of sugar phosphates (x1, x2, x3, x4, x7) 
(Figure 5.1.3), observed in transformed cells, can be explained in part by the increased 
specific activities for G6PD (vB), PK (vK), LDH (vT), and decreased activity of TKT (vG,vH) 
(Figure 5.1.5.A). Interestingly, the differences between the phenotypes of K12- and K13-
tranformed cells (Guerrero et al., 2000; Guerrero et al., 2002) are reflected by the 
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 magnitude of the changes in fluxes and not by the sign of these changes. Changes in 
enzyme activities are also in the same direction (with the same sign of change) for both 
transformed cells with the exception of PK activity which is only increased significantly 
in the K13 cell line.  
Figure 5.1.5. Specific activities and satisfied predictions.  
A. Comparison of specific activities. See legend of Figures 5.1.2 and 5.1.3 for meaning of bar height, error bars,
colours and triangles. As a reference for specific activities, HK = 130.17 mU·mg prot-1, LDH = 2.83 U·mg prot-1,
G6PD = 215.02 mU·mg prot-1, TKT = 35.72 mU·mg prot-1 and PK = 6.98 U·mg prot-1 for non-transformed NIH-3T3
cells. P-values using two-tailed Student’s t-test: *: p < 0.1, **: p < 0.05; ***: p < 0.01. B. Satisfied predictions
represented in the table of dependences connecting changes in fluxes and concentrations with changes in enzyme
activities. See legend of Figure 5.1.4 for meaning of superscripts "f" and "b", and positive-negative symbols ("+","-
","±"). Symbols marked in green or red refers to control coefficients that can or cannot explain, respectively, the
observed change in a flux or concentration with respect to the direction of a measured change in an enzyme
activity. 
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The measured changes in specific enzyme activities accounts for changes in the enzyme 
concentrations. It should be noted that in vivo, changes affecting an enzyme activity can 
be as a result of changes on its expression but also due to a variety of events including: 
changes in cofactors, post-transductional modification or changes in oligomerization 
state among others. One example of this is the case of PK. Among the different PK 
isoforms, the M2-PK isoenzyme is expressed in all proliferating cells, including 
embryonic, tumour and NIH-3T3 cells (Mazurek et al., 2007). The M2-PK isoenzyme 
occurs in a highly active tetrameric form and in a dimeric form with low affinity for PEP 
(Mazurek, 2011). The tetramer to dimer ratio of M2-PK is not static and depends on 
F16BP levels in addition to any effects due to other external mechanisms (Mazurek, 
2011). 
The measured changes of the specific activities for G6PD (vB), PK (vK), and LDH (vT) 
satisfy the predictions based on the sign of the control coefficients. Interestingly, Figure 
5.1.5.B shows that the set of observed changes in fluxes and concentrations 
accompanying K12- and K13-transformation cannot be attributed to the perturbation of 
a single enzyme activity. According to results depicted in Figure 5.1.5.B, simultaneous 
activation of G6PD and some of the glycolytic enzymes is required in order to fully 
explain the observed pattern of changes in fluxes and metabolite concentrations. The 
experimentally measured increase in G6PD and in some glycolytic enzymes (LDH (vT) 
and PK (vK)) confirms this prediction and helps to explain qualitatively almost all 
observed increases in fluxes and decreases in concentrations, although it is likely that 
other glycolytic enzyme activities could also be increased. The predictions of Figure 
5.1.5.B are also in agreement with the available literature on tumour metabolism that 
suggests the action of transcription factors, as c-MYC and the hypoxia-inducible 
transcription factor 1 (HIF1), which are associated with the activation of oncogenes 
including transforming RAS. This leads to the reprogramming of different components 
of the cell metabolism, including higher expression for most of the genes encoding 
glycolytic enzymes (Gordan et al., 2007; Kim et al., 2007; Kim et al., 2004; Kroemer and 
Pouyssegur, 2008; Pelicano et al., 2006; Semenza, 2010; Vizán et al., 2008). Among the 
enhanced enzymes are mammalian isoforms of HK (HK1 and 2), PK (M2-PK) and LDH 
(LDH-A). We have also observed changes in LDH for both K12 and K13 cells in addition 
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to changes in PK for K13 cells. However, HK activity is not significantly altered by either 
of the two transformed cell lines. Interestingly, in the previous work of Guerrero et al 
(Guerrero et al., 2000; Guerrero et al., 2002) for the same K12- and K13-transformed 
NIH-3T3 cells used in the present study, they showed an increased expression of 
GAPDH for both transformed cell lines with respect to the non-transformed ones. From 
Figure 5.1.5.B we can predict that this increase of GAPDH (vF) can also contribute to the 
observed metabolic phenotype of transformed cells.  
Taking into account that control is distributed among the enzymes of glycolysis, it is not 
surprising that simultaneously increasing a number of different glycolytic enzymes is 
required in order to achieve a large increase in glycolytic flux. Thus, in a linear pathway, 
all the control coefficients are positive and their sum is equal to one (Fell, 1997), which 
means that, if the control is shared between several enzymes, then the magnitude of 
each individual control coefficient is expected to be quite low.  A very low control 
coefficient indicates that in order to alter the flux significantly by using modifications of 
a single enzyme, a very large change in the enzyme concentration is required. However, 
a simultaneously balanced change in all glycolytic enzyme concentrations should result 
in both a directly proportional change in the glycolytic flux and also the absence of 
change in intermediate metabolites (Kacser and Acerenza, 1993). The observed slight 
decrease in all measured metabolites could be the consequence of increased external 
demands.  
However, it is also interesting to notice that according to Figure 5.1.5.B the observed 
increase in the flux through the oxidative part of PPP is not predicted by an increase in 
measured glycolytic activities, but is clearly satisfied by an increase in G6PD activity. 
Comparing K12 and K13 cells, there is a perfect agreement between the higher G6PD 
activity and the higher flux through the oxidative part of the PPP. Regulation of the 
expression of G6PD is altered in many tumours, resulting in a significant increase in 
G6PD activity, and it has been suggested that G6PD may act as a potential oncogene 
(Kuo et al., 2000). Increased G6PD activity in NIH-3T3 cells, transfected with human 
G6PD cDNA, leads to tumorigenic transformations, dividing more quickly and inducing 
tumors in nude mice (Kuo et al., 2000). The decreased levels of PenP (x2) are not 
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compatible with the increased activity of G6PD, but are compatible with an increased 
demand of ribose (reaction step D). Also, the decreased levels of PenP can be at least in 
part a consequence of the slight decrease in the TKT activity. The two key enzymes of 
the PPP, G6PD and TKT, were both previously identified as potential targets in cancer 
therapy (Boren et al., 2002; Boros et al., 1997; Comin-Anduix et al., 2001; Rais et al., 
1999), and recently, the increased G6PD/TKT ratio was proposed as a tumour 
metabolome feature (Rais et al., 1999). The observed notorious increase of G6PD 
resulted in a higher G6PD/TKT ratio in both transformed cell lines with respect to non-
transformed cells in agreement with the results of Montoya et al (Ramos-Montoya et al., 
2006). Here, we have also found that this ratio is higher in K13 than in K12.  
Finally, it is interesting to note the fact that metabolic adaptations observed in 
transformed cells require changes in more than one enzyme, which suggests that a 
multi-hit strategy would be required to counteract metabolic adaptations in 
transformed cells.  These results support the suggestions of Moreno-Sanchez et al 
(Moreno-Sanchez et al., 2010) who proposed that a "multi-targeted MCA advised 
therapy" would be required to design efficient treatments in cancer based on the fact 
that control is shared among several steps in metabolic networks.  
In summary, it can be concluded that, the study of flux distribution in combination with 
metabolic control analysis performed by analyzing solely the sign of fixed-sign control 
coefficients, is a reliable approach to identify the key enzymes involved in metabolic 
reprogramming. The use of this methodology has allowed us to, firstly, identify an 
increase in glycolysis and PPP fluxes as metabolic features of KRAS-induced metabolic 
reprogramming and, secondly, to propose G6PD, PK and LDH as the key enzymes 
responsible for this metabolic transition. 
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Chapter 5.2 
Metabolic Reprogramming Induced by         
H-RAS Oncogenic Activation Assessed by 
13C-assisted Metabolomics 
5.2.1  Brief introduction and scope 
In the chapter 5.1 we have analyzed the metabolic reprogramming induced by K-RAS 
oncogenic activation employing NIH-3T3 cells transformed with K-RAS oncogene 
mutated either in codon 12 or 13 (K12- and K13-transformed cells). A feasible and 
accurate flux map distribution has been determined and key enzymes driving the 
metabolic transition from normal to transformed cells have been revealed. Although K-
RAS isoforms is the RAS isoform most frequently mutated in human cancers, H-RAS has 
a mutation rate of 3% in human cancers (Takashima and Faller, 2013), being 
predominantly mutated in salivary gland (15%), urinary tract (11%), and cervix (9%) 
(Pylayeva-Gupta et al., 2011). Regardless of isoform type or codon location, all these 
activating mutations render RAS proteins constitutively activated, initiating intracellular 
signaling cascade autonomously and resulting in uncontrolled cell proliferation and 
abnormal cell survival.  
The metabolic consequences of H-RAS oncogenic activation have been studied from 
different perspectives and using different systems. However, all the studies performed 
so far have examined HRas-induced metabolic reprogramming in a partial manner, 
considering only a fraction of the metabolic network. Regarding glycolysis, it has been 
reported that H-RAS oncogenic activation promotes an increase in glucose transporters, 
consumption of glucose and production of lactate (de Groof et al., 2009; Telang et al., 
2007) and HIF1α levels (Chen et al., 2001). With regard to mitochondrial metabolism, 
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both increased (Telang et al., 2007) and decreased (Yang et al., 2010) mitochondrial 
metabolism has been described in HRas-mutated cells. On the other hand, some studies 
have also focused on lipid metabolism, concluding that H-RAS promotes an increased 
release of sphingosine (Kalas et al., 2012) and increased levels of acyl-CoA synthetase 
and phosphatidylethanolamine (Momchilova and Markovska, 1999).  
All these studies provide independent pieces of evidence that reveal a portion of the 
metabolic effects derived from H-RAS oncogenic activation. Nevertheless, there is a lack 
of a deep and comprehensive metabolic approach to understand this process. Although 
these studies provide interesting metabolism-related information, only Telang and 
collaborators offered truly but limited metabolic data, obtained through 13C-assisted 
metabolomics by using [U-13C]-glucose (Telang et al., 2007).  
Thus, with the aim to explore in great detail the metabolic reprogramming induced by 
the mutation HRasV12 in human cells, we assessed BJLT+/hTERT+/HRasV12- (BJ) and  
BJLT+/hTERT+/HRasV12+ (BJ-HRasV12) cells  through 13C-assisted metabolomics using 13C-
glucose and 13C-glutamine in parallel experiments. In order to achieve this aim: i) 
extracellular fluxes concerning the main metabolic substrates were determined and 
nutrient sensitivity analysis was performed; ii) 13C-assisted metabolomics parallel 
experiments using [1,2-13C2]-glucose and [U-13C]-glutamine were carried out and mass 
isotopomer distribution of several metabolites as well as state of different metabolic 
pathways were determined, and iii) mitochondrial metabolism was analyzed by 
measuring oxygen consumption rate in the presence of different carbon substrates. 
5.2.2 Results 
5.2.2.1 H-RAS oncogenic activation promotes global metabolic network 
reorganization 
The intimate interconnection between signaling and metabolic events is of major 
relevance to ensure cell proliferation and survival. Such a tight relation is particularly 
essential in cancer, where oncogenes trigger a metabolic rewiring that guarantees the 
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Figure  5.2.1. Extracellular fluxes and nutrient sensitivity analysis for BJ and BJ-HRasV12 cells 
Metabolite consumption/production and cell proliferation were determined over a period of 24h. A. Glucose (Glc)
and glutamine (Gln) consumptions and lactate (Lac) and glutamate (Glu) production. Bars represent mean ± SD of
n=6.  B. Cell proliferation under the indicated nutritional conditions. Cells were counted through flow citometry and
relative increment in total cell number compared with cells grown in complete media is depicted. Concentration of
each nutrient is shown below the plot. Bars represent mean ± SD of n=3. Significant differences compared with BJ
cells were assessed by two-tailed Student’s t-test. * p<0.05, **p<0.01.  
fulfillment of the metabolic requirements. Glucose and glutamine account for the two 
major sources of energy and building blocks for synthesis of macromolecules. Then, we 
first determined how H-RAS oncogenic activation affected the metabolism of these two 
nutrients in BJ cells (Figure 5.2.1.A). We observed that H-RAS activation induced an 
increase of 80% in glucose uptake and 90% in lactate secretion. Likewise, we also found 
a 45% increase in glutamine consumption and a 30% increase in glutamate secretion, 
highlighting the importance of the mitochondrial metabolism in BJ-HRasV12 cells. 
5.2.2.2 BJ-HRasV12 cells display increased sensitivity to glucose or glutamine 
deprivation 
We next examined if the increased glucose and glutamine consumption induced by H-
RAS resulted in increased sensitivity of BJ-HRasV12 cells to glucose or glutamine 
deprivation (Figure 5.2.1.B). Measurements of cell proliferation after 24h of culture in 
low glucose concentration (1 mM) or glutamine-free media showed that BJ-HRasV12 
proliferation decreased around 60 and 80% respectively, whereas BJ cells experienced a 
 
 
 
 
 
 
 
-1.0
-0.5
0.0
0.5
1.0
1.5
2.0
Glc Lac Gln x5 Glu x10
M
et
ab
ol
ite
co
ns
um
pt
io
n/
pr
od
uc
tio
n
µm
ol
 x
 h
-1
x 
10
6
ce
l-1
BJ
BJ-HRasV12
0
20
40
60
80
100
120
Pr
ol
ife
ra
tio
n
(%
)
BJ
BJ-HRasV12
A
Glc (mM)
Gln (mM)
10
2
1
2
10
0
B
**
** **
** **
*
5. Results and Discussion 
 
104 
 
 decrease of 40% and 60%. It is worth noting that both cell lines grow at similar rate 
when cultured in complete media (data not shown) (Hahn et al., 1999). Then, these 
results further support the enhanced nutrient requirements of BJ-HRasV12 cells 
described in the previous section. 
5.2.2.3 13C-assisted metabolomics reveals a differential utilization of glucose- 
and glutamine-derived carbons in BJ-HRasV12 cells 
Given the clear changes detected in the metabolism of glucose and glutamine, we 
sought to explore the fate of the carbons of both substrates as well as the utilization of 
the main metabolic pathways involved in central carbon metabolism in BJ and BJ-
HRasV12 cells. To this end, we cultured BJ and BJ-HRasV12 cells in the presence of 
either [1,2-13C2]- glucose or [U-13C]-glutamine and the mass isotopomer distribution of 
several metabolites was analyzed by GC-MS (see raw data in Appendix I).  
5.2.2.3.1 H-RAS oncogenic activation induces an increase in lactate production 
One of the main features of the Warburg effect is the increased conversion of glucose 
into lactate. The production of lactate from glucose through direct glycolysis or through 
PPP was quantified analyzing the mass isotopomer distribution of lactate in 
combination with the concentration of this metabolite in the cell culture media using 
data from experiments where up to 50% of [1,2-13C2]-glucose was used as tracer.     
[1,2-13C2]-glucose metabolized through direct glycolysis yields m2 lactate, whereas its 
metabolization through PPP yields m1 lactate. Then, pathway-specific production of 
lactate can be calculated based on this fact by using the equations described in Section 
4.13.1. As shown in Figure 5.2.2.A, BJ-HRasV12 cells exhibited a 2-fold increase in the 
flux from glucose to lactate via glycolysis and via PPP. Also, lactate coming from other 
sources of carbon (OS) different than glucose was estimated using the methods 
described in the above-mentioned section. Results showed that BJ-HRasV12 exhibited 
over 2-fold increase in the flux of lactate from OS (Figure 5.2.2.A) indicating that BJ-
HRasV12 cells can metabolize other substrates in a larger amount than BJ cells.  
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Figure 5.2.2. Glycolysis and PPP utilization in BJ and BJ-HRasV12 
BJ and BJ-HRasV12 cells were cultured for 8 and 24h in the presence of 50% [1,2-13C2]-glucose. Media for lactate
concentration and mass isotopomer distribution determinations and pellets for RNA ribose mass isotopomer
analysis were taken at 8 and 24h. A. Pathway-specific produced lactate fluxes. Lactate production and mass
isotopomer distribution of lactate were combined as described in Section 4.13.1 to estimate the lactate produced
from glucose through direct glycolysis or diverted through PPP and the lactate coming from other sources (OS).
B. Total 13C-ribose from RNA, represented as the sum of m1+m2+m3+m4 (∑m). C. Ribose mass isotopomer
distribution. D. Specific activities of a panel of PPP and glycolytic enzymes. Data represents the BJ-HRasV12/BJ ratio.
The value for each specific enzyme activity expressed in U x 106 cells-1 are as follows: HK (Hexokinase): BJ=23.74, BJ-
HRasV12=45.31; GAPD (Glyceraldehyde-3-phosphate dehydrogenase): BJ=8.94, BJ-HRasV12=29.38; PK (Pyruvate
Kinase): BJ=275.48, BJ-HRasV12=1463.39; LDH (Lactate dehydrogenase): BJ=1650.09, BJ-HRasV12=1622.35; G6PD
(Glucose-6-phosphate dehydrogenase): BJ=33.74, BJ-HRasV12=49.57; TKT (Transketolase): BJ=1.65, BJ-
HRasV12=4.34.. In all cases, bars represent mean ± SD of n=3. Significant differences compared with BJ were
assessed by two-tailed Student’s t-test. * p<0.05, **p<0.01.  
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5.2.2.3.2 H-RAS oncogenic activation induces an increase in ribose synthesis 
Since our results indicate that BJ-HRasV12 cells displayed increased lactate production 
not only through glycolysis but also through PPP, the mass isotopomer distribution of 
the end-product of this pathway, ribose, was analyzed. Ribose can be synthesized 
through the oxidative and the non-oxidative branches of PPP, resulting mainly in m1 
and m2 labeled ribose respectively when up to 50% [1,2-13C2]-glucose is used as tracer. 
First, we observed that H-RAS oncogenic activation slightly enhanced the synthesis of 
ribose after 24h of incubation (Figure 5.2.2.B). Moreover, analysis of mass isotopomer 
distribution of ribose from RNA revealed an increase in m1 and m2 labeled ribose after 
24h incubation, indicating that both oxidative and non-oxidative pathways were 
activated in BJ-HRasV12 cells (Figure 5.2.2.C). In order to investigate whether changes in 
fluxes are accompanied by changes at proteomic level, we examined a panel of enzyme 
activities involved in glycolysis and PPP (Figure 5.2.2.D). Key glycolytic enzymes such as 
HK, GAPDH and PK were found to be incremented in a range from 2- to 5-fold in BJ-
HRasV12 cells compared to BJ cells. A striking exception was the case of LDH, which was 
found to be slightly diminished in BJ-HRasV12 cells. Likewise, the specific activity of the 
two key enzymes of PPP was determined. In consistence with the mass isotopomer 
distribution found in ribose, G6PD and TKT activities were found to be overactivated in 
BJ-HRasV12 cells. This data indicates that H-RAS oncogenic activation promotes not 
only an increase in metabolic fluxes but also changes in the concentration of the 
enzymes that participate in these pathways. 
5.2.2.3.3. H-RAS oncogenic activation induces an increase of glucose-derived carbons in 
the TCA cycle 
After characterizing the metabolic reprogramming in the upper part of the carbon 
metabolic network, we wanted to explore the glucose utilization in the mitochondria. 
Thus, we analyzed the mass isotopomer distribution of several TCA cycle intermediates. 
Since cells were cultured in the presence of [1,2-13C2]-glucose, TCA cycle metabolites 
were expected to mostly show m2 labeling as a result of the first turn in the TCA cycle  
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Figure 5.2.3. Glucose-derived carbons entrance into the TCA cycle 
A. Carbon atom transition map for TCA cycle intermediates using 50% [1,2-13C2]-glucose as tracer. Pyruvate can
enter into the TCA cycle via pyruvate dehydrogenase (PDH, black molecules) or pyruvate carboxylase (PC, red
molecules). For each metabolite, black and red molecules represent the labeling pattern corresponding to the first
turn, while blue molecules are the result of the reaction of a formed [1,2-13C2]-oxaloacetate with an unlabeled
acetyl-CoA (second turn of TCA cycle). As an example, in the first turn, the initial labeled oxaloacetate coming from
PC (red molecule) reacts with an unlabeled acetyl-CoA while, in the second turn (blue molecules), a labeled
oxaloacetate coming from PC or PDH reacts with an unlabelled acetyl-CoA. Note the differential mass isotopomer
distribution of glutamate according to the reaction employed to enter pyruvate into the mitochondria. B. Mass
isotopomer distribution of C2-C5 and C2-C4 glutamate fragments. Cells were cultured as described in Figure 5.2.2
                          …/… 
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(Figure 5.2.3.A). [2,3-13C2]-pyruvate can enter into the TCA cycle via PDH, yielding a 
molecule of [1,2-13C]-acetylCoA, or via PC, producing a molecule of [2,3-13C2]-
oxaloacetate. The usage of these two reactions can be assessed by mass isotopomer 
distribution analysis of the glutamate molecule fragments C2-C5 and C2-C4 as 
described in Section 4.11.2. Thus, we observed an increase in m1 and m2 labeled C2-C5 
and C2-C4 glutamate fragments in BJ-HRasV12 cells, indicating that these cells retained 
more label from glucose in glutamate than BJ cells (Figure 5.2.3.B). Nevertheless, no 
differences were found in the relative contribution of PDH and PC to glucose-derived 
carbons entrance into the mitochondria, being the former the main entrance pathway in 
both cell lines (Figure 5.2.3.C).  
Furthermore, mass isotopomer distribution of other TCA cycle intermediates such as 
citrate, malate, fumarate and α-ketoglutarate were analyzed. In general, we observed 
that a greater extent of glucose-derived carbons is routed into the mitochondria in BJ-
HRasV12 cells compared with BJ cells (Figure 5.2.4). The main differences were found in 
m2 labeling, which was clearly higher in the mutated cells in all the analyzed 
metabolites. Additionally, also m1, m3 and m4 labeling were significantly increased in 
BJ-HRasV12 cells, suggesting a more intense mitochondrial activity in these cells.  
5.2.2.3.4 H-RAS oncogenic activation induces an increase of glutamine-derived carbons 
in the TCA cycle 
Although a significant part of the glucose is routed into the mitochondria, glutamine is 
the main substrate employed in the mitochondrial metabolism. In order to understand 
how H-RAS alters mitochondrial and glutamine metabolism, we cultured cells in the 
presence of 100% [U-13C]-glutamine. Glutamine is transformed in glutamate and 
subsequently deaminated to α-ketoglutarate, which is decarboxilated to fumarate in a 
process named oxidative glutamine metabolism (Figure 5.2.5.A black arrows). Then, 
…/… 
and media after 24h was used for glutamate mass isotopomer distribution analysis. Glutamate molecules were
fragmented by EI ionization yielding C2-C5 and C2-C4 fragments. C. Relative contribution of PDH and PC to
pyruvate entry into TCA cycle.C2-C5 and C2-C4 glutamate fragments mass isotopomer distribution for 24h was
employed in the calculations, performed as described in Section 4.13.2. In all cases, bars represent mean ± SD of
n=3. Significant differences in comparison with BJ cells were assessed by two-tailed Student’s t-test. * p<0.05,
**p<0.01. 
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glutamine generates m4 labeled TCA cycle intermediates in the first turn (Figure 5.2.5.A,  
black molecules) and m2 labeled intermediates in the second turn (Figure 5.2.5.A, blue  
molecules). Alternatively, α-ketoglutarate can be carboxilated to isocitrate which is 
subsequently transformed to citrate in a process described as a glutamine reductive 
carboxilation (Figure 5.2.5.A red arrows and molecules). This process is characterized by 
the generation of m5 citrate and m3 labeled TCA cycle intermediates, such as malate, 
fumarate and α-ketoglutarate. As it is shown in Figure 5.2.5.B, we measured a robust 
and significant increase in m4 citrate, malate and fumarate, demonstrating an activated 
glutaminolysis in BJ-HRasV12 cells. Also, m5 and m3 citrate were incremented,  
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Figure 5.2.4. Glucose-derived carbons utilization in the TCA cycle 
TCA cycle intermediates mass isotopomer distribution after 24h of culture in the presence of 50% [1,2-13C2]-glucose.
Bars represent mean ± SD of n=3. Significant differences compared with BJ cells were assessed by two-tailed
Student’s t-test .* p<0.05, **p<0.01. 
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Figure 5.2.5. Glutamine-derived carbons utilization in the TCA cycle 
A. Carbon atom transition map using [U-13C]-glutamine as tracer. Oxidative (black molecules represent first round
and blue molecules second round) and reductive (red molecules) glutamine metabolism are represented.
Chapter 5.2 
111 
 
suggesting an enhanced glutamine reductive metabolism. In order to know if H-RAS 
induces changes in the relative use of the oxidative and reductive glutamine 
metabolism, the relative contribution of glutamine to citrate synthesis via oxidative or 
reductive metabolism was estimated by calculating m4/m5 citrate ratio. No differences 
were found in this ratio, which was 2.21 ± 0.06 and 2.25 ± 0.01 for BJ and BJ-HRasV12 
cells, suggesting that H-RAS oncogenic activation enhances both reductive and 
oxidative glutamine metabolism. 
5.2.2.4 BJ-HRasV12 cells show an enhanced mitochondrial metabolism and 
oxygen consumption 
TCA cycle reactions are coupled to electron transport chain where oxygen is consumed. 
Thus, oxygen consumption measurement is a very reliable assay to explore the 
performance of mitochondrial metabolism. Keeping on searching the metabolic 
consequences of H-RAS oncogenic activation on glucose and glutamine metabolism, 
we determined the oxygen consumption rate (OCR) in BJ and BJ-HRasV12 cells in the 
presence of basal media (non-supplemented DMEM) or in the presence of media 
supplemented exclusively with glucose (10 mM) or glutamine (2 mM). We also used the 
complex-I inhibitor rotenone and complex-V inhibitor oligomycin to calculate the 
portion of oxygen consumed in the mitochondria and the portion of oxygen consumed 
associated to ATP production respectively (see Section 4.9). As shown in Figure 5.2.6.A 
we found that BJ-HRasV12 cells displayed an increased basal mitochondrial OCR either 
in basal media or in the presence of glutamine compared with BJ cells, indicating that 
the oncogenic activation of H-RAS conferred to BJ cells an increased capability of 
mitochondrial substrate oxidation. Additionally, this increase in oxidation of glutamine 
was found to be coupled to ATP production (Figure 5.2.6.B), indicating that this 
substrate represents a more important energetic source in BJ-HRasV12 cells. On the 
 
 
Note that m3 labeled malate can be reintroduced into TCA cycle producing  m3 labeled oxaloacetate, citrate and
isocitrate and m2 labeled α-ketoglutarate, succinate and fumarate B. TCA cycle intermediates mass isotopomer
distribution after 8 h of incubation with [U-13C]-glutamine. Bars represent mean ± SD of n=3. Significant differences
compared with BJ cells were assessed by two-tailed Student’s t-test.* p<0.05, **p<0.01. 
5. Results and Discussion 
 
112 
 
Figure 5.2.6 Oxygen consumption rate of BJ and BJ-HRasV12 cells 
Oxygen consumption rate (OCR) was determined by Seahorse XF24 Extracellular Flux Analyzer instrument. 4x104
cells/well were seeded in XF24 plates and, after 24h, media was replaced by non-buffered media supplemented with
the indicted carbon sources prior to OCR determination. Basal media corresponds to non-supplemented DMEM.
A. Basal mitochondrial respiration. It was determined by registering total oxygen consumption and subtracting the
remaining portion of oxygen consumption after addition of complex-I inhibitor rotenone, as described in Section
4.9.  B. ATP-coupled respiration. It was determined by registering total oxygen consumption and subtracting the
remaining portion of oxygen consumption after addition of complex-V inhibitor oligomycin, as described in Section
4.9. Bars represent mean ± SD of n=3 independent experiments. Significant differences compared with BJ cells were
assessed by two-tailed Student’s t-test.* p<0.05, **p<0.01. 
 
 
 
 
 
 
 
 
contrary, no differences between BJ and BJ-HRasV12 cells were detected in the OCR in 
the presence of glucose. Notably, OCR decreased in both cell lines in this condition, 
compared with assays performed in the presence of basal-media or glutamine, 
suggesting that mitochondrial metabolism is downregulated in the presence of glucose. 
5.2.2.5 H-RAS oncogenic activation promotes lipogenesis 
Mitochondrial metabolism is a source of precursors for synthesis of macromolecules 
such as lipids. Given the detected activation of mitochondrial metabolism, we explored 
the metabolic status of lipogenesis. Citrate can be exported to the cytoplasm and 
cleaved by ACLY to oxaloacetate and acetyl-CoA, which in turn is used for lipid 
synthesis. Palmitate is the first fatty acid synthesized in lipogenesis. Then, in order to 
examine the status of lipogenesis, we analyzed the mass isotopomer distribution of 
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palmitate in BJ and BJ-HRasV12 cells cultured in the presence of [1,2-13C2]-glucose or  
[U-13C]-glutamine (Figure 5.2.7.A-B). A notable increase in m2 and m4 labeled palmitate 
was found in BJ-HRasV12 cells compared with BJ cells when they were cultured with 
[1,2-13C2]-glucose for 8h (Figure 5.2.7.A). Likewise, a parallel increase was also found 
when cells were cultured with [U-13C]-glutamine for 8h (Figure 5.2.7.B). These results 
suggest that a greater amount of glucose- and glutamine-derived carbons is routed 
into lipogenesis in BJ-HRasV12 cells compared with BJ.  
Next, we quantified the contribution of consumed glucose and glutamine to lipid 
synthesis in each cell line using the equations described in Section 4.13.3. Thus, our 
calculations showed that glucose contributed to lipid synthesis in a greater extent in BJ-
HRasV12 cells than in BJ cells (Figure 5.2.7.C). Approximately, 35% of glucose was 
routed towards fatty acid synthesis in BJ cells, whereas it was around 42% in BJ-
HRasV12 cells. On the contrary, although BJ-HRasV12 cells consumed a larger amount 
of glutamine, it contributed in a minor extent to lipid synthesis in these cells. BJ-
HRasV12 cells routed into lipogenesis around 26% of the consumed glutamine, whereas 
this value was 33% in BJ cells. Hence, it suggests that part of the consumed glutamine 
has different fates in BJ-HRasV12 than in BJ cells.  
In order to provide independent and parallel evidence for enhanced lipogenesis in BJ-
HRasV12 cells and its importance in cell proliferation and viability, we cultured BJ and 
BJ-HRasV12 cells in the presence of 25 µM of C75 FAS inhibitor. An increased sensitivity 
of BJ-HRasV12 cells to lipogenesis impairment through FAS inhibition was observed, as 
shown in Figure 5.2.7.D, which is in consistence with the metabolic data, fully supporting 
an upregulation of lipogenesis in these cells. Taken together this data indicates that 
lipogenesis might play a pivotal role in H-RAS induced metabolic reprogramming. 
5.2.3  Discussion 
Our study provides an exhaustive characterization of the metabolic reprogramming 
induced by H-RAS oncogenic activation in BJ cells. Here, we have first shown that 
 
5. Results and Discussion 
 
114 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2.7. Fatty acid synthesis in BJ and BJ-HRasV12 cells 
A-B. Mass isotopomer distribution of palmitate after incubation of cells with 50% [1,2-13C2]-glucose or [U-13C]-
glutamine over a period of 8 or 24h. C. Glucose and glutamine contribution to palmitate synthesis. These ratios were
calculated as described in Section 4.13.3 using data from 8h incubation. D. Cell viability in the presence of 25 µM of
the fatty acid synthase (FAS) inhibitor C75. 1500 cells/p96 well were seeded and after 24h media was replaced by
media containing increasing concentrations of the inhibitor. After 24h of incubation, cell viability was determined by
MTT assay as described in Section 4.2. Results for each cell line were normalized to the absorbance of the
corresponding cell line cultured in complete media. In all cases, bars represent mean ± SD of n=3. Significant
differences compared with BJ cells were assessed by two-tailed Student’s t-test.* p<0.05, **p<0.01. 
0
10
20
30
40
50
Glucose Glutamine
C
on
tri
bu
tio
n 
to
 p
al
m
ita
te
 
sy
nt
he
si
s (
%
)
BJ
BJ-HRasV12
0
2
4
6
8
10
12
m1 m2 m3 m4 m5 m6 m7 m8
13
C
 –
Pa
lm
ita
te
 (%
)
BJ 8h
BJ-HRasV12 8h
BJ 24h
BJ-HRasV12 24h
[1,2-13C2]-glucose
0
2
4
6
8
10
12
m1 m2 m3 m4 m5 m6 m7 m8
13
C
 –
Pa
lm
ita
te
 (%
)
BJ 8h
BJ-HRasV12 8h
BJ 24h
BJ-HRasV12 24h
[U-13C]-glutamine
A
B
0.0
0.2
0.4
0.6
0.8
BJ BJ-HRasV12
R
el
at
iv
e 
pr
ol
ife
ra
tio
n 
(%
)
C D
**
**
**
** **
**
*
Chapter 5.2 
115 
 
H-RAS oncogenic activation promoted an increase in glucose consumption and 
glycolytic flux. This finding is in agreement with previous reports describing that Rat1 
fibroblasts  transformed with H-RAS (Chen et al., 2001) and overexpression of mutated 
N-RAS in 3T3-L1 mouse fibroblasts (Kozma et al., 1993) increase glucose uptake by 
upregulating glucose transporters. Additionally, K-RAS has also been demonstrated to 
upregulate glycolytic flux in inducible Kras(G12D)-driven pancreatic adenocarcinoma 
mouse model (Ying et al., 2012). One of the described mechanisms of action leading to 
this upregulation is by increasing the expression of the FB3 isoform of the enzyme 
PFK/FBPase (PFKFB3), producing high levels F26BP, the allosteric activator of PFK1, and 
subsequently increasing the glycolytic flux (Clem et al., 2008; Telang et al., 2006; Yalcin 
et al., 2009). Furthermore, different RAS isoforms also activate HIF1α expression, which 
in turn upregulates the expression of many glycolytic enzymes and promotes glucose 
shunt towards lactate by negatively regulating PDH flux, increasing then lactate 
secretion (Blum et al., 2005; Chun et al., 2010). Despite in the present work the levels of 
F26BP and HIF1α have not been tested, these two potential mechanisms are perfectly 
suitable to explain our results. 
Moreover, our results indicated that BJ-HRasV12 cells display an activation of the PPP. 
This is fully supported by the increase in lactate produced from glucose via PPP, the 
percentage of m1 and m2 labeled ribose, and G6PD and TKT specific enzyme activities. 
Similar results have been reported in NIH3T3 mouse fibroblasts transfected with a 
mutated copy of K-RAS oncogene (de Atauri et al., 2011; Vizan et al., 2005). The 
observed increase in the use of oxidative branch of the PPP well might be intended to 
redox homeostasis maintenance. It has been documented that H-RAS and K-RAS 
oncogenic activation induce an increment in ROS levels (Dolado et al., 2007) (Hu et al., 
2012) and the activation of the oxidative branch of the PPP might represent a 
compensatory mechanism activated in order to deal with oxidative stress (Recktenwald 
et al., 2008; Young et al., 2004). Additionally, the activation of the oxidative branch of 
the PPP provides cells with NADPH required for lipogenesis, which, as shown here, is 
also enhanced in BJ-HRasV12 cells. With regard to the nonoxidative branch, K-RAS has 
also been described to activate this branch of the PPP for ribose biosynthesis in 
pancreatic adenocarcinoma cancer cells (Ying et al., 2012). Thus, it seems that RAS 
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exerts a variety of effects on PPP, all of them converging in the partial or complete 
upregulation of this pathway. 
BJ-HRasV12 cells also exhibited increased consumption of glutamine. The high 
dependence of K-RAS mutated cells on glutamine for proliferation and tumorigenicity 
has been highlighted previously in distinct cell models (Gaglio et al., 2009; Son et al., 
2013; Weinberg et al., 2010). As mentioned above, taking into account the activation of 
HIF1α by RAS, it might be supposed that RAS induces a pseudohypoxic status. In 
hypoxia, it has been described that K-RAS mutated cell line H460 shows increased 
glutamine consumption compared with cells cultured in non-hypoxic conditions, 
suggesting that HIF1α activation can enhance glutamine consumption and might 
explain the observed phenotype (Metallo et al., 2012).  
The increase in glucose and glutamine consumption in BJ-HRasV12 cells resulted in 
increased 13C labeling in most of the metabolic intermediates analyzed, suggesting an 
increased flux from glucose and from glutamine to metabolic intermediates in BJ-
HRasV12 compared with BJ cells. However, an integrative approach based on 13C 
metabolic flux analysis (13C-MFA) is still required to unmistakably determine increments 
or decrements in intracellular fluxes. Uptake of the different extracellular metabolites 
and mass isotopomer distribution of the intracellular ones must be combined, using 
computational approaches, to solidly reach this kind of conclusions.  
Although BJ-HRasV12 cells exhibited greater 13C labeling in most of the analyzed TCA 
cycle intermediates when cells were cultured in the presence 13C substrates, only 
glutamine was proven to increase mitochondrial respiration. Despite the increase of 
glucose-derived carbons in the mitochondria in BJ-HRasV12 cells observed using [1,2-
13C2]-glucose, no differences compared with BJ cells were detected in OCR in the 
presence of this substrate. On the contrary, the increase in glutamine-derived carbons 
in the mitochondria in BJ-HRasV12 cells paralleled the increase in OCR in the presence 
of this substrate. A more intense mitochondrial activity in both human HRas-mutated 
cells and KRas-mutated mouse model has been previously reported (Telang et al., 2007; 
Weinberg et al., 2010) and it has been suggested that mitochondrial activity is required 
for KRas-mediated tumorigenicity because it is the main source of ROS, which are 
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essential for this process (Weinberg et al., 2010). However, the role of RAS on 
mitochondrial metabolism still remains unclear. Coversely, it  has  been  reported  that 
activation of K-Ras(G12V) in human cells causes mitochondrial dysfunction, leading to 
decreased respiration, elevated glycolysis, and increased generation of ROS (Hu et al., 
2012). Also, in mouse NIH3T3 fibroblasts transformed with H-Ras(Q61L) mitochondrial 
respiration was found to be suppressed (Yang et al., 2010). Taken together, this body of 
evidence suggests that the action of RAS on mitochondrial metabolism is very 
dependent on the cell system under study and the experimental techniques and 
conditions used. Differences between cell models (rodent or human), RAS isoforms (H-
RAS or K-RAS), the presence of different metabolic substrates in the experiments (single 
carbon substrates vs. multiple carbon substrates) or the experimental procedures to 
reach conclusions on mitochondrial metabolism (OCR, TCA cycle labeled intermediates, 
glutamine consumption or ROS generation) might explain the differences found in the 
role of RAS in mitochondrial metabolism (Bellavia et al., 2012; Hamad et al., 2002; 
Santillo et al., 2001). Here, our study provides a complete and reliable picture of the 
effects of H-RAS oncogenic activation on mitochondrial metabolism, since we have 
carried out a comprehensive and integrative approach using human BJ cells 
transformed with genetically defined elements and combining several techniques that 
support our conclusions. 
Mitochondrial metabolism is the main source of precursors required for lipid synthesis. 
According to the increase of 13C labeling in TCA cycle intermediates, a subsequent 
increase of 13C-palmitate was found when BJ-HRasV12 cells were cultured with both 
[1,2-13C2]-glucose or [U-13C]-glutamine. Some previous evidences support an increased 
lipogenesis in HRas-mutated cells mediated by the action of PI3K pathway (Yang et al., 
2002), which exerts part of the RAS effects on metabolism are mediated by PI3K/AKT 
pathway (Pylayeva-Gupta et al., 2011). This pathway induces the expression of SREBPs, 
which in turn enhances the expression of many lipogenic enzymes, providing a suitable 
mechanistic explanation for the increased lipogenesis observed in BJ-HRasV12 cells 
(Porstmann et al., 2005). Likewise, the inhibition of some components of this pathway 
has been proposed as potential therapeutic approach in RAS-mutated cells (Yang et al., 
2002) and other tumors with mutations in the RAS downstream effectors PI3K or AKT 
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(Bauer et al., 2005; Hatzivassiliou et al., 2005). This fact is also fully supported by our 
results. As shown here, FAS inhibition using C75 inhibitor preferentially inhibited BJ-
HRasV12 cells growth, indicating that H-RAS oncogenic activation renders cells more 
dependent on lipogenesis and suggesting that BJ-HRasV12 cells have an unavoidable 
increased requirement of lipids.  
Interestingly, the portion of glucose and glutamine dedicated to lipid synthesis was 
different in BJ-HRasV12 in comparison with BJ cells. BJ-HRasV12 used proportionally 
more glucose for synthesis of palmitate. Conversely, BJ-HRasV12 cells, despite 
consuming more glutamine, routed less amount of this aminoacid into palmitate 
synthesis, suggesting that glutamine might have other fates in these cells. Recently it 
has been described that KRas-mutated pancreatic cancer cells metabolize glutamine 
through an alternative pathway in which glutamine-derived aspartate is converted into 
oxaloacetate which in turn is transformed into malate and then pyruvate through ME, 
increasing the NADPH/NADP ratio (Son et al., 2013). The existence of this metabolic 
route would allow KRas-mutated cells to obtain NADPH for lipid synthesis and also for 
maintenance of redox homeostasis under high ROS levels conditions, such as those 
described to exist when RAS is mutated. Thus, the activation of this pathway might offer 
an explanation about the decreased contribution of glutamine to palmitate synthesis 
despite being this aminoacid more largely consumed in BJ-HRasV12 cells.  
In summary, H-RAS oncogenic activation reprograms glucose and glutamine 
metabolism by enhancing glycolytic and PPP fluxes as well as mitochondrial 
metabolism. Although both glucose- and glutamine-derived carbons are routed into 
the mitochondria in a greater extent in BJ-HRasV12 cells, glutamine is the main 
responsible for sustaining the activated mitochondrial metabolism in these cells, while 
glucose-derived carbons in the mitochondria are primarily used to fuel lipogenesis. In 
this sense, lipogenesis is overactivated in BJ-HRasV12 cells, which are more reliant on 
this pathway and more sensitive to FAS inhibition than BJ cells. 
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Chapter 5.3 
The Role of G6PD in Colon Cancer Cell    
Line HT29 and its Regulation by Glutamine 
Availability and Proliferation Signaling 
Pathways 
5.3.1 Brief Introduction and Scope 
In the previous chapters we found that G6PD enzyme is upregulated in RAS-mutated 
cell lines. Also, additional unpublished observations of our group in tissue samples of 
colon cancer tumors demonstrated an imbalance of the PPP in favor of the oxidative 
PPP branch, controlled by the key enzyme G6PD. RAS signaling pathway is frequently 
mutated in colon cancer tumors, being mutations in RAS and BRAF genes among the 
most common (Phipps et al., 2013; Pylayeva-Gupta et al., 2011; Yokota et al., 2011). 
Herein, we sought to explore the role of G6PD in RAS pathway-activated cell lines, such 
as colon cancer cells, to study the potentiality of the oxidative branch of PPP as 
therapeutic intervention point in cells with activated RAS pathway. To achieve this goal, 
i) G6PD specific enzyme activity was determined in a panel of colon cancer cell lines 
displaying different status of the RAS signaling pathway, ii) G6PD was inhibited in the 
cell line that displayed the highest G6PD activity and the effect on proliferation and cell 
cycle was studied and, iii) regulation of G6PD by glutamine metabolism was studied in 
order to understand some of the processes observed. 
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5.3.2  Results 
5.3.2.1 G6PD is overexpressed in RAS- and BRAF-mutated colon cancer cells 
In order to explore the relation between RAS signaling pathway activation and G6PD 
activity,  we examined the G6PD status in a panel of colon cancer cell lines consisted of 
four RAS pathway-activated cell lines (HT29, SW480, SW620 and HCT116) and one with 
no RAS pathway activation (Caco-2) in comparison with the normal colonocites cell line 
NCM460. The results shown in Figure 5.3.1.A clearly corroborated the relation between 
RAS pathway status and G6PD activity.  While SW480 SW620, and HCT116 cells harbor 
mutations in K-RAS gene (Kobunai et al., 2010; Simi et al., 2008), HT29 cell line does not 
carry mutations in RAS gene (Ikediobi et al., 2006; Janakiraman et al., 2010), but 
mutation V600E in the RAS downstream effector BRAF is well documented in this cell 
line (Ikediobi et al., 2006; Loh et al., 2008; Oliveira et al., 2003; Tan et al., 2008). Thus, 
RAS pathway-activated cells displayed 1.5- to 2.6-fold increase in G6PD activity in 
comparison with NCM460 cell line. On the contrary, no activating mutations in RAS 
signaling pathway have been described in Caco-2 cells (Jarry et al., 2004).  
As HT29 cell line displayed the highest G6PD activity among the cell lines examined and 
considering that BRAF(V600E) is one of the most well-documented mutations described 
in this cell line, we wondered if G6PD was effectively being regulated by BRAF. Then, 
HT29 cells were cultured in the presence of the highly selective BRAF inhibitor PLX4720 
(Tsai et al., 2008) and G6PD expression and specific enzyme activity were examined. As 
shown in Figure 5.3.1.B-C, a prominent decrease in G6PD expression after 48 hour of 
incubation in the presence of the inhibitor was detected. In accordance to that, after 72 
hours a decrease in G6PD activity was observed. These results indicate that the RAS 
downstream effector BRAF is also involved in the regulation of G6PD.  
Although no mutations in RAS gene have been described in HT29 cells (Ikediobi et al., 
2006), once confirmed the functional relation between BRAF and G6PD and given the 
high G6PD activity detected in HT29, we found interesting to study the role of this 
enzyme in these cells in greater detail. This decision was also based on two previous 
findings. On the one hand, HT29 cells synthesize around 70% of RNA ribose through  
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the oxidative branch of the PPP (Alcarraz-Vizan et al., 2010). Likewise, unpublished data 
from our group has demonstrated an increment of the oxidative/nonoxidative ratio 
branch of PPP in HT29 cancer cells compared with the colonocytes cell line NCM460. 
Taken together, this body of evidence suggested that HT29 could be a good cell model 
to explore the role of G6PD in proliferation and survival in RAS pathway-activated colon 
cancer cells.  
Figure 5.3.1 G6PD state in colon cancer cell lines and BRAF-mediated G6PD regulation 
A. G6PD specific activity in a panel of colon cancer cell lines. Results are expressed as percentage of G6PD activity
with respect to normal colonocites cell line NCM460. The presence (+) or absence (-) of mutation in RAS or BRAF
genes is indicated below the plot. B-C. G6PD expression (B) and specific activities (C) in HT29 cell line after
incubation with 10 µM of BRAF inhibitor PLX4720 (BRAFi) for 48 and 72 hours respectively. Results are expressed as
fold change with respect to control. Bars represent mean ± SD of n=2 in A and C and n=5 in B. Significant
differences compared with NCM460 in A and with control condition in B and C were assessed by two-tailed
Student’s t-test. * p<0.05, **p<0.01.  
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5.3.2.2 G6PD inhibition does not affect proliferation of BRAF-mutated cell line 
HT29  
In order to test the dependence of HT29 cells on G6PD to proliferate, we inhibited this 
enzyme by means of interference RNA. Figure 5.3.2.A-C shows the strong inhibition of 
G6PD achieved at RNA, activity and protein levels in cells transfected with siRNA pool 
against G6PD (siG6PD cells) in comparison with cells transfected with a non-targeting 
siRNA pool (siNEG cells). Next, the effect of G6PD inhibition on proliferation was 
assessed. However, no differences in proliferation and viability (data not shown) were 
found between siNEG and siG6PD cells (Figure 5.3.2.D). 
G6PD has also been described to be modulated along cell cycle progression, being its 
activity increased during late G1 and S phase. This suggests that it might play an 
essential role on cell cycle progression. Accordingly, the effect of G6PD inhibition on cell 
cycle was examined. As it was found in proliferation, no changes were detected in cell 
cycle phase distribution between siNEG and siG6PD cells (Figure 5.3.2.E). 
G6PD plays a pivotal role in synthesis of macromolecules and maintenance of the 
reduced pool of glutathione for ROS counteraction. ROS is produced in many different 
physiological conditions, such as hypoxia (Chandel et al., 1998; Cheung et al., 2012; 
Rouschop et al., 2013). Then we hypothesized that G6PD might play a more essential 
role under conditions of high oxidative stress. To test this hypothesis, HT29 cells were 
transfected with siRNA pool against G6PD or non-targeting siRNA pool and cultured for 
72h. At that point, hypoxia was induced by shifting transfected cells to 1% O2 culture 
conditions for 72h more. On the contrary to what we expected, no significant 
differences were found in proliferation between siNEG and siG6PD cells (data not 
shown). 
5.3.2.3 Glutamine availability regulates G6PD expression and activity 
The oxidative branch of PPP provides the cell with NADPH required for many 
biosynthetic processes as well as for ROS homeostasis. However, other sources of 
NADPH exist in the cell, such as ME or IDH. These sources are primarily fueled with 
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carbons coming from glutamine. In fact, it has been demonstrated in KRAS-driven 
pancreatic cancer cells that glutamine serves as a primary substrate for a set of 
reactions involving ME that lead to an increased NADPH/NADP ratio (Son et al., 2013). 
These results suggest that these glutamine-dependent reactions might be replacing the 
role of G6PD in NADPH production. As a consequence, G6PD might play an additional 
and more important role under glutamine-deprived conditions. Then, we studied the 
effects of G6PD knockdown under glutamine-deprived cell culture conditions. Our 
results showed that HT29 cell line was very dependent on glutamine for proliferation, 
but no significant differences between siNEG and siG6PD cells were found (Figure 5.3.3). 
Figure 5.3.2 Role of G6PD in HT29 cell proliferation and cell cycle progression 
A. G6PD expression 72 hours after transfection of siRNA targeting G6PD (siG6PD) or non-targeting siRNA (siNEG).
B-C. G6PD specific activity (B) and protein levels (C) at 96 hours after transfection. Specific activity is expressed as
fold change with respect to siNEG cells D. Effect of G6PD knockdown on cell proliferation. It was determined by cell
counting through flow citometry at 144 hours after transfection. E. Cell cycle phase distribution 96 hours after
transfection. In all cases, bars represent mean ± SD of n=3. Significant differences compared with siNEG were
assessed by two-tailed Student’s t-test. * p<0.05, **p<0.01.  
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Throughout the experiments performed in the absence of glutamine, we detected that 
G6PD was overexpressed after 48h of glutamine withdrawal in non-transfected HT29 
cells compared with cells cultured in complete media (Figure 5.3.4.A). In accordance, an 
increase in G6PD activity was also detected after 96h of glutamine deprivation (Figure 
5.3.4.B). These results evidence a metabolic relation between G6PD and glutamine 
metabolism in this cell line.  
5.3.2.4 G6PD regulation by glutamine availability involves NRF2 activation  
In light of the glutamine-mediated regulation of G6PD, we wanted to know the 
potential mechanism that coordinates this process. It has been described that RAS 
pathway-activated cells display an enhanced levels of the transcription factor NRF2 
(DeNicola et al., 2011). Furthermore, G6PD has been reported to be regulated by this 
transcription factor (Mitsuishi et al., 2012b) which in turn, is regulated by its inhibitor 
KEAP1. Under normal conditions, NRF2 is constantly ubiquitinated through KEAP1 and 
degraded in the proteasome (see Figure 1.7 in Section 2.2.3) Following exposure to 
oxidative stress, KEAP1 is inactivated and releases NRF2, which migrates into the 
nucleus and activates an antioxidant response program that involves several PPP genes 
(Mitsuishi et al., 2012a). Besides, glutamine deprivation has been correlated with an 
increase in ROS production (Son et al., 2013). Taken together, we reasoned that 
glutamine deprivation well might trigger a broad genetic program initiated by an 
increase in ROS intracellular levels and mediated by NRF2. 
 
Figure 5.3.3 Role of G6PD in HT29 cell proliferation in the 
presence or absence of glutamine 
The dependence of HT29 cell proliferation on G6PD under
glutamine starvation was evaluated by replacing media by either
complete media containing 2 mM glutamine (+Q) or glutamine-
free media (-Q) at 72 hours after transfection of siRNA targeting
G6PD (siG6PD) or non-targeting siRNA (siNEG). After 72 hours,
cell number was determined by flow citometry and results are
expressed as percentage with respect to +Q condition for each
transfectant. Bars represent mean ± SD of n=3.  
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Figure 5.3.4 G6PD, NRF2-target genes and NRF2 levels under glutamine deprivation 
HT29 cells were cultured for 48, 72 and 96h in complete media containing 2 mM glutamine (+Q) or glutamine-free
media (-Q). A. G6PD expression. B. G6PD specific activity. C. Expression of the NRF2 target genes HMDX1 and
NQO1, and the NRF2-codifying gene NFE2L2. D. NRF2 protein levels in cells cultured in complete media (+Q) or
glutamine-free media (-Q) for 24 hr E. ROS levels. In A, B and C values are expressed as fold change with respect to
cells cultured in complete media. Bars represent mean ± SD of n=3. Significant differences compared with complete
media condition were assessed by two-tailed Student’s t-test. * p< 0.05 **p<0.01. 
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As a preliminary approach to explore NRF2 activation, we examined the status of some 
validated NRF2 target genes, such as HMDX1 and NQO1 (DeNicola et al., 2011; 
Mitsuishi et al., 2012b) and also the NRF2 codifying gene NFE2L2 in HT29 cells cultured 
in complete media (+Q) or glutamine-free media (-Q) for 72 and 96h. Interestingly, in 
addition to G6PD, NRF2 target genes HMDX1 and NQO1 were also overexpressed in 
glutamine-free culture conditions, while NFE2L2 was not (Figure 5.3.4.C). In order to 
verify that NRF2 was really activated, protein levels of this transcription factor were 
determined by western blotting. As shown in Figure 5.3.4.D, an increase in NRF2 protein 
levels was detected after culturing HT29 cells in glutamine-free media for 24h. It clearly 
indicates that glutamine deprivation activates a genetic response mediated by NRF2. 
Since KEAP1 release of NRF2 factor is produced after oxidation of KEAP1 cysteine 
residues under high ROS levels, we examined ROS levels after glutamine removal in 
order to provide a mechanistic explanation for NRF2 accumulation (Figure 5.3.4.E). 
Accordingly, a prominent increase in ROS levels was detected when cells were cultured 
without glutamine, suggesting that ROS production triggers NFR2 accumulation and 
the subsequent increase in NRF2-target genes expression.  
5.3.3 Discussion 
Here, we have shown that the levels of G6PD are associated to the genetic activation of 
RAS signaling pathway and regulated by glutamine availability. RAS proteins are 
involved in the transduction of proliferative signals from ligand-activated receptor to 
the nucleus. They activate a plethora of downstream effectors involved in many cellular 
processes (Pylayeva-Gupta et al., 2011), thereby existing several potential mechanisms 
to explain the relation between RAS signaling pathway and G6PD. Since BRAF is a 
downstream effector of RAS, here we assume that the oncogenic activation of BRAF and 
RAS result in a partially common metabolic phenotype. 
G6PD expression and activity is controlled by, among others, the action of the 
transcription factor NRF2, which regulates G6PD promoter through its antioxidant 
response element (ARE) (Mitsuishi et al., 2012b). Recently, DeNicola and collaborators 
described the oncogene-induced NRF2 transcription in primary cells, tissues of mice 
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expressing K-Ras(G12D) and B-Raf(V619E), and in human pancreatic cancer (DeNicola et 
al., 2011). It promotes NRF2 overexpression and stabilization and the subsequent 
orchestration of a ROS detoxification program, involving G6PD upregulation. Thus, this 
mechanism provides a suitable explanation for the relation between G6PD and RAS 
signaling pathway.  
NRF2 transcription factor is also activated in response to high ROS levels through the 
modification of the cysteine residues of its inhibitor KEAP1 (Mitsuishi et al., 2012b). In 
this regard, it has been documented that RAS signaling pathway activation via ectopic 
expression of different mutant isoforms of RAS leads to increased levels of oxidative 
stress (Chiaradonna et al., 2006; Maciag and Anderson, 2005), although some 
differences among RAS isoforms regarding effect of RAS on ROS levels have been 
detected (Santillo et al., 2001). Then, this increase in ROS levels might also trigger NRF2 
activation and G6PD upregulation. Additional studies have also confirmed the relation 
between RAS signaling pathway and the oxidative branch of PPP (de Atauri et al., 2011; 
Vizan et al., 2005). 
Furthermore, our results have shown that 80% inhibition of G6PD activity had no effect 
on cell proliferation and viability in BRAF-mutated HT29 cell line. G6PD plays an 
important role in redox homeostasis and anabolic metabolism. The absence of effect on 
cell proliferation and viability after G6PD inhibition may be explained on the basis of 
both physiological processes. In terms of redox homeostasis, HT29 has been described 
to express high levels of the CD44v protein, a variant of the cancer-stem-cell marker 
CD44 (Ishimoto et al., 2011). The high expression of this protein confers to the cell the 
capacity to maintain low levels of ROS by enhancing GSH synthesis and activating an 
antioxidant gene expression program involving ROS detoxification genes such as GPX1, 
GPX2, PRDX1 and PRDX2. Consequently, G6PD may not be essential for redox 
homeostasis in cells expressing high levels of CD44v. In fact, not even in the challenging 
condition of glutamine withdrawal, in which there was a notable increase in ROS levels, 
we detected significant changes in proliferation when G6PD was inhibited. Regarding to 
the role of G6PD in anabolism, it is possible that cells circumvent the inhibition of G6PD 
by redirecting ribose synthesis flux through the nonoxidative branch of the PPP, which 
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would allow cells to obtain the required precursors for synthesis of macromolecules. In 
fact, it has been demonstrated in HT29 cell line that inhibition of TKT or G6PD enzymes 
with oxythiamine or dehydroepiandrosterone, respectively, leads to a compensatory 
response by enhancing ribose synthesis flux through the non-inhibited branch of PPP, 
highlighting the metabolic flexibility of this pathway (Ramos-Montoya et al., 2006). The 
role of the nonoxidative branch of the PPP in KRAS-mutated tumors has been also 
documented. In KRAS-mutated pancreatic tumors, ribose biogenesis is carried out by 
driving glycolysis intermediates via nonoxidative PPP and this pathway is essential for 
tumorigenic activity of pancreatic cancer cells (Ying et al., 2012). Similar results were 
found in additional studies in pancreatic cancer cells (Boros et al., 2005). 
Another explanation for the absence of effect on HT29 cell proliferation and viability 
after G6PD inhibition lays on the role of P53. HT29 is a P53-deficient cell line that 
harbors the mutation P53(R273H). Wild-type P53 negatively regulates G6PD activity 
impairing active dimer formation by direct protein binding (Jiang et al., 2011). Although 
mutant P53(R273H) retains the capacity of binding to G6PD, it has lost the capacity of 
inhibiting G6PD activity (Jiang et al., 2011), what might result in a tremendously high 
G6PD activity in this cell line, as quantified here. In the presence of such a great amount 
of active G6PD enzyme, inhibition of enzyme activity around 80% by interference RNA 
might still left enough active G6PD as to maintain the oxidative PPP flux required for 
cell proliferation and survival. Accordingly, similar degree of G6PD inhibition in P53-
proficient cell line HCT116, which displayed 50% of G6PD activity in comparison with 
HT29, led to a decrease of 30% in cell proliferation and survival (unpublished 
observations in our research group). In general, high G6PD activity leads to increased 
synthesis of the PPP metabolic intermediate 6-phosphogluconate (6PG), and this fact 
can be used to design a better approach for targeting PPP with therapeutic purposes. 
6PG has been proposed as potential inhibitor of proliferation (Sukhatme and Chan, 
2012) and its accumulation takes place when 6PGD enzyme is inhibited. As HT29 cell 
line has high levels of G6PD, it results in enhanced production of 6PG. Then, inhibition 
of 6PGD might result in a great accumulation of 6PG, which might lead to an inhibition 
of proliferation. 
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We have also demonstrated that glutamine withdrawal leads to an increase in ROS 
levels and subsequently to NRF2 stabilization. The increment in ROS levels in the 
absence of glutamine has been previously reported as consequence of the role of this 
aminoacid in fueling the mitochondrial reactions that convert aspartate into pyruvate 
(Son et al., 2013). These reactions involve the ME, a source of NADPH required for redox 
homeostasis. Nevertheless, the induction of NRF2 under this condition has not been 
studied before and may play a pivotal role in proliferation and survival under nutrient-
limited conditions. 
In summary, in this chapter we have demonstrated that G6PD is overactivated in colon 
cancer cells with oncogenic activation of the RAS signaling pathway. Nevertheless, 
G6PD seems to be dispensable for proliferation and survival in BRAF-mutated and P53-
deficient HT29 colon cancer cell line. Interestingly, a new connection between PPP and 
glutamine metabolism has been unveiled, where G6PD is overexpressed in HT29 cells 
under glutamine-deprived conditions in a process that is accompanied with a 
concomitantly increase in ROS levels and NRF2 induction.  
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Chapter 5.4 
The Pentose Phosphate Pathway as  
Potential Cancer Therapeutic Target and its 
Role in Tumor Metabolism in Breast Cancer 
Cell Line MCF7 
5.4.1  Brief introduction and scope 
In the previous chapter, we have inhibited G6PD in colon cancer cell line HT29 but no 
effects on cell proliferation and survival have been detected. Besides ribose synthesis, 
G6PD regulates ROS levels, and the balance between ROS production and removal has 
been demonstrated to be altered in some tumors and proposed as an attractive 
therapeutic target (Trachootham et al., 2009). An example of these tumors is the case of 
breast tumors, which display increased levels of ROS and a greater reliance on the ROS 
detoxification systems, which increases gradually as tumor progresses (Brown and 
Bicknell, 2001; Jerby et al., 2012; Kang, 2002; Portakal et al., 2000; Toyokuni et al., 1995). 
Since PPP is involved in ROS levels modulation, we tested the potential of the main 
enzymes of this pathway, G6PD and TKT, as therapeutic targets in the metastatic breast 
cancer cell model MCF7. Metastases of breast cancer display an increased expression of 
enzymes of the PPP such as G6PD and 6PGL (Chen et al., 2007). Additionally, advanced 
breast tumors display an increased need to detoxify ROS as demonstrated by the 
increased expression of the PPP enzymes detected in a genome-scale study based on 
the gene expression analysis of a large cohort of clinical samples (Jerby et al., 2012). 
Also, MCF7 cells have an increased expression of G6PD compared with the near-normal 
breast cancer cells MCF10 (Drabovich et al., 2012). Taken together, we reasoned that the 
PPP enzymes might be of potential therapeutic interest particularly in advanced breast 
cancer and we selected MCF7 cells, a cell model of metastatic breast cancer, to validate 
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this hypothesis. To this end i) G6PD and TKT were inhibited and its role in proliferation 
and survival was assessed, ii) the metabolic role of these enzymes was evaluated by 
performing a 13C-assissted metabolomics experiment using [1,2-13C2]-glucose and iii) 
the metabolic relation between PPP and glutamine metabolism was explored to explain 
some of the results obtained. 
5.4.2  Results 
5.4.2.1 G6PD inhibition, but not TKT, decreases cell proliferation and survival 
PPP has been hypothesized to play a critical role in tumor metabolism. In order to 
assess the dependence of MCF7 breast cancer cells on this pathway, we inhibited the 
main enzymes of PPP by means of siRNA targeted to TKT (siTKT) or G6PD (siG6PD). A 
non-targeting siRNA (siNEG) was used as a negative control in all experiments. As 
shown in Figures 5.4.1.A-B, both enzymes were effectively inhibited at mRNA level more 
than 75%, and specific enzyme activities were reduced around 50% at 96 hours after 
transfection in both cases.  
PPP is an anabolic pathway that plays a fundamental role in cell growth. Then, we 
explored the role of TKT and G6PD in cell proliferation and survival. Notably, G6PD 
impairment reduced cell proliferation around 35%, while no effects were detected when 
TKT was inhibited (Figure 5.4.1.C, left). In accordance to that, G6PD knockdown resulted 
in a marked increase in cell death, as shown in Figure 5.4.1.C (right). Given that one of 
the essential roles of PPP is to provide cells with ribose for proliferation, we 
hypothesized that inhibition of these enzymes might influence on cell cycle progression. 
Cell cycle is classically divided into three different phases named G1, S and G2. G1 
phase covers the period of time required for cell growth and macromolecules synthesis, 
such as DNA, lipids, etc, being this phase essential for a properly progression through 
the cell cycle and cell division. Accordingly, G6PD and TKT enzymes have been reported 
to be enhanced during late G1 and S phase and specific upregulation of the oxidative 
branch has been demonstrated (Vizan et al., 2009).  Then, an arrest in G1 phase was 
expected when TKT and G6PD were inhibited. Effectively, a slight arrest in G1 phase  
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Figure 5.4.1. Role of PPP enzymes TKT and G6PD on cell proliferation and survival 
A. TKT and G6PD mRNA expression 72 h after transfection of non-targeting siRNA (siNEG) or siRNA against TKT
(siTKT) or G6PD (siG6PD). Fold change is calculated with respect to siNEG (mean ± SD of n=3). B. TKT (left) and
G6PD (right) activity 120h after siTKT or siG6PD transfection respectively (mean ± SD of n=3). C. Effect of TKT and
G6PD knockdown on cell proliferation (left) and survival (right). Cells were stained with propidium iodide and
counted by flow citometry at 144 hours after siRNA transfection (mean ± SD of n=2 for siTKT and n=5 for siG6PD).
D. Effect of TKT and G6PD knockdown on cell cycle progression. Cell cycle analysis was performed at 120 hours after
siRNA transfection (mean ± SD of n=3). Significant differences compared with siNEG were assessed by two-tailed
Student’s t-test. * p<0.05, **p<0.01  
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Figure 5.4.2. Role of PPP enzymes in redox homeostasis 
Relative ROS levels measured by flow citometry using H2DCFA probe at the indicated time points after transfection
(mean ± SD; n=3). ROS levels are expressed as fold change with respect to siNEG.  Significant differences compared
with siNEG were assessed by two-tailed Student’s t-test. * p<0.05, **p<0.01 
and a subsequent decrease in S phase were found when inhibiting any of the enzymes 
of the PPP (Figure 5.4.1.D). 
As it has been mentioned earlier, PPP is also important in redox homeostasis, since the 
oxidative pathway is one of the main systems of NADPH production, which in turn is 
employed for maintaining the budget of reduced glutathione to counteract ROS 
production. As redox homeostasis plays an important role in cancer cell survival, 
particularly in breast cancer cells, the impact of inhibition of TKT and G6PD in ROS levels 
was assessed.  Our results showed that G6PD depletion induced a clear increase in ROS 
intracellular levels (Figure 5.4.2). However, no changes were detected when TKT was 
inhibited, indicating that TKT does not participate in ROS levels regulation. 
5.4.2.2 PPP inhibition promotes a whole-network metabolic reprogramming 
PPP is involved in several essential processes in healthy and tumor cells. In order to 
obtain a deeper knowledge of the implications of this pathway in cancer cell 
metabolism, we performed a 13C-assisted metabolomics experiment by using [1,2-13C2]-
glucose. First, extracellular fluxes of glucose, lactate and glutamine were measured 
(Figure 5.4.3.A). TKT knockdown produced a decrease in glucose uptake of 20% which 
was in accordance with a decrease in lactate production of the same magnitude. On the 
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Figure 5.4.3. Metabolic role of TKT and G6PD enzymes 
13C-assisted metabolomics experiment was performed by replacing cell culture media by fresh media containing
50% [1,2-13C2]-glucose at 96 hours after transfection. Incubation with the tracer was carried out over a period of 24h
and extracellular fluxes and mass isotopomer distribution of different metabolites were determined over this period.
A. Main extracellular fluxes consisted of glucose and glutamine consumption and lactate production (mean ± SD of
n=3) B. Total 13C-Ribose represented as the sum of m1+m2+m3+m4 (∑m) (mean ± SD of n=3) C. Phase plane
analysis for ribose synthesis.  Ribose m1 and m2 were analyzed and plotted as percentage of total 13C-Ribose (∑m)
                            …/…
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 contrary, G6PD depletion did not affect glucose consumption but an increase in lactate 
production of more than 30% was found. However, the most striking finding was that 
both TKT and G6PD knockdown cells increased glutamine consumption rate by more 
than 50%, being this increase more prominent for the latter (100%). Thus, although the 
flux through PPP has often been described to be small, these observations highlight the 
importance of this pathway in the global metabolic network. After that, we sought to 
determine in which extent the PPP was affected when TKT and G6PD were 
downregulated and whether other changes in metabolism were occurring.  
As an approach to estimate the impact of these inhibitions on PPP, mass isotopomer 
distribution of ribose from RNA. First, the percentage of newly synthesized ribose (∑m) 
over the total ribose was determined (Figure 5.4.3.B) and a significant decrease in ribose 
synthesis was found in both TKT and G6PD knockdown cells. Glucose can be 
metabolized through either the oxidative or the nonoxidative branch of the PPP, 
yielding m1 or m2 labeled ribose respectively. Figure 5.4.3.C depicts the contribution of 
the oxidative and the nonoxidative PPP to ribose synthesis. TKT inhibition clearly 
promoted a decrease in utilization of nonoxidative pathway (m2/Ʃm) by around 50% 
and, simultaneously increased flux through the oxidative branch (m1/Ʃm). On the other 
hand, G6PD inhibition slightly affected the oxidative branch and no significant changes 
were found in the nonoxidative one. The calculation of the oxidative/nonoxidative ratio 
also corroborated these findings (Figure 5.4.3.D). Thus, a prominent increase in this ratio 
was found when TKT was inhibited while a small decrease was observed when G6PD 
was downregulated, suggesting that TKT exerts a higher control over the PPP. 
Additionally, to further asses the role of TKT and G6PD in PPP, mass isotopomer 
distribution of lactate from media was also analyzed. Lactate is mainly produced from 
glucose, even more in cancer cells. Since glucose can be either processed through direct 
 
 
 
 
…/… 
(mean ± SD of n=3) D. Oxidative vs. nonoxidative branch of PPP calculated as m1 ribose/ m2 ribose (mean ± SD of
n=3) E. Pathway-specific produced lactate. Lactate produced flux from glucose via either PPP or glycolysis and from
other sources (OS) was calculated using lactate production in combination with mass isotopomer distribution of
lactate as described in section 4.13.1 (mean ± SD of n=3). F. The ratio between PPP and glycolysis fluxes was
calculated by dividing the values for PPP by glycolysis for each condition (mean ± SD of n=3). Significant differences
compared with siNEG were assessed by two-tailed Student’s t-test * p<0.05, **p<0.01. 
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glycolysis or diverted into PPP and reintroduced in glycolysis, the carbons of the end-
product of glycolysis lactate contains information of the route followed by glucose 
carbons. Then, mass isotopomer distribution of lactate when cells are incubated with 
[1,2-13C2]-glucose integrates information of the glucose-derived carbon flow. Using 
lactate production in combination with lactate mass isotopomer distribution, pathway-
specific production of lactate from glucose can be estimated as described in Section 
4.13.1, (Figure 5.4.3.E). The results clearly indicated a decrease in glycolytic flux when 
TKT was inhibited whereas the opposite result was obtained for G6PD knockdown. 
Likewise, data showed a very small flux of glucose transformed into lactate through PPP 
in all conditions, indicating than most of the glucose-derived ribose is used for 
biosynthetic purposes instead of being reincorporated into glycolysis and finally 
transformed into lactate. A decrease in flux from glucose to lactate via PPP was 
observed when TKT was inhibited and, paradoxically, a small increase was detected 
when G6PD was depleted. It was expected that G6PD knockdown led to a decreased 
flux from glucose to lactate via PPP, since its inhibition blocks the entrance of G6P into 
PPP. Nevertheless, when ratio PPP/glycolysis fluxes was calculated no changes were 
detected when TKT was inhibited and a decrease was observed in G6PD knockdown 
cells (Figure 5.4.3.F), confirming a blockade of oxidative PPP flux in relation to glycolytic 
flux. Taken together, these results indicate that TKT inhibition led to a decrease in 
glucose consumption which impacted in a balanced manner in glycolysis and PPP flux, 
since PPP/glycolysis ratio was maintained. However, G6PD enhances both glycolytic and 
PPP in a different magnitude, provoking a decrease in PPP/glycolysis ratio. This result is 
in accordance with the metabolic role of G6PD shunting carbons from glycolysis 
intermediates into the PPP. Besides, lactate produced from other sources (OS) different 
from glucose was calculated in each condition, although no differences were detected 
(Figure 5.4.3.E) 
Cancer cells display higher requirements of lipids to sustain proliferation. Since the 
oxidative branch of PPP is one of the main sources of NADPH as reducing equivalents, 
we studied the impact of these inhibitions on lipid synthesis by analyzing palmitate 
production from glucose (Figure 5.4.4). Remarkably, lipid synthesis was clearly impaired  
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after G6PD knockdown by more than 50%, whereas no changes were detected when 
TKT was inhibited. 
5.4.2.3 PPP and glutaminolysis are functionally interconnected 
One of the most unexpected findings observed in the previous results was the marked 
increase in glutamine consumption when TKT and G6PD were impaired, which 
suggested an interconnection between PPP and glutamine metabolism. As it is for PPP, 
also glutaminolysis is involved in NADPH production, since it supplies carbons required 
for TCA cycle reactions that can generate malate, which is subsequently oxidized by 
malic enzyme into pyruvate producing reducing power in the form of NADPH. 
Additionally, NADP-dependent isocitrate dehydrogenase isoforms are fueled with 
glutamine-derived metabolites, so replenishment of the TCA cycle intermediates is 
critical for NADPH generation and redox homeostasis. Then, at least in case of G6PD 
knockdown, we reasoned that the observed increase in glutamine uptake might be 
intended to counteract ROS production by activating NADPH-generating reactions. To 
test this hypothesis, G6PD and TKT knockdown cells were grown in the absence (-Q) or 
presence (+Q) of glutamine and intracellular levels of ROS were determined. As shown 
in Figure 5.4.5.A, no additional increase in ROS levels was detected when G6PD was 
inhibited and transfected cells were cultured in the absence of glutamine compared 
with those cultured in the presence of glutamine, indicating that the observed increase 
in glutamine uptake was not intended to ROS counteraction.  
 
Figure 5.4.4. Role of PPP enzymes in lipid synthesis 
13C-assisted metabolomics experiment was performed by
replacing cell culture media by fresh media containing
50% [1,2-13C2]-glucose at 96 hours after transfection.
Incubation with the tracer was carried out over a period of
24h and total 13C-Palmitate was measured and
represented as sum of m1+m2+…+m6 (∑m) (mean ± SD
of n=3). Significant differences compared with siNEG were
assessed by two-tailed Student’s t-test. * p<0.05, **p<0.01
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Figure 5.4.5. Role of glutamine under PPP inhibition  
To determine the role of PPP enzymes in the presence or absence of glutamine, 96 hours after transfection, media
was replaced by complete (+Q) or glutamine-free (-Q) media for 16 h and ROS levels (A), glutathione content (B)
and ATP/ADP ratio (C) were determined. A. ROS levels expressed as fold change compared with siNEG in each
condition (mean± SD of n=6 from two independent experiments). B. Total glutathione content (mean ± SD of n=3).
C. ATP/ADP ratio (mean ± SD of n=3). D. Relative cell proliferation. 72 hours after transfection media was replaced
by fresh complete or glutamine-free media and cells were counted by flow citometry after 72 hours. Results are
expressed as percentage of siNEG in complete media (mean ± SD of n=3). Significant differences compared with
+Q siNEG (B and D) or with siNEG in each condition (A and C) were assessed by two-tailed Student’s t-test *
p<0.05, **p<0.01, n.s, denotes non-significant differences, 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Glutamine is also used to produce glutathione, an antioxidant tripeptide involved in 
redox homeostasis. It is synthesized from cysteine, glycine and glutamate, being the 
latter a direct product of glutamine metabolism. Then, we hypothesized that the 
increase in glutamine uptake might be directed towards glutathione synthesis in order 
to maintain redox homeostasis. To elucidate the contribution of glutamine to 
glutathione budget when PPP was impaired, total levels of glutathione were measured 
5. Results and discussion 
140 
 
when TKT or G6PD were inhibited in the absence or presence of glutamine (Figure 5.4.5. 
B). A decrease in total glutathione levels was found in siNEG condition without 
glutamine in comparison with the same condition in the presence of glutamine, 
indicating that glutamine significantly contributes to glutathione synthesis. Also a 
decrease in glutathione was found when TKT or G6PD were depleted in the presence of 
glutamine. Nevertheless, no additional decrease in glutathione levels was found when 
glutamine was removed from media and PPP was inhibited, what points out that the 
increase in glutamine consumption was not intended to increase glutathione budget.  
As the results obtained so far suggested that the increase in glutamine uptake observed 
was not primarily involved in redox homeostasis, we explored other potential 
mechanisms that could explain this process. One of the fates of glutamine is the 
production of ATP by oxidative phosphorilation in the mitochondria. Considering that 
glutamine is one of the main energetic substrates, we wanted to know if TKT and G6PD 
knockdown cells were more dependent on glutamine for energetic purposes. Then, we 
examined ATP/ADP ratio under presence or absence of glutamine in control and 
knockdown cells (Figure 5.4.5.D). Notably, we detected a significant decrease in the 
energetic status when TKT or G6PD were inhibited in the absence of glutamine, 
suggesting that PPP inhibition renders cells more dependent on glutamine metabolism 
for energy production. 
Taking into account the energetic utilization of glutamine as demonstrated above, we 
reasoned that it might play an essential role in proliferation when PPP enzymes were 
inhibited. Then, cells were transfected and cultured in the absence or presence of 
glutamine (Figure 5.4.5.D). According to the results obtained so far, we speculated that 
TKT and G6PD knockdown cells should be more sensitive to glutamine deprivation. As 
demonstrated previously, we observed a decrease in proliferation when G6PD was 
inhibited in the presence of glutamine. However, we did not find any additional 
difference when either TKT or G6PD were inhibited in glutamine-free media. Note that 
siNEG cells neither showed a significant decrease in proliferation under glutamine 
deprivation, demonstrating that MCF7 cells are glutamine-independent to proliferate. 
These facts indicate that, although glutamine consumption increased when PPP was 
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inhibited and it was primarily used to sustain ATD/ADP ratio, glutamine was not 
essential for proliferation. It suggests that this cell line displays a high level of metabolic 
flexibility in order to adapt to changing nutritional conditions.  
5.4.3  Discussion 
Our study provides several insights into the role of PPP in the metabolism of MCF7 
breast cancer cell line. Previous studies suggest the importance of this pathway in 
breast cancer tumors, especially in those in advanced state such as MCF7 cell line 
(Drabovich et al., 2012; Jerby et al., 2012). Here, we have first shown that G6PD plays a 
pivotal role in cell proliferation and survival, while TKT seems to be dispensable in these 
processes. We have also demonstrated that the inhibition of G6PD led to a significant 
decrease in cell growth and viability. The high dependency of this cell line on this 
pathway is clearly supported by the fact that just 50% inhibition of G6PD specific 
activity led to a 35% decrease in cell proliferation. Several reports have also 
corroborated the role of G6PD in cell proliferation (Ho et al., 2000; Li et al., 2009), 
although the exact mechanism by which G6PD is important for cell proliferation is still 
unclear. G6PD is the key in the synthesis of ribose via oxidative pathway. However, we 
have demonstrated here that the impact of G6PD on ribose synthesis is low whereas it 
is high on ROS levels, suggesting that G6PD plays a more crucial role in redox 
homeostasis than in ribose synthesis in MCF7 cell line. This idea has been documented 
in other study concluding that G6PD is dispensable for pentose synthesis but essential 
for defense against oxidative stress (Pandolfi et al., 1995). In addition, G6PD ablation 
renders cell more sensitive to the action of oxidative agents, indicating the essential role 
of this enzyme in protection against oxidative damage (Cheng et al., 2004; Gao et al., 
2009). Then, it is more likely that cell death caused by G6PD inhibition is due to ROS 
homeostasis deregulation. G6PD is involved in NADPH production, which is used for 
maintenance of the reduced pool of glutathione which in turn is responsible for ROS 
levels. Thus, measurement of NADP/NADPH ratio would provide valuable and more 
direct information of the consequences of G6PD inhibition. As indicated by ROS levels, a 
decrease in NADPH levels is highly probable. This fact is also supported by the observed 
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decrease in the synthesis of fatty acids, for which NADPH is essentially required. Not 
only might the damage produced by high levels of ROS be the cause of decreased cell 
proliferation and survival, but also a limited amount of reducing equivalents in the form 
of NADPH. The assessment of cell proliferation and survival in the presence of the 
antioxidant N-acetyl-cysteine or palmitate would provide additional evidence of the 
mechanism involved in G6PD-inhibition induced cell death. It is worth of noting that 
although G6PD had the greatest impact on cell proliferation and ROS levels 
maintenance, TKT inhibition showed the highest impact on pathway-specific ribose 
synthesis. Levels of total newly synthesized ribose were similarly decreased in both TKT 
and G6PD inhibited cells, but TKT showed a greater regulatory capacity over the non-
oxidative pathway than G6PD over the oxidative one. This fact can be related to the 
protein level of each enzyme in the cell. It is described that G6PD usually works at 
around 2% of its total maximum rate (Riganti et al., 2012), what indicates that the 
enzyme is in excess in the cell and its inhibition will have a low impact on the synthesis 
of the end-product of the pathway catalyzed. This is corroborated by the fact that 50% 
inhibition of G6PD specific enzyme activity provoked a slight decrease in m1 ribose. On 
the contrary, the results indicated that TKT probably works at its maximum rate in the 
cell, since 50% inhibition of the enzyme provoked a proportional inhibition in m2 ribose. 
Additionally, TKT inhibition also increased m1 ribose. It can be due to either the 
impossibility of reintroducing ribose synthesized by the oxidative branch into glycolysis 
or to a compensatory activation of the flux through the oxidative branch, what resulted 
in m1 ribose accumulation. Taken together, all these findings suggest that although 
both oxidative and nonoxidative pathways are tightly connected, the functions of 
controlling ROS levels and synthesizing ribose might be partially decoupled. 
One of the most striking findings in this study is the uncovered link between PPP and 
glutaminolysis. The results provided here clearly demonstrate that the increase in 
glutamine consumption was because of energy requirements. In the case of TKT 
inhibition, the observed decrease in glucose consumption and lactate production well 
might be associated to a decrease in glycolytic ATP production. In MCF7 cells, the 
contribution of glucose to total ATP turnover has been estimated to be around 30 % 
(Guppy et al., 2002). TKT inhibition might entail a reduction of the network dimension 
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and consequently a decrease in the amount of glucose than can be uptaken. In order to 
compensate this situation and sustain the level of ATP, additional sources of energy 
must be used in a greater extent, such as glutamine, even more if there are no changes 
in cell proliferation.  
In the case of G6PD, we detected no changes in glucose consumption but an increase in 
glucose-derived lactate production. In fact, glycolytic flux was incremented (Figure 
5.4.3.E), suggesting that less carbons are routed into the mitochondria. This result can 
be explained on the basis of HIF activation. The increment in ROS levels can stabilize 
and activate HIF dependent signaling pathway (Chandel et al., 1998), which upregulates 
glycolysis and divert glycolytic flux away from mitochondria by PDH complex 
inactivation (Kim et al., 2006; Papandreou et al., 2006). This reasoning is supported by 
the increased lactate levels in G6PD knockdown cells despite of neither increase in 
glucose consumption nor increase in lactate from other sources (Figure 4.4.3.E). Since 
MCF7 cell line produces around 80% of ATP by oxidative phosphorylation in the 
mitochondria (Guppy et al., 2002), it is likely that the inhibition of pyruvate entry into 
the mitochondria by inactivation of PDH complex led to an increased use of other 
energetic substrates such as glutamine. Under these circumstances, glutamine would 
play a determining role in maintaining ATP levels as demonstrated by the decrease in 
ATP/ADP ratio of G6PD inhibited cells in the absence of glutamine.  
Despite the energetic role of glutamine under PPP inhibition, it is timely to note that 
simultaneous glutamine depletion and G6PD or TKT knockdown did not cause an 
additional decrease in cell proliferation. In fact, MCF7 cells displayed low sensitivity to 
glutamine deprivation in terms of cell proliferation and ATP levels (Kung et al., 2011), 
suggesting that this cell line has a certain metabolic flexibility to maintain energy 
homeostasis. Then, although glutamine turns into a more important source of energy 
when G6PD or TKT are inhibited, the lack of this aminoacid might be replaced by an 
increased consumption of other nutrients in order to sustain proliferation.  
In summary, PPP plays a pivotal role in several cellular processes in MCF7 cells. On the 
one hand, G6PD is important in proliferation and survival as well as in regulating ROS 
levels in these cells. However, it exerts a low regulation over ribose synthesis flux 
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through the oxidative branch of PPP. On the other hand, TKT seems to be dispensable 
for proliferation, but it exerts a high control over ribose synthesis flux through the 
nonoxidative branch of PPP. The inhibition of each enzyme entails a different metabolic 
response. Whereas G6PD inhibition enhances glycolytic flux and promotes lactate 
secretion, TKT impairment reduces glucose consumption and glycolytic flux. 
Nevertheless, the inhibition of each enzyme increases the consumption of glutamine, 
which is used to maintain energy homeostasis although it is not essential for cell 
proliferation.  
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6. GENERAL DISCUSSION 
Throughout the different chapters of this thesis, the metabolic adaptations induced by 
RAS oncogenic activation and the potential of metabolism as a new field of therapeutic 
opportunities have been explored. In this regard, we have unveiled the essential traits of 
the metabolic reprogramming induced by mutated RAS and explored the PPP enzymes 
as potential therapeutic targets in colon and breast cancer cells. 
In the Chapters 5.1 and 5.2, the metabolic reprogramming induced by RAS oncogenic 
activation has been studied using two different cell models: NIH3T3 mouse fibroblasts 
transfected with a mutated copy of the K-RAS gene in either codon 12 (K12-transfected 
cells) or 13 (K13-transfected cells) (Chapter 5.1) and human BJ cells transfected with a 
copy of H-RAS mutated in codon 12 (Chapter 5.2). Although the experimental 
approaches carried out to study each situation have been different, some conclusions 
can be reached about the metabolic reprogramming induced by mutated RAS. It is 
worth of noting that the work presented in Chapter 5.1 is a continuation of the work 
published by Vizan et al, in which NIH3T3 K12 and K13 cells were studied at metabolic 
level using 13C-assisted metabolomics (Vizan et al., 2005).   
In Chapters 5.1 and 5.2, the results have shown a parallel metabolic phenotype between 
K-RAS and H-RAS oncogenic activation with regard to glycolysis and PPP, although the 
magnitude of the change in PPP has been determined to be higher in KRas-transfected 
NIH3T3 cells. However, the proteomic changes at enzymatic level accompanying these 
metabolic phenotypes were different in the situations considered. Both systems display 
an increase in G6PD and PK (only in K13) enzyme activity. However, HK was activated in 
BJ-HRasV12 cells while it changed in neither NIH3T3 K12 nor K13. Similarly, LDH 
increased substantially in NIH3T3 K12 and K13 compared with control NIH3T3, but it 
decreased slightly in BJ-HRasV12 compared with BJ. These results suggest that different 
metabolic changes can result in a similar metabolic phenotype. In other words, a high 
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glycolytic flux can be obtained by upregulating different steps of glycolysis. This 
observation can be explained on the basis of MCA. The dependencies matrix shown in 
figure 5.1.4.D clearly exemplifies how an increase in LDH flux (JT) can be achieved by 
activating not only LDH (vT) but also PK (vK) or GAPDH (vF), demonstrating that different 
metabolic mechanisms can take place to induce an increase in a metabolic flux. In a 
parallel manner, different enzymes or combinations of them can be modified to result in 
increased glycolytic flux. 
With regard to mitochondrial metabolism in K-RAS and H-RAS mutated cells, the lack of 
parallel data for each system complicates the comparison. In NIH3T3 K12 and K13 cells, 
no differences in mitochondrial metabolism have been found in the analysis performed 
in Chapter 5.1, although previously published data showed that K-RAS induced an 
increase in glucose-derived carbons in the TCA cycle intermediate glutamate (Vizan et 
al., 2005). However, other authors using also NIH3T3 KRas-transfected cells concluded 
that K-RAS activation induces mitochondrial dysfunction and decreases mitochondrial 
respiration (Chiaradonna et al., 2006a; Chiaradonna et al., 2006b; Gaglio et al., 2011). On 
the other hand, in BJ-HRasV12 cells a substantial increase in mitochondrial metabolism 
has been detected in BJ-HRasV12 cells compared with BJ. This increase is supported by 
an increase of glucose- and glutamine-derived carbons in TCA cycle intermediates as 
well as an enhanced consumption of glutamine and O2 in the presence of this 
aminoacid.  
The differences found between KRas-transfected NIH3T3 and HRas-transfected BJ cells 
well might be attributed to the origin of the cells employed as well as to the transfected 
RAS isoform. Similar differences to the ones presented here have been reported 
previously in other studies. A study performed using human KRas-transfected cells 
indicated that K-RAS oncogenic activation leads to mitochondrial dysfunction (Hu et al., 
2012). Additionally, studies with mouse H-RAS mutated transfectants suggest that RAS 
oncogenic activation also leads to mitochondrial dysfunction (Yang et al., 2010), and to 
an impairment of mitochondrial respiration combined with a gradual acquisition of the 
Warburg effect after an initial activation of mitochondrial metabolism (de Groof et al., 
2009). On the contrary, human HRasV12-expressing cells have been reported to 
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increase mitochondrial metabolism (Telang et al., 2007). Taken together, these findings 
suggest that, whereas glycolytic phenotype is a robust metabolic change induced by 
RAS activation, changes in mitochondria are more fragile and sensitive to the cell model 
employed and the RAS isoform transfected. In these regard, despite of the high degree 
of sequence homology between RAS isoforms, H-RAS, K-RAS and N-RAS proteins exert 
different downstream activities, in part because of the ability of RAS isoforms to localize 
in different cellular microdomains (Bellavia et al., 2012; Omerovic et al., 2007). This 
different intracellular compartmentalization could help RAS isoforms to contact 
different downstream effectors finally leading to different biological outcomes and 
partially different metabolic phenotypes. As an example, it has been proposed that K-
RAS and H-RAS genes differently regulate the redox state of the cell (Bellavia et al., 
2012). This fact suggests that different isoforms of RAS could regulate mitochondrial 
metabolism in various ways, leading to different mitochondrial phenotypes. 
The activation of the PPP in RAS-mutated cancer cells prompted us to validate this 
finding in other RAS-pathway activated cells, such as colon cancer cells. After finding 
that RAS-pathway activated colon cancer cells displayed increased levels of G6PD, this 
enzyme was inhibited in BRAF-mutated cell line HT29. Nevertheless, no changes were 
observed in cell proliferation and survival when G6PD was impaired in this cell line. 
Therefore, since G6PD plays a pivotal role in regulating ROS levels, the inhibition of PPP 
was performed in a cell line with high levels of oxidative stress, such as breast cancer 
cell line MCF7. In this model, G6PD inhibition induced a notable decrease in cell 
proliferation, whereas TKT inhibition provoked no changes. As a whole, the results 
suggest that different cancer cells have distinct metabolic dependencies. MCF7 breast 
cancer cells displayed a greater reliance on the oxidative branch of the PPP than HT29 
colon cancer cells. It suggests that the metabolism of each cell line is tuned in a 
different way in order to cover their metabolic requirements. Then, it can be deduced 
from the obtained results that G6PD inhibition in HT29 either did not affect any 
essential process or a metabolic reorganization took place in order to circumvent G6PD 
inhibition.  Thus, when G6PD is inhibited, HT29 cells might use nonoxidative PPP branch 
to synthesize ribose and use glutamine to produce NADPH, as discussed in Chapter 5.3. 
On the other hand, our results indicate that MCF7 cells mainly use oxidative branch of 
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PPP to synthesize ribose for RNA, but little impact on ribose synthesis was found on 
ribose synthesis when G6PD was inhibited. However, a greater change was observed in 
ROS, suggesting that ROS and ribose synthesis might be decoupled and most of the 
ribose synthesized through the oxidative branch of PPP might be reintroduced into 
glycolysis instead of using for RNA synthesis. Therefore, it would indicate that the 
primary use of this pathway is to synthesize NADPH instead of ribose.  
On the contrary to HT29, when G6PD was inhibited in MCF7 cells, a decrease in cell 
proliferation was found, indicating that the metabolism of these could not be readapted 
to avoid this metabolic insult. Then, the results presented here reveal a metabolic 
fragility in this cell model.  
The different consequences of G6PD inhibition in MCF7 and HT29 might also be 
explained on the basis of P53 state in each cell model. HT29 is a P53-deficient cell line 
that harbors P53(R273H) mutation, whereas MCF7 is a P53-proficient cell line. As 
discussed in Chapter 5.3, wild-type P53 binds to G6PD and impairs dimer formation, 
inhibiting G6PD activity. P53(R272H) mutant maintains the capability of binding to 
G6PD but it cannot inhibit the enzymatic activity. Therefore, according to this regulatory 
system, the concentration of active G6PD enzyme in HT29 is expected to be higher than 
in MCF7. Consequently, the higher is the concentration of the enzyme, the more difficult 
is the total inhibition of the reaction or flux. When G6PD is overactivated due to P53 
mutation, it might be more interesting to inhibit the enzyme 6PGD. A high G6PD activity 
leads to the production of high 6PG, which has been proposed to display an inhibitory 
growth effect in P53-mutated cell line H1975 (Sukhatme and Chan, 2012). Therefore, 
blockade of the 6PDG reaction would lead to a rapid accumulation of this metabolite 
and subsequent inhibition of proliferation. In addition, this option would be even more 
interesting in cancer cells with high glycolytic flux, since enhanced glycolysis provides 
high amounts of PPP precursors. 
Furthermore, a very interesting metabolic relation between PPP and glutamine 
metabolism has been unveiled in this thesis. In MCF7 cells, inhibition of PPP enzymes 
G6PD and TKT led to an increase in glutamine consumption whereas HT29 cells cultured 
in the absence of glutamine experienced an increase in G6PD expression and activity. 
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However, whether the response observed in each case is intended to fulfill the same 
requirement is unclear. In P53-proficient MCF7 cells, the inhibition of G6PD led to 
increased ROS levels and glutamine consumption. A potential mechanism to explain 
this response might be based on P53 activation. Under high oxidative stress conditions, 
P53 is activated and results in increased expression of the P53 target gene glutaminase 
2, which increases the intracellular levels of glutamate, α-ketoglutarate, reduced 
glutathione and mitochondrial ATP production (Hu et al., 2010; Suzuki et al., 2010). As 
shown in Chapter 5.4, our results support the idea that glutamine enhances ATP 
production, since G6PD inhibition in MCF7 cells cultured in glutamine-free media 
displayed a decreased ATP/ADP ratio. On the other hand, HT29 cells cultured in 
glutamine-free media resulted in increased ROS levels. In this case, despite the 
observed increase in ROS, the fact that HT29 is a P53-decificent cell line together with 
the absence of glutamine in cell culture media make unfeasible the activation of the 
same mechanism triggered in MCF7 cells. However, NRF2-mediated response involving 
G6PD upregulation was detected, which might be intended to restore NADPH levels. 
The importance of maintaining NADPH homeostasis in cancer cells has been previously 
reported by Jeon and colaborators (Jeon et al., 2012). Therein, NADPH generation 
through PPP is impaired under glucose deprivation. Under these conditions, AMP-
kinase induces alternative routes to maintain NADPH levels and inhibit cell death. The 
inhibition of the acetyl-CoA carboxylases 1 and 2  (ACC1 and ACC2) by AMPK maintains 
NADPH levels by decreasing NADPH consumption in fatty-acid synthesis and increasing 
NADPH generation by means of fatty acid oxidation. In a parallel manner, glutamine 
deprivation well might induce a NRF2-mediated metabolic reorganization in HT29 cells 
by activating oxidative PPP flux to provide cells with NADPH. This mechanism might be 
positively influenced by P53 mutation in HT29. P53 has been reported to negatively 
regulate NRF2-dependent transcription of antioxidant genes (Faraonio et al., 2006). 
Thus, the absence of functional P53 would boost NRF2-mediated response, enhancing 
the upregulation of NRF2 target genes such as G6PD. 
In summary, in this thesis we have provided and extensive and deep body of evidence 
of the metabolic reprogramming induced by RAS oncogenic activation as well as 
explored the role of PPP enzymes in cancer cell metabolism. The study of the RAS-
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induced metabolic reprogramming has revealed a variety of metabolic changes which 
can potentially represent specific metabolic dependencies of RAS-mutated cells and 
tumors. On the other hand, the inhibition of G6PD might be a promising therapeutic 
intervention point in some tumors according to the levels of oxidative stress or the 
mutational status of other regulatory proteins, such as P53. Furthermore we have also 
provided new knowledge to understand the regulation of metabolic processes, such as 
the interplay between PPP and glutamine metabolism. Collectively, all the results 
provided in this thesis, fully support the intimate relationship between oncogenes and 
metabolism and highlight the importance of metabolism in cancer cell proliferation and 
survival.  
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7. CONCLUSIONS 
1. The study of flux distribution in combination with metabolic control analysis 
performed by analyzing solely the sign of fixed-sign control coefficients, is a reliable 
approach to identify the key enzymes involved in metabolic reprogramming. The use 
of this methodology has allowed us to identify an increase in glycolysis and PPP 
fluxes as metabolic features of KRAS-induced metabolic reprogramming and to 
propose G6PD, PK and LDH as the key enzymes responsible for this metabolic 
transition. 
2. H-RAS oncogenic activation reprograms glucose and glutamine metabolism by 
enhancing glycolytic and PPP fluxes as well as mitochondrial metabolism. Glutamine 
is responsible for sustaining the activated mitochondrial metabolism in BJ-HRasV12, 
while glucose-derived carbons in the mitochondria are primarily used to fuel 
lipogenesis. Moreover, lipogenesis is overactivated in BJ-HRasV12 cells, which are 
more sensitive to FAS inhibition than BJ cells. 
3. G6PD enzyme is overactivated in colon cancer cells with oncogenic activation of the 
RAS signaling pathway. Nevertheless, G6PD seems to be dispensable for 
proliferation and survival in BRAF-mutated HT29 cell line. Furthermore, a new 
connection between PPP and glutamine metabolism has been unveiled, as G6PD is 
overexpressed in HT29 cells under glutamine-deprived conditions by a mechanism 
involving a concomitantly increase in ROS levels and NRF2 induction.  
4. G6PD enzyme is important in proliferation, survival and regulation of ROS levels in 
breast cancer MCF7 cells. However, it exerts a low regulation over ribose synthesis 
flux through the oxidative branch of PPP. G6PD inhibition enhances glycolytic flux, 
promotes lactate secretion and increases glutamine consumption, which is used to 
maintain energy homeostasis, although it is not essential for cell proliferation.  
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5. TKT enzyme is dispensable for proliferation of breast cancer MCF7 cells, but it exerts 
a high control over ribose synthesis flux through the nonoxidative branch of PPP. 
TKT impairment reduces glycolytic flux and increases the consumption of glutamine, 
which is intended to maintain energy homeostasis but it is not essential for cell 
proliferation.  
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8. RESUMEN EN ESPAÑOL / SUMMARY IN 
SPANISH 
8.1 INTRODUCCIÓN 
8.1.1  Visión general de las bases del cáncer 
El cáncer es un término genérico que incluye un elevado número de enfermedades en 
las cuales las células de los tejidos proliferan descontroladamente y son capaces de 
invadir otros tejidos dando lugar a la formación de metástasis. Para el desarrollo y la 
progresión de un tumor es necesario que las células tumorales adquieran ciertas 
capacidades a lo largo del proceso cancerígeno. Estas capacidades se pueden clasificar 
en: generación de señales de crecimiento, insensibilidad a las señales de inhibición de la 
proliferación, evasión de la apoptosis, capacidad de invasión y metástasis, potencial 
ilimitado de replicación y capacidad de estimulación de procesos angiogénicos 
(Hanahan and Weinberg, 2011). Recientemente se han incorporado dos nuevas 
capacidades, que son la evasión del sistema inmunitario y la reprogramación del 
metabolismo, permitiendo esta última satisfacer las necesidades energéticas y 
biosintéticas particulares de la célula tumoral.  
8.1.2  Metabolismo tumoral 
El metabolismo es el conjunto de reacciones químicas que posibilitan la vida y que 
tienen lugar dentro de las células de los organismo vivos. Todas las células de nuestro 
cuerpo requieren de la aportación de nutrientes, los cuales pueden ser empleados en 
reacciones que tienen como finalidad la obtención de energía (catabolismo) o bien en 
procesos de síntesis de macromoléculas necesarios para la proliferación (anabolismo). 
Estas necesidades nutricionales son particularmente altas en células proliferantes, ya 
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que deben duplicar todo su material ante de dividirse. Por tanto, dado que el cáncer es 
una enfermedad basada en la proliferación descontrolada de las células de los tejidos, 
no es de extrañar que el metabolismo de las células tumorales se vea particularmente 
alterado.  
Las primeras observaciones de la existencia de un metabolismo diferencial en células 
tumorales tuvo lugar a principios del siglo XX, cuando Otto Warburg demostró que 
muestras de tumores presentaban un consumo de glucosa mayor que los tejidos 
normales y, que incluso en presencia de oxígeno, metabolizaban la glucosa a través de 
glucólisis anaerobia en lugar de fosforilación oxidativa (Jones and Schulze, 2011; 
Warburg et al., 1927). Esta característica del metabolismo tumoral es comúnmente 
conocida como efecto Warburg.  
Durante los últimos años, el estudio del metabolismo tumoral, pese a haber sido 
considerado como un efecto colateral derivado de la activación de oncogenes o 
inactivación de genes supresores de tumores, ha cobrado especial relevancia. Muchas 
de las vías de señalización implicadas en la proliferación y supervivencia celular y que se 
encuentran frecuentemente mutadas en cáncer, como PI3K/AKT o RAS, ejercen parte de 
sus efectos mediante la regulación del entramado metabólico, siendo éstos esenciales 
para la correcta ejecución de las señales transmitidas por estas vías. Por tanto, las vías 
de señalización que controlan tanto la proliferación y la supervivencia como el 
metabolismo se encuentran íntimamente relacionadas y esta conexión es esencial para 
que los procesos celulares se sucedan de manera apropiada y coordinada.  
8.1.2.1 Obtención de ATP: bioenergética de la célula tumoral y el efecto 
Warburg 
Tal como describió Warburg, la mayoría de células tumorales metabolizan la glucosa 
principalmente mediante glucólisis aeróbica en lugar de fosforilación oxidativa. Dado 
que la glucólisis aeróbica menos eficiente que la fosforilación oxidativa en la producción 
de ATP por molécula de glucosa, las razones por las cuales las células tumorales 
adoptan este metabolismo glucolítico constituyen todavía hoy un tema controvertido. 
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Algunas ventajas para la célula tumoral que podrían derivarse de este fenotipo 
metabólico serían la utilización de una ruta metabólica de producción de energía rápida 
para un sustrato que puede ser limitante en algunas condiciones, la obtención de 
elevadas concentraciones de intermediarios glucolíticos necesarios para procesos 
biosintéticos, una menor dependencia del oxígeno en condiciones de hipoxia que se 
pueden dar habitualmente en tumores sólidos y una posible protección frente al 
desencadenamiento de procesos apoptóticos originados en la mitocondria. 
El efecto Warburg se encuentra regulado por algunos de los oncogenes más 
frecuentemente mutados en cáncer como c-MYC (Dang et al., 2009; Shim et al., 1997), 
RAS (Chun et al., 2010) o P53 (Kondoh et al., 2005; Pilkis et al., 1981; Vousden and Ryan, 
2009), los cuales modulan la expresión de muchas de las enzimas glucolíticas.  
Aunque la glucosa es el principal sustrato energético, también otros nutrientes pueden 
ser metabolizados con finalidad energética. Uno de los más relevantes es la glutamina, 
que además de participar en numerosos procesos biosintéticos, también puede ser 
oxidada en el ciclo de los ácidos tricarboxílicos (TCA, del inglés Tricarboxylic Acid) para 
dar lugar a la síntesis de ATP mediante fosforilación oxidativa. De hecho, algunos 
estudios demuestran el papel esencial de la glutamina en la proliferación y 
supervivencia de células tumorales (DeBerardinis and Cheng, 2010; DeBerardinis et al., 
2007).  
8.1.2.2 Proliferación celular: procesos biosintéticos en el metabolismo tumoral 
La proliferación celular conlleva duplicar todo el material celular, incrementando las 
necesidades de la célula de precursores metabólicos para la síntesis de macromoléculas. 
Se ha propuesto que las células proliferantes, y en particular las células tumorales, en 
lugar de maximizar los procesos de obtención de energía mediante el uso de la 
fosforilación oxidativa mitocondrial, deben maximizar la capacidad de producción de 
sustratos precursores de macromoléculas para poder proliferar (DeBerardinis et al., 
2008). Así, la mitocondria actuaría como centro biosintético donde se producen muchos 
de los precursores necesarios. Asimismo, las células tumorales presentan elevadas 
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necesidades de lípidos para duplicar sus membranas, hecho que comporta una salida 
de metabolitos del ciclo de TCA, en este caso de citrato para la síntesis de ácidos 
grasos. Dicha salida de metabolitos del ciclo de TCA constituye el proceso conocido 
como cataplerosis. Las células tumorales presentan frecuentemente una sobreactivación 
de las vías metabólicas encargadas de las síntesis de ácidos grasos, las cuales son 
reguladas por señales de proliferación frecuentemente alteradas en cáncer (Santos and 
Schulze, 2012). Para evitar el vaciado del ciclo del CAT, los procesos catapleróticos 
deben ser compensados con la entrada de otros metabolitos en el ciclo de TCA en el 
proceso inverso a la cataplerosis conocido como anaplerosis. El principal metabolito 
que cubre esta función en células proliferantes y en especial en células tumorales es la 
glutamina. Este aminoácido participa en multitud de procesos biosintéticos de manera 
directa, mediante la donación de sus grupos nitrogenados para la síntesis de 
nucleótidos así como a través de su conversión a glutamato y α-cetoglutarato, 
participando en la síntesis de aminoácidos, glutatión, ATP y equivalentes reducidos en 
forma de NADPH (DeBerardinis and Cheng, 2010). Además la glutamina también 
contribuye a la síntesis de lípidos no solo a través del metabolismo oxidativo 
mitocondrial sino también mediante el proceso de carboxilación reductiva, a través de 
la cual el α-cetoglutarato derivado de la glutamina es transformado en isocitrato a 
través de la carboxilación mediada por la isocitrato deshidrogenasa y la posterior 
transformación catalizada por la aconitasa, siendo esta carboxilación reductiva 
especialmente relevante en condiciones de hipoxia (Metallo et al., 2012).  
Los procesos biosintéticos requieren tanto de precursores metabólicos como de 
coenzimas reducidos en forma de NADPH, siendo éste último imprescindible para la 
síntesis de ácidos grasos, aminoácidos, nucleótidos y  el mantenimiento de los niveles 
intracelulares de glutatión reducido. Una de las rutas metabólicas más implicadas tanto 
en la síntesis de macromoléculas como de NADPH es la ruta de las pentosas fosfato 
(PPP, del inglés Pentose Phosphate Pathway) (Riganti et al., 2012). Esta vía metabólica se 
divide en dos ramas. Por un lado, la rama oxidativa, compuesta por las enzimas 
glucosa-6-fosfato deshidrogenasa (G6PD) y 6-fosfogluconato deshidrogenasa (6PGD), 
tiene como finalidad la síntesis de NADPH y de ribosa-5-fosfato (R5P). Por otro lado, la 
rama no oxidativa, está catalizada por la transcetolasa (TKT) y la transaldolasa (TALDO) y 
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se encarga tanto de la síntesis de R5P como del reciclaje del exceso de pentosas hacia 
la glucólisis. Ambas ramas de la PPP han sido relacionadas con diversos aspectos del 
fenotipo tumoral. Se ha descrito que la vía oxidativa se encuentra sobreactivada en 
ciertos tipos de cáncer (Kekec et al., 2009; Langbein et al., 2008) así como en procesos 
de transformación por oncogenes (de Atauri et al., 2011), y que su sobreexpresión se 
correlaciona con una mayor proliferación y permite la formación de tumores en ratones 
atímicos (Kuo et al., 2000; Leopold et al., 2003; Tian et al., 1998). Por otro lado, se ha 
demostrado que algunos tumores emplean preferentemente la vía no oxidativa para la 
síntesis de ribosa (Boros et al., 1997; Ying et al., 2012). 
En el contexto del metabolismo tumoral, la PPP está regulada por algunos de los 
oncogenes y genes supresores de tumores más importantes, como RAS, PI3K, AKT o 
P53 (de Atauri et al., 2011; Jiang et al., 2011; Mitsuishi et al., 2012b; Vizan et al., 2005; 
Ying et al., 2012). 
8.1.2.3 Mantenimiento del estado redox 
Como consecuencia del metabolismo celular se producen una serie de subproductos 
que deben ser eliminados o neutralizados para evitar su toxicidad. Algunos de estos 
subproductos son las denominadas Especies Reactivas de Oxígeno (ROS, del inglés 
Reactive Oxygen Species) y el incremento de su concentración en la célula da lugar a lo 
que se conoce como estrés oxidativo. 
El estrés oxidativo está asociado con numerosos procesos que tienen lugar en la célula 
tumoral. Los niveles de ROS son finamente regulados mediante procesos de producción 
y eliminación, ya que a bajas concentraciones promueven la proliferación celular pero 
un incremento descontrolado resulta altamente tóxico para la célula (Boonstra and Post, 
2004; Trachootham et al., 2009). Así, el crecimiento tumoral se ha asociado con elevados 
niveles de ROS (Kawanishi et al., 2006; Szatrowski and Nathan, 1991), los cuales inducen 
efectos sobre el fenotipo tumoral a diferentes niveles, incluyendo proliferación, 
viabilidad, apoptosis y progresión del ciclo celular, metabolismo energético, movilidad y 
adhesión celular, y angiogénesis (Sosa et al., 2013). Un ejemplo de ello lo encontramos 
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en los tumores de mama, que elevados niveles de estrés oxidativo (Brown and Bicknell, 
2001; Kang, 2002; Portakal et al., 2000; Toyokuni et al., 1995). 
Los mecanismos tumorales que conducen a unos niveles elevados de ROS no están 
totalmente claros. Sin embargo, la activación de oncogenes, defectos en el 
metabolismo, un mal funcionamiento de la mitocondria o pérdida del gen supresor de 
tumores P53 son factores intrínsecos que causan un incremento de los niveles de ROS 
(Cook et al., 2004). Un ejemplo paradigmático de éstos es la activación del oncogén 
RAS, que ha sido relacionada con el incremento de los niveles de estrés oxidativo (Irani 
et al., 1997; Weinberg et al., 2010). Además, existen otros factores extrínsecos que 
pueden afectar a los niveles de ROS intracelular (Cook et al., 2004).  
Dado que las células tumorales presentan niveles de ROS incrementados, parece lógico 
que al mismo tiempo hayan desarrollado mecanismos adaptativos para controlarlos y 
neutralizar los potenciales efectos tóxicos. En el caso de células con RAS mutado se ha 
descrito la activación de una variedad de mecanismos relacionados con esta finalidad, 
como la activación de la vía oxidativa de la PPP (de Atauri et al., 2011; Vizan et al., 2005), 
la síntesis de niveles elevados de antioxidantes como peroxiredoxina-3 y tiorredoxina 
peroxidasa C (Young et al., 2004) o la activación del sistema de detoxificación KEAP1-
NRF2 (DeNicola et al., 2011) entre otros (Trachootham et al., 2006).  
El mantenimiento de los niveles de ROS mediante el sistema de detoxificación KEAP1-
NRF2 es particularmente interesante. Los niveles del factor de transcripción NRF2 se 
encuentran frecuentemente elevados en varios tipos de tumores y se ha demostrado 
que este factor de transcripción está involucrado en la adquisición de propiedades 
malignas por parte de las células tumorales (Kim et al., 2010; Singh et al., 2006; Solis et 
al., 2010; Wang et al., 2008). Existen diversos mecanismos que conducen a una 
sobreactivación de NFR2 (Mitsuishi et al., 2012a), entre los que destaca la señalización 
mediada por oncogenes, como por ejemplo RAS (DeNicola et al., 2011). Una fracción 
importante de los genes regulados por NRF2 corresponde a genes del metabolismo, 
como so los que codifican para las enzimas G6PD, fosfoglicerato deshidrogenasa  
(PGD), TKT, TALDO, enzima málico (ME) e isocitrato deshidrogenasa (IDH) (Mitsuishi et 
al., 2012b). Estos genes no sólo están involucrados en el control redox sino también en 
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la síntesis de una gran variedad de intermediarios metabólicos necesarios para la 
síntesis de macromoléculas. Así pues, NRF2 ejerce una acción dual en el metabolismo 
tumoral, participando simultáneamente en el control de los niveles de estrés oxidativo y 
en la síntesis de macromoléculas.  
Las implicaciones del metabolismo en el mantenimiento de la homeostasis redox van 
más allá de las mediadas por NRF2. Una de las ventajas que se ha asociado al efecto 
Warburg es que una menor utilización de la mitocondria reduciría los niveles de ROS 
procedentes del metabolismo oxidativo. Además, el incremento de la concentración de 
los intermediarios glucolíticos permitiría disponer de mayor concentración de sustratos 
para la vía oxidativa de la PPP, cuyo papel en la protección frente al estrés oxidativo ha 
sido ampliamente documentado (Cheng et al., 2004; Gao et al., 2009a; Ho et al., 2000). 
En este aspecto juega un papel importante la enzima glucolítica piruvato quinasa M2 
(PKM2), que bajo elevadas concentraciones de ROS reduce su actividad y disminuye el 
flujo glucolítico, provocando la acumulación de intermediarios glucolíticos que 
permiten incrementar el flujo a través de la vía oxidativa de la PPP (Anastasiou et al., 
2011). También el metabolismo de la glutamina participa en el mantenimiento de la 
homeostasis redox aportando intermediarios que participan en reacciones en las que se 
produce NADPH, como la reacción catalizada por el ME (DeBerardinis et al., 2007). 
A nivel mecanístico, cabe mencionar que los procesos para el control de los niveles de 
estrés oxidativo expuestos anteriormente son en parte inducidos por algunos 
oncogenes, como por ejemplo RAS (Mazurek et al., 2001; Son et al., 2013). Así, algunos 
de los oncogenes que inducen el efecto Warburg y la generación de ROS 
simultáneamente, como RAS, activan un programa metabólico dual con el objetivo de 
proveer a la célula tumoral con los precursores metabólicos necesarios y la protección 
frente a elevados niveles de ROS, cubriendo así dos requisitos esenciales para la 
progresión tumoral. 
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8.1.3  Estudio del metabolismo tumoral 
El auge de la biología molecular durante los últimos años ha propiciado que el estudio 
del metabolismo tumoral se haya centrado principalmente en la regulación de ciertas 
reacciones metabólicas y/o enzimas por oncogenes o genes supresores de tumores. 
Aunque la biología tumoral, por si misma o en combinación con otras disciplinas como 
la transcriptómica o la proteómica, genera información valiosa para el estudio del 
metabolismo, ésta no es suficiente para un estudio detallado del mismo. Para ello, 
datos bioquímicos y metabólicos son esenciales. Por tanto, dada la extensión y la 
complejidad del entramado metabólico, el estudio del metabolismo se debe llevar a 
cabo desde un perspectiva integrada, estudiando sus diferentes niveles de regulación 
mediante herramientas experimentales y computacionales. Posiblemente, la Biología de 
Sistemas Computacional sea la disciplina más involucrada en este tipo de estudios 
(Borodina and Nielsen, 2005; Cascante and Marin, 2008; Hiller and Metallo, 2012). 
Asimismo, el estudio del metabolismo queda también integrado dentro de la disciplina 
conocida como metabolómica, la cual tiene como objeto el estudio y la cuantificación 
de todos los metabolitos de un organismo. (Fiehn, 2002). Sin embargo, el 
funcionamiento de la red metabólica no puede ser estudiado tan sólo mediante el 
análisis de la concentración de metabolitos, que es consecuencia de la transformación y 
transporte de los mismos a través de reacciones metabólicas, en lo que se conoce como 
flujos metabólicos. Con el objetivo de superar estas limitaciones, el análisis de la 
distribución de flujos metabólicos y los cambios asociados a ellos son explorados a 
nivel celular en una nueva disciplina emergente llamada flujómica (Cascante and Marin, 
2008; Winter and Kromer, 2013). 
8.1.3.1 Flujómica: el análisis de los flujos metabólicos 
Los flujos metabólicos intracelulares pueden ser estudiados a diferentes niveles, desde 
el análisis de balance de flujos (FBA, del inglés Flux Balance Analysis), basado 
principalmente en la estequiometria de todas las reacciones metabólicas del sistema en 
estudio (Orth et al., 2010), hasta el uso de precursores de las vías metabólicas marcados 
con 13C, en lo que se conoce como análisis de flujos metabólicos basado en 13C (13C-
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MFA, del inglés 13C-Metabolic Flux Analysis) (Sauer, 2006). El uso de sustratos marcados 
con 13C ofrece datos adicionales para la restricción del espacio de soluciones (valores 
posibles de flujos) obtenido mediante métodos de FBA. La aproximación experimental 
más común para llevar a cabo 13C-MFA es la metabolómica basada en 13C. En estos 
experimentos las células son cultivadas en presencia de sustratos metabólicos marcados 
con 13C (trazador), los cuales son metabolizados por las células y dan lugar a la 
formación de metabolitos que contienen átomos de 13C procedentes del trazador. 
Dependiendo de la vía metabólica a través de la cual ha sido metabolizado el trazador, 
los átomos de 13C son incorporados en diferente número y posición en los nuevos 
metabolitos, produciendo metabolitos con una distribución isotopomérica distinta, 
tanto en número de 13C (isotopómero de masa) como en posición del 13C dentro de la 
molécula (isotopómero de posición). En los experimentos de metabolómica basada en 
13C se pueden utilizar una gran variedad de trazadores dependiendo de las rutas 
metabólicas a estudiar (Metallo et al., 2009). Entre los trazadores más comunes se 
encuentran aquellos derivados de la glucosa (13C-glucosa) o la glutamina (13C-
glutamina), que han sido ampliamente utilizados con distintas distribuciones 
isotopoméricas, como por ejemplo la [1,2-13C2]-glucosa (Marin et al., 2003; Vizan et al., 
2009), la [U-13C]-glucosa (Gaglio et al., 2011), la [U-13C]-glutamina, [1-13C]-glutamina o 
la [5-13C]-glutamina (Metallo et al., 2012).  
Una vez finalizado el experimento, los metabolitos intracelulares y/o extracelulares son 
analizados mediante cromatografía de gases o cromatografía de líquidos acoplada a 
espectrometría de masas (GC-MS o LC-MS, del inglés, Gas or Liquid Chromatography 
coupled to Mass Spectrometry) o bien mediante resonancia magnética nuclear (NMR, del 
inglés Nuclear Magnetic Resonance) para determinar la presencia de 13C y, si es posible, 
su posición en la molécula. Así pues, se obtiene la distribución isotopomérica de los 
distintos metabolitos marcados con 13C. Dicha distribución, en combinación con 
medidas de los flujos extracelulares relacionados con el trazador y/o otros sustratos, 
puede ser utilizada para determinar algunos flujos intracelulares, o bien la relación entre 
algunos de ellos, mediante el uso de fórmulas matemáticas simples basadas en el 
conocimiento previo de la red metabólica en estudio. Esta aproximación es conocida 
como MIDA (Análisis de la Distribución de Isotopoméros de Masa, del inglés, Mass 
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Isotopomer Distribution Analysis) (Alcarraz-Vizan et al., 2010; Marin et al., 2003; Ramos-
Montoya et al., 2006). 
Además, la distribución de isotopómeros de masa de los metabolitos, puede ser 
introducida en modelos computacionales que simulan de manera detallada el 
funcionamiento de la red metabólica, permitiendo estimar de manera más precisa los  
flujos intracelulares (Hiller and Metallo, 2012; Selivanov et al., 2006; Selivanov et al., 
2004). 
8.1.3.2 Análisis de control metabólico: identificación de las  enzimas clave  
En los sistemas metabólicos es frecuente la existencia de reacciones limitantes. Estas 
reacciones son particularmente relevantes, ya que variaciones en las enzimas que las 
catalizan cambian el flujo de la correspondiente vía metabólica en la que participan. El 
Análisis de Control Metabólico (MCA, del inglés Metabolic Control Analysis) es una 
aproximación matemática aplicada al estudio de los mecanismos reguladores de las 
redes metabólicas (Fell, 1997; Kacser and Burns, 1973). El análisis de MCA se lleva a 
cabo mediante la determinación de los coeficientes de sensibilidad, los cuales estiman 
en qué medida la perturbación de un parámetro (del sistema Km, Vmax, concentración de 
enzima…) afecta al valor en estado estacionario de una variable del sistema (flujo, 
concentración de un metabolito), siendo los más importantes los coeficientes de control 
(Fell, 1997; Kacser and Burns, 1973). En MCA, la elasticidad (εqk) es el parámetro de 
sensibilidad de la velocidad de una reacción aislada (vq) con respecto a los cambios en 
la concentración (xk) de uno de sus sustratos, un inhibidor o cualquier otro efector 
cinético de la reacción aislada  (Ecuación 1 en Sección 2.3.2) (Cornish-Bowden, 2000; 
Fell, 1997).  
Igualmente, el coeficiente de control de flujo o concentración es una propiedad del 
sistema definida como la sensibilidad de la concentración de un metabolito (xg) o un 
flujo (Jq) en estado estacionario a cambios en un parámetro p, normalmente la 
concentración de enzima (vk) (Ecuaciones 2 y 3 en Sección 2.3.2) . 
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Cuanto mayor sea el coeficiente de control de una enzima, mayor será su contribución 
al control y a la regulación de la vía metabólica, siendo el flujo de dicha vía o la 
concentración o actividad del metabolito en cuestión más sensible a cambios en la 
actividad de esta enzima. 
Se han propuesto diferentes aproximaciones para la derivación de los coeficientes de 
control a partir de las elasticidades (Cascante et al., 1989a; Cascante et al., 1989b; Fell 
and Sauro, 1985; Reder, 1988; Westerhoff and Kell, 1987). Sin embargo, el signo de los 
coeficientes de control (positivo o negativo) puede ser suficiente para predecir si un 
flujo o concentración se incrementará o reducirá cuando la actividad de una enzima del 
sistema determinada cambie. Los coeficientes de control pueden ser de signo fijo, 
indeterminado o cero, dependiendo de la estructura de la red metabólica y las 
regulaciones, reflejadas principalmente en el signo positivo o negativo de las 
elasticidades: las elasticidades con respecto a los sustratos y activadores son siempre 
positivas mientras que las elasticidades con respecto a los inhibidores son siempre 
negativas (o productos en reacciones reversibles). Los coeficientes de control positivos 
indican que cambios en la concentración de un metabolito (xg) o flujo (Jq) seguirán la 
misma dirección que cambios en la actividad de la enzima (vk). Por el contrario, los 
coeficientes de control negativos indican que cambios en vk inducirán un cambio en 
sentido inverso en xg o Jq.  Así, los coeficientes de control de signo fijo se pueden 
utilizar para evaluar qué enzimas del entramado metabólico podrían explicar los 
incrementos o decrementos observados en flujos y concentraciones o bien predecir 
posibles cambios tras el aumento o disminución de alguna actividad enzimática. 
8.1.4  El metabolismo tumoral como potencial diana antitumoral 
8.1.4.1 La reprogramación metabólica inducida por oncogenes como potencial 
diana terapéutica en cáncer  
La reprogramación metabólica inducida por oncogenes conlleva que las células 
tumorales desarrollen una elevada dependencia de ciertos procesos metabólicos y/o 
enzimas, ofreciendo por tanto un conjunto de posibles dianas terapéuticas. La mutación 
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de ciertos oncogenes, como RAS o MYC, induce profundos cambios en el metabolismo  
que permiten a la célula dotarse de los recursos metabólicos necesarios para el proceso 
tumorigénico. Por ejemplo, se ha demostrado que ciertas enzimas son proteínas clave y 
esenciales para la progresión de tumores con RAS o c-MYC mutados (Dang et al., 2009; 
Gao et al., 2009b; Son et al., 2013; Telang et al., 2006). Los tumores con RAS mutado 
presentan especial dependencia de la glucólisis (Telang et al., 2006) y de una ruta 
alternativa del metabolismo de la glutamina en la cual el aspartato derivado de la 
glutamina es convertido en oxaloacetato por la transaminasa GOT, el cual es 
transformado en malato y después en piruvato mediante el ME, produciendo NADPH. 
(Son et al., 2013). Por otro lado, los tumores con c-MYC mutado son especialmente 
dependientes del metabolismo de la glutamina (Dang et al., 2009; Gao et al., 2009b). Así 
pues, estas dependencias metabólicas constituyen potenciales puntos de intervención 
terapéutica. 
8.1.4.2 La PPP como potencial diana antitumoral 
La PPP participa en dos procesos clave del metabolismo tumoral: la síntesis de ribosa y 
la síntesis de NADPH, éste último necesario para el mantenimiento del glutatión 
reducido y la lipogénesis. Por ello, las enzimas clave de la PPP, G6PD y TKT, han sido 
postuladas como potenciales dianas antitumorales. Por una lado, se ha descrito que la 
inhibición de la G6PD disminuye la proliferación en fibroblastos y líneas tumorales (Ho 
et al., 2000; Li et al., 2009), así como del tumor ascítico de Ehrlich en modelos in vivo 
(Boros et al., 1997; Rais et al., 1999). Por otro lado, también se ha demostrado que la 
inhibición de la TKT disminuye la proliferación tumoral in vitro, en células de 
adenocarcinoma de páncreas, e in vivo en ratones con tumor ascítico de Ehrlich (Boros 
et al., 1997; Rais et al., 1999). Conjuntamente, estos resultados indican que la inhibición 
de la PPP es una potencial estrategia terapéutica para combatir la progresión tumoral. 
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8.2. RESULTADOS Y DISCUSIÓN 
8.2.1. El metabolismo del carbono y el signo de los coeficientes 
de control en las adaptaciones metabólicas inducidas por K-RAS 
El oncogén K-RAS se encuentra mutado en aproximadamente el 25% de los tumores 
(Fernandez-Medarde and Santos, 2011). Dado el papel fundamental que juega el 
metabolismo en la progresión tumoral, conocer las adaptaciones metabólicas inducidas 
por la mutación de este oncogén y las enzimas clave que las promueven puede 
contribuir sustancialmente a desvelar mecanismos esenciales para la progresión de 
tumores con K-RAS mutado. En este capítulo, se han empleado células de ratón NIH3T3 
transfectadas con el oncogén K-RAS mutado en los codones 12 (K12) y 13 (K13). Para 
determinar las principales diferencias metabólicas entre las células no transfectadas, las 
K12 y las K13, i) se determinaron experimentalmente las concentraciones de 
metabolitos extra- e intracelulares, ii) se definió el sistema metabólico de estudio, así 
como sus regulaciones, y se obtuvo el intervalo de valores posibles para cada reacción 
que conforma el sistema, iii) se identificaron los coeficientes de control de signo fijo y 
iv) se emplearon estos coeficientes de control para identificar las enzimas 
potencialmente responsables de los cambios en los flujos observados en las células K12 
y K13 respecto a las células no transfectadas. 
Para determinar los flujos intra- y extracelulares se midieron experimentalmente los 
principales flujos de entrada y salida de la célula (glucosa, lactato, glutamina y 
glutamato) y la concentración de algunos metabolitos intracelulares (hexosas fosfato, 
pentosas fosfato, triosas fosfato, fructosa-1,6-bifosfato y fosfoenolpiruvato). 
Posteriormente se determinó el sistema metabólico de estudio (Figura 5.1.1) y se 
obtuvo el mapa de flujos metabólicos correspondiente a cada tipo celular mediante 
FBA, usando la metodología sugerida por Llaneras y Picó (Llaneras and Pico, 2007) 
conocida como intervalo de satisfacción de restricciones (interval constraint satisfaction 
approach). Asimismo, en el análisis también se usaron restricciones isotopoméricas 
correspondientes a la relación entre los flujos glucolítico y a través de la PPP (Vizan et 
al., 2005). La distribución de flujos resultante se muestra en la Figura 5.1.2, donde se 
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observa un incremento de los flujos en las reacciones de la glucólisis y de la vía 
oxidativa de la PPP en las células K12 y K13 respecto a las células no transfectadas. En 
concordancia con estos resultados, se observó que las concentraciones de los 
intermediarios metabólicos de estas de estas vías estaban disminuidas en las células 
mutadas (Figura 5.1.3).  
Para determinar las enzimas responsables de la reprogramación metabólica observada, 
se empleó el análisis de los coeficientes de control de signo fijo.  Con el objetivo de 
identificar estos coeficientes de control, en el sistema metabólico utilizado se aplicó la 
aproximación matricial propuesta por Cascante et al mostrada en la figura 5.1.4.A-B 
(Cascante et al., 1989a; Cascante et al., 1989b). El signo de los coeficientes de control de 
flujo y concentración obtenidos son presentados en la tabla de dependencias de la 
Figura 5.1.4.D y conjuntamente ofrecen una herramienta predictiva que puede ser 
empleada para evaluar el impacto de cambios en actividades enzimáticas sobre los 
flujos y concentraciones, o bien, para hipotetizar qué cambios enzimáticos permiten 
explicar los cambios observados en los flujos y concentraciones. Teniendo en cuenta la 
matriz de dependencias mostrada en la Figura 5.1.4.D, se determinó experimentalmente 
la actividad específica de varias enzimas y se comprobó si los cambios en ellas 
concordaban con la distribución de flujos previamente obtenida (Figura 5.1.5.B). Se 
detectaron incrementos en las actividades específicas de las enzimas G6PD, PK y LDH, 
mientras que la actividad de la TKT se encontró disminuida y no se detectaron cambio 
en la actividad HK. En la Figura 5.1.5.B, los cambios en las actividades enzimáticas que 
dan lugar a cambios en los flujos que satisfacen la distribución observada de los 
mismos, se encuentran indicados en verde. Por el contrario, aquellos que no la 
satisfacen se encuentran marcados en rojo. Así pues, estos resultados nos permiten 
confirmar que el incremento observado en los flujos de la glucólisis y de la vía oxidativa 
de la PPP, así como la disminución de las concentraciones de azúcares fosfato en las 
células K12 y K13 respecto a las células no transfectadas, podrían ser explicados por el 
incremento de la actividad específica de las enzimas G6PD, PK y LDH y la disminución 
de la actividad TKT. Además, tal como se observa en la Figura 5.1.5.B, para explicar 
completamente el fenotipo metabólico observado en las células K12 y K13 son 
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necesarios cambios simultáneos en varias enzimas, como la G6PD y algunas enzimas 
glucolíticas. 
8.2.2.  Estudio de la reprogramación metabólica inducida por la 
activación oncogénica de H-RAS mediante el uso de la 
metabolómica basada en 13C 
En el capítulo 5.1 se ha analizado la reprogramación metabólica inducida por la 
activación oncogénica de K-RAS empleando células de ratón NIH3T3 transformadas con 
el oncogén K-RAS mutado en el codón 12 (K12) o 13 (K13).  Aunque la isoforma K-RAS 
es la más frecuentemente mutada en cáncer, H-RAS se encuentra mutada en un 3% de 
los tumores, siendo los más frecuentes los de glándula salival (15%), tracto urinario 
(11%) y cérvix (9%)(Pylayeva-Gupta et al., 2011). 
Las consecuencias metabólicas de la activación oncogénica de H-RAS han sido 
estudiadas desde diferentes perspectivas y empleando diferentes sistemas. Sin 
embargo, todos los estudios llevados a cabo hasta el momento han analizado la 
reprogramación metabólica inducida por la activación oncogénica de H-RAS de una 
manera parcial, considerando sólo una parte de la red metabólica y estudiando solo 
una porción de los metabólicos derivados de esta activación (Chen et al., 2001; de Groof 
et al., 2009; Kalas et al., 2012; Momchilova and Markovska, 1999; Telang et al., 2007; 
Yang et al., 2010). Así pues, esta reprogramación metabólica no ha sido estudiada 
desde una perspectiva global y profunda. 
Por tanto, con el objetivo de explorar en detalle la reprogramación metabólica inducida 
por la mutación HRasV12, en este capítulo se utilizaron células BJLT+/hTERT+/HRasV12- (BJ) y  
BJLT+/hTERT+/HRasV12+ (BJ-HRasV12) en combinación con técnicas de metabolómica basada 
en 13C. Así pues, para realizar el estudio: i) se determinaron los flujos extracelulares 
correspondientes a los principales sustratos metabólicos y se determinó la sensibilidad 
de cada línea a la falta de ciertos nutrientes, ii) se realizaron experimentos de 
metabolómica basada en 13C utilizando como trazadores la [1,2-13C2]-glucosa y la [U-
13C]-glutamina en paralelo y se analizó la distribución isotopomérica de distintos 
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metabolitos así como el funcionamiento de diferentes rutas metabólicas, y iii) se analizó 
el metabolismo mitocondrial mediante la determinación de la tasa de consumo de 
oxígeno en presencia de diferentes nutrientes. 
La glucosa y la glutamina representan las dos principales fuentes de energía y 
precursores para la síntesis de macromoléculas. Por tanto, se exploró el efecto de la 
activación oncogénica de H-RAS sobre el metabolismo de estos dos sustratos 
metabólicos. Así, se observó que la activación de H-RAS inducía un incremento en el 
consumo de glucosa y glutamina así como en la producción de lactato y glutamato 
(Figura 5.2.1.A). Además, las células BJ-HRasV12 presentaron mayor sensibilidad a la 
depleción de estos nutrientes (Figura 5.2.1.B). 
A continuación, se exploró más en profundidad el metabolismo de la glucosa y la 
glutamina mediante la realización de experimentos de metabolómica basada en 13C 
utilizando en paralelo la [1,2-13C2]-glucosa y la [U-13C]-glutamina como trazadores.  
El experimento realizado con [1,2-13C2]-glucosa reveló que las células BJ-HRasV12 
presentan un incremento en el flujo de glucosa a lactato vía glucólisis y vía PPP (Figura 
5.2.2.A). Además, también presentan un incremento en el flujo de producción de lactato 
procedente de otras fuentes distintas de la glucosa.  
Con el objetivo de evaluar el efecto de la mutación H-RasV12 sobre la PPP, se llevó a 
cabo el análisis de la distribución de isotopómeros de masa de la ribosa aislada de RNA. 
Primero se observó que las células BJ-HRasV12 sintetizaron más ribosa que las células 
BJ (Figura 5.2.2.B). Además, el análisis de la distribución isotopomérica de este 
metabolito mostró una activación tanto de la vía oxidativa como de la vía no oxidativa 
de la PPP. Con la finalidad de explicar los resultados obtenidos en cuanto a activación 
del flujo glucolítico y de la PPP, se determinó la actividad enzimática de algunas de las 
enzimas involucradas en estas vías (Figura 5.2.2.D). Enzimas clave como la HK, la 
gliceraldehido-3-fosfato deshidrogenasa (GAPDH) y la PK se encontraron 
incrementadas entre un 20 y un 400%. Asimismo, también se encontraron 
incrementadas las actividades de las enzimas de la PPP, G6PD y TKT. Sin embargo, 
paradójicamente la actividad LDH se encontró disminuida en las células BJ-HRasV12. 
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Posteriormente, se analizó también la distribución isotopomérica de varios metabolitos 
del ciclo de TCA para estudiar los efectos de la activación oncogénica de H-RAS sobre 
el metabolismo mitocondrial (Figura 5.2.3.A). El análisis de la distribución de 
isotopómeros de masa del glutamato reveló, en primer lugar, un incremento del 
porcentaje de moléculas de glutamato con carbonos procedentes de la glucosa en la 
células BJ-HRasV12 con respecto a las células BJ (Figura 5.2.3.B). En segundo lugar, 
también se constató que ambas líneas celulares emplean principalmente la enzima 
piruvato deshidrogenasa (PDH), en lugar de la piruvato carboxilasa (PC), para introducir 
los carbonos procedentes de la glucosa en la mitocondria (Figura 5.2.3.C). De manera 
análoga al glutamato, también se determinó un mayor porcentaje de carbonos 
procedentes de la glucosa en otros metabolitos del ciclo de TCA, como α-cetoglutarato, 
malato o fumarato (Figura 5.2.4). 
La glutamina es uno de los principales sustratos metabólicos mitocondriales. Por tanto, 
para profundizar en el efecto de la activación oncogénica de H-RAS sobre el 
metabolismo mitocondrial y de la glutamina, las células fueron cultivadas en presencia 
de [U-13C]-glutamina. Los resultados mostraron un incremento significativo en la marca 
de 13C en todos los metabolitos del ciclo de TCA analizados en las células BJ-HRasV12 
en comparación con las células BJ (Figura 5.2.4.B), indicando una activación del 
metabolismo mitocondrial y de la glutamina en las células mutadas.  
Con el objetivo de complementar los resultados obtenidos a nivel de metabolismo 
mitocondrial, se analizó el consumo de oxígeno en presencia de diferentes sustratos 
metabólicos. Tal como se muestra en la Figura 5.2.6.A, se detectó que las células BJ-
HRasV12 presentan un incremento en la respiración mitocondrial basal en medio basal 
(sin suplementar) y en presencia de glutamina en comparación con las células BJ, 
indicando que la activación oncogénica de H-RAS confiere a las células BJ una 
capacidad incrementada para la oxidación de glutamina en la mitocondria. Además, se 
detectó que el incremento en la respiración de glutamina estaba asociado a la 
producción de ATP (Figura 5.2.6.B), lo que sugiere que este sustrato es una fuente 
energética más importante en las células BJ-HRasV12 que en las BJ. 
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El metabolismo mitocondrial es una importante fuente de precursores para la síntesis 
de macromoléculas, como por ejemplo lípidos. Con la finalidad de estudiar los posibles 
cambios inducidos por la mutación H-RasV12 en la síntesis de lípidos, se analizó la 
distribución isotopomérica del palmitato, el primer ácido graso sintetizado en la 
lipogénesis. Así pues, se detectó en este ácido graso un incremento del porcentaje de 
carbonos procedentes tanto de glucosa como de glutamina en las células BJ-HRasV12 
en comparación con las BJ (Figura 5.2.7.A-B). Además, el cálculo del porcentaje de cada 
nutriente que contribuye a la síntesis de lípidos permitió determinar que la glucosa 
consumida contribuye en mayor medida a la síntesis de ácidos grasos en las células BJ-
HRasV12 (Figura 5.2.7.C). Por el contrario, aunque las células BJ-HRasV12 consumen una 
mayor cantidad de glutamina, ésta contribuye en menor medida a la síntesis de lípidos 
en comparación con las células BJ. Este hecho sugiere que parte de la glutamina 
consumida tiene un destino distinto en las células BJ-HRasV12 comparado con las BJ. 
Además, la inhibición de la lipogénesis mediante el uso del inhibidor de la enzima ácido 
graso sintasa (FAS) C75 provocó una mayor inhibición de la proliferación en las células 
BJ-HRasV12 que en las BJ, en concordancia con los datos metabólicos previamente 
obtenidos y corroborando que esta vía metabólica juega un papel importante en la 
transformación mediada por H-RAS (Figura 5.2.7.D). 
8.2.3. El papel de la G6PD en la línea celular de cáncer de colon 
HT29 y su regulación por la disponibilidad de glutamina y por las 
vías de señalización que estimulan la proliferación 
En los capítulos anteriores se ha determinado que la actividad de la enzima G6PD y el 
flujo a través de la vía oxidativa de la PPP se encuentran incrementados en líneas 
celulares con la vía de RAS sobreactivada. Además, observaciones no publicadas 
realizadas en nuestro grupo de investigación han puesto de manifiesto un desbalance 
en el uso de la PPP a favor de la vía oxidativa en células de cáncer de colon. Por otro 
lado, la vía de RAS se encuentra frecuentemente activada en tumores de colon, 
principalmente a través de mutaciones en los genes RAS y BRAF (Phipps et al., 2013; 
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Pylayeva-Gupta et al., 2011; Yokota et al., 2011). En este capítulo, se exploró el papel de 
la G6PD como potencial punto de intervención terapéutica en líneas celulares con la vía 
de RAS sobreactivada, como es el caso de algunas líneas de cáncer de colon. Para ello i) 
se determinó la actividad G6PD en un panel de líneas celulares de cáncer de colon con 
diferente estado de activación de los genes RAS y BRAF, ii) se procedió a la inhibición de 
la G6PD en la línea de cáncer de colon que mostró una  mayor actividad de esta enzima 
y se estudió el efecto sobre la proliferación y el ciclo celular, y iii) se profundizó en la 
regulación de este enzima por el metabolismo de la glutamina.  
La actividad G6PD se encontró incrementada en todas las líneas celulares de cáncer de 
colon con mutaciones en RAS o BRAF en comparación con la línea celular control 
NCM460 (Figura 5.3.1.A), siendo la línea HT29 la que presentó un nivel más elevado. 
Dado que esta línea celular no presentaba mutaciones en RAS sino en BRAF (Ikediobi et 
al., 2006; Janakiraman et al., 2010; Loh et al., 2008; Oliveira et al., 2003; Tan et al., 2008), 
se validó el efecto de esta mutación sobre la G6PD con la finalidad de confirmar la 
relación entre ambos fenómenos. La inhibición de BRAF mediante el inhibidor químico 
PLX4720 indujo una inhibición de la expresión y de la actividad G6PD en comparación a 
la condición control, confirmando así dicha relación (Figura 5.3.1.B-C). Dado que la línea 
HT29 presentaba la mayor actividad de G6PD, se empleó esta línea celular para evaluar 
el papel de esta enzima en la proliferación, viabilidad y ciclo celular. Para ello se llevó a 
cabo la inhibición de la G6PD mediante RNAi (Figura 5.3.2.A-B-C), la cual no produjo 
cambios en ninguno de los aspectos examinados en comparación con las células 
transfectadas con el siRNA control (Figura 5.3.2.D-E).  
La enzima G6PD se encuentra involucrada en la síntesis de NADPH. Por otro lado, 
algunos estudios sugieren que la glutamina puede ser utilizada para sintetizar NADPH, 
proporcionando carbonos al TCA para reacciones que sintetizan NADPH, como el ME. 
Por tanto, se evaluó el papel de la G6PD en la proliferación en ausencia de glutamina en 
busca de un efecto sinérgico entre la deprivación de glutamina y la inhibición de la 
G6PD. Sin embargo, no se detectaron cambios significativos entre las células 
transfectadas con el siRNA contra G6PD y las transfectadas con el siRNA control en 
presencia o ausencia de glutamina (Figura 5.3.3).  
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En los experimentos en ausencia de glutamina se detectó que las células no 
transfectadas sobreexpresaban la G6PD, tanto a nivel de RNA como de actividad, 
poniendo de relevancia la existencia de una relación metabólica entre ambas vías 
(Figura 5.3.4.A-B). Así pues, se procedió a estudiar en más profundidad esta relación. Se 
determinó que la falta de glutamina induce no solo la sobreexpresión de G6PD, sino 
también la transcripción de los genes HMDX1 y NQD1, todos ellos genes diana del 
factor de transcripción NRF2 (Figura 5.3.4.C). Por tanto, se comprobó el nivel de 
proteína de este factor de transcripción y se constató un incremento de su expresión en 
ausencia de glutamina (Figura 5.3.4.E). Dado que el mecanismo principal de activación 
de NRF2 es mediante un incremento de los niveles de ROS intracelulares, se examinaron 
los niveles de ROS en ausencia y en presencia de glutamina (Figura 5.3.4.E). Así, se 
determinó que la falta de glutamina induce un incremento los niveles de ROS que 
podría explicar la activación de NRF2 y la consiguiente sobreexpresión de los genes 
diana analizados, entre ellos la enzima G6PD. 
8.2.4  La vía de las pentosas fosfato como potencial diana 
antitumoral y su papel en el metabolismo tumoral en células de 
cáncer de mama MCF7 
En este capítulo se examinó el potencial de las principales enzimas de la PPP, la G6PD y 
la TKT, como dianas antitumorales en células de cáncer de mama metastásico MCF7. 
Estudios previos demuestran que las células de cáncer mama, y en particular las células 
de cáncer mama avanzado, presentan elevados niveles de estrés oxidativo y una 
elevada dependencia de las vías de detoxificación de ROS (Brown and Bicknell, 2001; 
Jerby et al., 2012; Kang, 2002; Portakal et al., 2000; Toyokuni et al., 1995), por lo que, 
dado que una de las principales funciones de la PPP es controlar el nivel redox 
intracelular, es interesante explorar esta vía metabólica como potencial diana 
antitumoral en este tipo de tumores. Para ello i) se inhibieron las enzimas TKT y G6PD 
en la línea celular MCF7 mediante RNAi y se analizó la proliferación, viabilidad y ciclo 
celular, ii) se analizó el papel metabólico de estas enzimas mediante técnicas de 
metabolómica basada en 13C utilizando como trazador la [1,2-13C2]-glucosa y iii) se 
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exploró la relación de la PPP con otras rutas metabólicas como el metabolismo de la 
glutamina, con la finalidad de explicar algunos de los resultados obtenidos.  
Para determinar la importancia de la G6PD y la TKT en la proliferación, viabilidad y ciclo 
celular, ambas enzimas fueron inhibidas mediante RNAi en la línea celular MCF7 (Figura 
5.4.1.A-B). Nuestros resultados mostraron que la inhibición de un 50% de la actividad 
G6PD reduce la proliferación celular en aproximadamente un 50%, disminuyendo al 
mismo tiempo la viabilidad en comparación con células transfectadas con un siRNA 
control (Figura 5.4.1.C). Por el contrario, la inhibición de la TKT no produjo efectos 
significativos sobre la proliferación ni la viabilidad. Asimismo, en ambas inhibiciones se 
detectó un leve incremento en la fracción de células en fase G1 y una disminución de la 
proporción en fase S (Figura 5.4.1.D). Dado que una de las funciones principales de la 
PPP es mantener la homeostasis redox, se determinaron los niveles de ROS en la 
inhibición de ambas enzimas y se observó que la inhibición de la G6PD induce un 
incremento en los niveles de ROS intracelulares en comparación con las células 
transfectadas con el siRNA control, mientras que no se detectaron cambios asociados a 
la inhibición de la TKT (Figura 5.4.2). 
Con el objetivo de profundizar en los cambio metabólicos inducidos por la inhibición de 
ambas enzimas, se llevó a cabo un experimento de metabolómica basada en 13C 
empleando [1,2-13C2]-glucosa. Este experimento reveló que la inhibición de la G6PD 
incrementa la producción de lactato y el consumo de glutamina (Figura 5.4.3.A). Por el 
contrario, la inhibición de la TKT reduce el consumo de glucosa y la producción de 
lactato pero aumenta el consumo de glutamina, aunque en menor magnitud que el 
observado en el caso de la G6PD. En ambas inhibiciones se observó un descenso en la 
síntesis de novo de ribosa (Figura 5.4.3.B). Analizando los efectos sobre la PPP en más 
profundidad, se observó que la inhibición de la G6PD redujo levemente (10%) la 
cantidad de ribosa sintetizada por la vía oxidativa. Sin embargo, la inhibición de la TKT 
disminuyó de manera notable (50%) la síntesis a través de la vía no oxidativa, al mismo 
tiempo que aumentaba el porcentaje de ribosa sintetizada por la vía oxidativa (Figura 
5.4.3.C-D). Ello indica que la TKT ejerce un mayor control sobre la rama de la PPP en la 
que participa que la G6PD sobre su respectiva en células MCF7.  
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Por otro lado, los resultados también mostraron que la inhibición de la TKT induce una 
disminución proporcional tanto del flujo glucolítico como del flujo de lactato 
sintetizado a través de la PPP, mientras que, por el contrario, en el caso de la G6PD se 
produjo un incremento no proporcional de ambos flujos (Figura 5.4.3.E). Así la 
inhibición de la G6PD disminuyó el ratio entre los flujos PPP/glucólisis (Figura 5.4.3.F), 
indicando un bloqueo de la entrada de carbonos procedentes de la glucólisis en la vía 
oxidativa de la PPP. 
La PPP es una las principales rutas metabólicas que sintetizan NADPH, necesario, entre 
otras cosas, para la síntesis de lípidos. Así pues, se examinó la síntesis de palmitato 
mediante el análisis de la incorporación de 13C en este ácido graso (Figura 5.4.4). Los 
resultados revelaron una notable disminución de la síntesis de palmitato bajo la 
inhibición de la G6PD mientras que no se detectaron cambios cuando se inhibió la TKT. 
Uno de los resultados más sorprendentes obtenidos fue el incremento del consumo de 
glutamina asociado a la inhibición de ambas enzimas. La glutamina interviene en 
funciones energéticas, anabólicas y de mantenimiento redox. Para profundizar en la 
relación entre el metabolismo de la glutamina y la PPP, se llevaron a cabo inhibiciones 
de la TKT y la G6PD en presencia y ausencia de glutamina y se analizaron los niveles de 
ROS, glutatión y el ratio ATP/ADP. Estos ensayos pusieron de manifiesto que el 
incremento observado en el consumo de glutamina es necesario para el mantenimiento 
de la homeostasis energética (ratio ATP/ADP) (Figura 5.4.5.C). Así pues, ya que la 
homeostasis energética es importante en la proliferación y supervivencia celular, se 
estudió el efecto de la deprivación de glutamina en combinación con la inhibición de la 
TKT y la G6PD sobre la proliferación celular. Sin embargo, si bien se confirmó la 
disminución de la proliferación cuando la G6PD es inhibida, no se encontraron 
diferencias adicionales cuando la TKT o la G6PD fueron inhibidas en ausencia de 
glutamina (Figura 5.4.5.D). 
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8.3. CONCLUSIONES 
1. La combinación del estudio de la distribución de flujos con el MCA basado en el 
análisis de los signos de los coeficientes de control de signo fijo, es una 
aproximación válida para identificar las enzimas clave involucradas en la 
reprogramación metabólica inducida por K-RAS. El uso de esta metodología nos ha 
permitido identificar un incremento en los flujos glucolítico y a través de la PPP 
como características básicas de la reprogramación metabólica inducida por K-RAS, 
así como proponer la G6PD, la PK y la LDH como enzimas clave responsables de 
dicha reprogramación.  
2.  La activación oncogénica de H-RAS reprograma el metabolismo de la glucosa y la 
glutamina a través del incremento de los flujos glucolítico y a través de la PPP así 
como del metabolismo mitocondrial. La glutamina es responsable de la activación 
del metabolismo mitocondrial en las células BJ-HRasV12, mientras que los carbonos 
procedentes de la glucosa que llegan a la mitocondria son principalmente utilizados 
en la lipogénesis. Además, la lipogénesis se encuentra sobreactivada en las células 
BJ-HRasV12, las cuales son más sensibles que las células BJ a la inhibición de la 
enzima FAS. 
3.  La enzima G6PD se encuentra sobreactivada en células de cáncer de colon con la vía 
de señalización de RAS activada. Sin embargo, G6PD no es esencial para la 
proliferación y supervivencia de la línea celular HT29 que tiene BRAF mutado 
(efector downstream de RAS). Además, se ha identificado una nueva conexión entre 
la PPP y el metabolismo de la glutamina en células HT29, según la cual la G6PD se 
sobreexpresa en condiciones de deprivación de glutamina a través de un mecanismo 
en el que tiene lugar el incremento de los niveles de ROS y la activación del factor 
de transcripción NRF2. 
4.  La enzima G6PD es importante en la proliferación, supervivencia y regulación de los 
niveles de ROS en células de cáncer de mama MCF7. Sin embargo, regula de manera 
poco significativa el flujo de síntesis de ribosa a través de la vía oxidativa de la PPP. 
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La inhibición de la G6PD aumenta el flujo glucolítico, promueve la secreción de 
lactato e incrementa el consumo de glutamina, siendo este último metabolito 
utilizado para mantener la homeostasis energética, aunque no es esencial para la 
proliferación celular.  
5.  La enzima TKT no es esencial para la proliferación de la línea celular de cáncer de 
mama MCF7, pero sin embargo regula de manera significativa el flujo de síntesis de 
ribosa a través de la vía no oxidativa de la PPP. La inhibición de la TKT reduce el flujo 
glucolítico e incrementa el consumo de glutamina, siendo este último metabolito 
utilizado para mantener la homeostasis energética pero no es imprescindible para la 
proliferación celular. 
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APPENDIX I: SUPPLEMENTARY DATA FOR MASS ISOTOPOMER DISTRIBUTION OF METABOLITES 
PRESENTED IN CHAPTER 5.2 
 
      Incubation m0 (%) m1 (%) m2 (%) m3 (%) m4 (%) m5 (%) m6 (%) ∑m (%) 
Metabolite Cells Tracer Time (h) mean SD mean SD mean SD mean SD mean SD mean SD mean SD mean SD 
                                        
Ribose BJ                                     
    [1,2-13C2]-Glc 8 89.79 0.42 5.67 0.14 3.07 0.21 1.11 0.04 0.33 0.04 0.03 0.01     10.21 0.42 
      24 72.10 0.22 15.48 0.06 8.53 0.14 2.84 0.01 0.98 0.02 0.08 0.02     27.90 0.22 
    [U-13C]-Gln 8 99.98 0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.00 0.01 0.00 0.00     0.02 0.00 
      24 99.89 0.18 0.10 0.18 0.00 0.00 0.00 0.00 0.01 0.01 0.00 0.00     0.11 0.18 
  BJ-HRasV12                                   
    [1,2-13C2]-Glc 8 88.79 0.28 6.52 0.15 3.12 0.09 1.26 0.06 0.27 0.02 0.03 0.01     11.21 0.28 
      24 70.83 0.38 16.12 0.33 8.94 0.05 3.02 0.04 1.00 0.02 0.09 0.02     29.17 0.38 
    [U-13C]-Gln 8 99.18 0.73 0.32 0.56 0.08 0.11 0.00 0.01 0.20 0.32 0.22 0.38     0.82 0.73 
      24 97.72 2.05 2.13 1.97 0.09 0.08 0.01 0.01 0.04 0.01 0.01 0.01     2.28 2.05 
Pyruvate BJ                                     
    [1,2-13C2]-Glc 8 88.20 0.89 0.65 0.09 10.51 0.73 0.65 0.07             11.80 0.89 
      24 84.34 0.25 0.63 0.11 14.25 0.11 0.78 0.08             15.66 0.25 
    [U-13C]-Gln 8 98.96 0.64 0.27 0.15 0.36 0.41 0.41 0.10             1.04 0.64 
      24 98.91 0.37 0.29 0.14 0.21 0.08 0.59 0.15             1.09 0.37 
  BJ-HRasV12                                   
    [1,2-13C2]-Glc 8 85.68 0.75 0.75 0.14 12.74 0.79 0.82 0.09             14.32 0.75 
      24 83.05 0.10 0.75 0.01 15.33 0.06 0.87 0.04             16.95 0.10 
    [U-13C]-Gln 8 98.71 0.37 0.40 0.10 0.34 0.32 0.55 0.06             1.29 0.37 
      24 98.81 0.24 0.37 0.06 0.10 0.11 0.72 0.11             1.19 0.24 
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      Incubation m0 (%) m1 (%) m2 (%) m3 (%) m4 (%) m5 (%) m6 (%) ∑m (%) 
Metabolite Cells Tracer Time (h) mean SD mean SD mean SD mean SD mean SD mean SD mean SD mean SD 
                                        
Lactate BJ                                     
    [1,2-13C2]-Glc 8 90.31 0.09 0.35 0.09 8.87 0.20 0.48 0.03             9.69 0.09 
      24 84.42 0.15 0.65 0.11 14.14 0.12 0.79 0.05             15.58 0.15 
    [U-13C]-Gln 8 99.72 0.04 0.09 0.02 0.03 0.01 0.16 0.02             0.28 0.04 
      24 99.23 0.20 0.24 0.18 0.11 0.03 0.42 0.02             0.77 0.20 
  BJ-HRasV12                                   
    [1,2-13C2]-Glc 8 87.76 0.04 0.50 0.08 11.14 0.08 0.61 0.01             12.24 0.04 
      24 83.03 0.15 0.72 0.15 15.38 0.18 0.87 0.03             16.97 0.15 
    [U-13C]-Gln 8 99.75 0.05 0.07 0.02 0.03 0.01 0.15 0.03             0.25 0.05 
      24 99.29 0.02 0.20 0.03 0.12 0.01 0.39 0.01             0.71 0.02 
Citrate BJ                                     
    [1,2-13C2]-Glc 8 95.38 1.44 0.35 0.03 1.81 0.18 0.71 0.19 0.98 0.59 0.45 0.32 0.33 0.24 4.62 1.44 
      24 91.16 0.17 0.85 0.05 6.24 0.21 0.87 0.05 0.77 0.17 0.01 0.01 0.00 0.00 8.74 0.17 
    [U-13C]-Gln 8 84.79 1.32 0.52 0.07 1.38 0.08 1.74 0.25 6.92 0.57 3.13 0.33 1.52 0.15 15.21 1.32 
      24 60.25 7.60 2.74 1.69 6.46 1.96 4.04 0.70 16.01 2.63 4.16 0.54 2.26 0.31 35.66 7.60 
  BJ-HRasV12                                   
    [1,2-13C2]-Glc 8 93.74 0.75 0.57 0.13 3.70 0.57 1.18 0.07 0.65 0.05 0.13 0.04 0.04 0.04 6.26 0.75 
      24 84.84 0.39 1.70 0.08 9.97 0.23 1.83 0.05 1.42 0.05 0.10 0.01 0.00 0.00 15.03 0.39 
    [U-13C]-Gln 8 71.73 1.27 1.24 0.19 3.32 0.20 3.39 0.13 12.30 0.54 5.47 0.26 2.55 0.10 28.27 1.27 
      24 53.76 6.56 5.87 1.64 10.19 2.04 5.46 0.64 20.64 1.77 5.07 0.27 2.79 0.19 50.02 6.56 
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Metabolite Cells Tracer Time (h) mean SD mean SD mean SD mean SD mean SD mean SD mean SD mean SD 
                                        
α-Ketoglutarate BJ                                     
    [1,2-13C2]-Glc 8 97.82 0.32 0.28 0.19 1.19 0.06 0.37 0.05 0.21 0.04 0.13 0.01     2.18 0.32 
      24 95.18 0.12 0.41 0.07 3.58 0.02 0.49 0.03 0.34 0.02 0.00 0.00     4.82 0.12 
    [U-13C]-Gln 8 40.96 0.10 1.29 0.03 1.23 0.00 7.09 0.08 1.70 0.01 47.72 0.02     59.04 0.10 
      24 24.01 2.65 4.00 1.69 4.03 1.04 15.17 1.79 3.55 0.26 49.24 3.03     75.99 2.65 
  BJ-HRasV12                                   
    [1,2-13C2]-Glc 8 97.04 0.33 0.20 0.22 2.13 0.07 0.34 0.03 0.24 0.01 0.05 0.01     2.96 0.33 
      24 91.47 0.15 1.31 0.05 5.61 0.08 0.96 0.03 0.60 0.02 0.05 0.01     8.53 0.15 
    [U-13C]-Gln 8 39.02 0.06 1.62 0.02 1.85 0.01 9.31 0.00 2.29 0.02 45.92 0.01     60.98 0.06 
      24 24.96 1.08 4.89 1.69 4.64 0.98 15.80 1.52 3.74 0.21 45.98 3.32     75.04 1.08 
Glutamate                                       
C2-C4 BJ                                     
    [1,2-13C2]-Glc 8 99.71 0.25 0.22 0.20 0.03 0.04 0.04 0.03             0.29 0.25 
      24 98.65 0.05 1.13 0.05 0.14 0.00 0.09 0.01             1.35 0.05 
    [U-13C]-Gln 8 18.35 0.33 0.66 0.06 2.66 0.02 78.34 0.38             81.65 0.33 
      24 19.96 0.07 2.04 0.30 5.57 0.54 72.44 0.16             80.04 0.07 
  BJ-HRasV12                                   
    [1,2-13C2]-Glc 8 99.40 0.13 0.48 0.09 0.05 0.02 0.06 0.03             0.60 0.13 
      24 96.82 0.30 2.70 0.28 0.30 0.04 0.17 0.16             3.18 0.30 
    [U-13C]-Gln 8 18.66 0.50 0.89 0.46 2.14 0.99 78.31 0.81             81.34 0.50 
      24 20.38 0.64 3.22 0.34 8.23 0.57 68.18 0.81             79.62 0.64 
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Metabolite Cells Tracer Time (h) mean SD mean SD mean SD mean SD mean SD mean SD mean SD mean SD 
                                        
Glutamate                                       
C2-C5 BJ                                     
    [1,2-13C2]-Glc 8 99.75 0.01 0.12 0.06 0.09 0.00 0.00 0.00 0.03 0.05         0.25 0.01 
      24 98.92 0.02 0.24 0.01 0.77 0.02 0.03 0.00 0.03 0.01         1.08 0.02 
    [U-13C]-Gln 8 17.35 0.27 0.20 0.00 1.35 0.02 2.57 0.14 78.54 0.19         82.65 0.27 
      24 18.89 0.08 1.31 0.05 5.03 0.18 2.32 0.07 72.45 0.38         81.11 0.08 
  BJ-HRasV12                                   
    [1,2-13C2]-Glc 8 99.66 0.11 0.11 0.08 0.20 0.01 0.01 0.00 0.02 0.02         0.34 0.11 
      24 96.36 1.25 0.76 0.02 1.91 0.11 0.15 0.02 0.83 1.11         3.64 1.25 
    [U-13C]-Gln 8 17.69 0.49 0.33 0.03 2.00 0.10 1.80 1.10 78.19 0.57         82.31 0.49 
      24 19.49 0.51 2.93 0.12 8.14 0.41 1.46 0.86 67.98 0.62         80.51 0.51 
Fumarate BJ                                     
    [1,2-13C2]-Glc 8 99.08 0.25 0.14 0.19 0.76 0.06 0.00 0.00 0.03 0.01         0.92 0.25 
      24 94.90 0.57 0.05 0.04 2.84 0.24 1.99 0.28 0.22 0.06         5.10 0.57 
    [U-13C]-Gln 8 75.00 3.76 0.52 0.35 4.06 0.47 2.50 1.31 17.92 1.76         25.00 3.76 
      24 54.97 2.71 2.64 0.90 11.67 2.29 6.20 0.60 24.52 1.21         45.03 2.71 
  BJ-HRasV12                                   
    [1,2-13C2]-Glc 8 99.54 0.33 0.04 0.03 0.43 0.30 0.00 0.00 0.00 0.00         0.46 0.33 
      24 92.04 0.90 0.72 0.05 3.97 0.34 2.88 0.60 0.38 0.07         7.96 0.90 
    [U-13C]-Gln 8 64.14 0.21 1.50 0.06 6.12 0.10 3.52 0.21 24.72 0.08         35.86 0.21 
      24 53.48 2.26 3.59 1.34 12.32 1.77 5.07 0.52 25.54 1.04         46.52 2.26 
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Metabolite Cells Tracer Time (h) mean SD mean SD mean SD mean SD mean SD mean SD mean SD mean SD 
                                        
Malate BJ                                     
    [1,2-13C2]-Glc 8 98.81 0.06 0.24 0.06 0.73 0.06 0.11 0.04 0.10 0.01         1.19 0.06 
      24 96.54 0.11 0.47 0.04 2.28 0.06 0.46 0.01 0.25 0.02         3.46 0.11 
    [U-13C]-Gln 8 66.71 2.80 0.96 0.31 4.29 0.41 4.32 0.25 23.72 1.90         33.29 2.80 
      24 55.24 2.18 4.01 1.23 9.72 0.89 5.07 0.33 25.95 2.41         44.76 2.18 
  BJ-HRasV12                                   
    [1,2-13C2]-Glc 8 97.78 0.06 0.30 0.03 1.42 0.11 0.32 0.09 0.18 0.02         2.22 0.06 
      24 93.82 0.14 1.25 0.05 3.64 0.08 0.86 0.02 0.44 0.02         6.18 0.14 
    [U-13C]-Gln 8 56.14 0.91 1.88 0.15 7.14 0.18 5.40 0.25 29.43 0.34         43.86 0.91 
      24 52.10 0.87 5.13 1.48 11.04 1.13 5.25 0.20 26.47 1.67         47.90 0.87 
Palmitate BJ                                     
    [1,2-13C2]-Glc 8 98.52 0.36 0.22 0.07 0.93 0.24 0.02 0.01 0.25 0.07 0.00 0.00 0.04 0.02 1.48 0.36 
      24 88.63 0.37 0.52 0.08 6.92 0.15 0.27 0.05 2.78 0.07 0.11 0.00 0.66 0.02 11.37 0.37 
    [U-13C]-Gln 8 98.44 0.05 0.23 0.05 0.84 0.03 0.02 0.00 0.34 0.02 0.01 0.00 0.09 0.01 1.56 0.05 
      24 90.16 0.81 0.57 0.15 6.24 0.48 0.28 0.04 2.07 0.18 0.10 0.01 0.48 0.03 9.84 0.81 
  BJ-HRasV12                                   
    [1,2-13C2]-Glc 8 96.45 0.16 0.20 0.05 2.32 0.13 0.05 0.01 0.78 0.07 0.02 0.01 0.14 0.00 3.55 0.16 
      24 82.62 2.12 0.71 0.10 9.78 1.17 0.54 0.06 4.56 0.57 0.26 0.04 1.26 0.15 17.38 2.12 
    [U-13C]-Gln 8 96.61 0.73 0.26 0.05 2.18 0.49 0.07 0.02 0.68 0.17 0.02 0.01 0.15 0.04 3.39 0.73 
      24 88.93 1.48 0.80 0.13 7.45 0.99 0.34 0.04 1.98 0.26 0.09 0.01 0.35 0.04 11.07 1.48 
 
 
 
Mass isotopomer distribution of analyzed metabolites in BJ and BJ-HRasV12 cells 
BJ and BJ H-RasV12 cells were cultured in the presence of 50% [1,2-13C2]-Glc (glucose) or 100% [U-13C]-Gln (glutamine) in parallel experiments for 8 
and 24 hours. Mass isotopomer distribution of each metabolite was analyzed as described in Section 4.11. Ribose, pyruvate, citrate, α-ketoglutarate, 
fumarate, malate and palmitate were extracted from pellets or cell cultured plates while lactate and glutamate were obtained from media. For 
palmitate, m/z corresponding from m0 to m8 were monitored, but only m1 to m6 were used for calculation of ∑m. Values are expressed as 
percentage of each mass isotopomer and denote mean ± SD of n=3.
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Mass isotopomer distribution of analyzed metabolites in siNEG, siTKT and siG6PD transfected cells 
MCF7 cells were transfected with non-targeting siRNA (siNEG) or siRNA against TKT (siTKT) or G6PD (siG6PD) and after 96 hours, media was replaced by fresh media containing 
50% [1,2-13C2]-glucose and incubated for 24h. Mass isotopomer distribution of each metabolite at the end of incubation was analyzed as described in Section 4.11. For palmitate, 
m/z corresponding from m0 to m8 were monitored, but only m1 to m6 were used for calculation of ∑m. Values are expressed as percentage of each mass isotopomer and 
denote mean ± SD of n=3. 
APPENDIX II: SUPPLEMENTARY DATA FOR MASS ISOTOPOMER DISTRIBUTION OF METABOLITES 
PRESENTED IN CHAPTER 5.4 
    m0 (%) m1 (%) m2 (%) m3 (%) m4 (%) m5 (%) m6 (%) Ʃm (%) 
Metabolite Condition mean SD mean SD mean SD mean SD mean SD mean SD mean SD mean SD 
                                    
Ribose                                   
  siNEG 79.55 0.18 14.25 0.18 4.11 0.06 1.68 0.17 0.38 0.51         20.42 0.51 
  siTKT 81.49 0.35 14.89 0.35 1.99 0.05 1.47 0.05 0.13 0.28         18.47 0.28 
  siG6PD 81.29 0.04 12.28 0.04 4.35 0.03 1.56 0.11 0.51 0.14         18.70 0.14 
Lactate                                   
  siNEG 89.32 0.35 1.35 0.05 9.33 0.30                 10.68 0.35 
  siTKT 91.84 0.16 1.02 0.03 7.13 0.19                 8.16 0.16 
  siG6PD 90.08 0.63 1.12 0.08 8.80 0.57                 9.92 0.63 
Palmitate                                   
  siNEG 88.54 1.77 0.95 0.35 6.09 0.84 0.80 0.14 2.58 0.36 0.26 0.03 0.60 0.09 11.28 1.78 
  siTKT 90.54 1.94 0.98 0.06 4.91 1.10 0.72 0.13 2.00 0.44 0.23 0.05 0.47 0.13 9.30 1.89 
  siG6PD 95.08 1.25 0.49 0.08 2.64 0.70 0.35 0.08 1.06 0.29 0.09 0.03 0.24 0.06 4.86 1.23 
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Metabolic concentrations and ﬂuxes are the constrained
components characterizing the collective action of cell metabolism,which are modulated by enzymatic activities. However, we have
partial knowledge of the components of cell metabolism and the
constraints relating them. Specially, we have limited knowledge
of the kinetic properties of the enzymes and their regulation.
Moreover, the observed heterogeneity in cell populations,
associated with phenomena like protein crowding, interactions
between glycolytic enzymes, and reversible associations with
structural proteins or organelles [1,2] should alter both compo-
nents and constraints. These limitations are likely to make
systems in part unpredictable, speciﬁcally the magnitude of the
changes following alterations in the activity of enzymes. Interest-
ingly, the predicted sign of changes in metabolite concentrations
andmetabolic ﬂuxes following changes in enzyme activity is likely to be
more robust and allows their prediction without requiring accurate
kinetic information. Metabolic control analysis (MCA) [3–5] is one
framework which permits the prediction of the signs of concentration
and ﬂux changes.
In the framework of MCA, systemic properties of the whole
network are described as a function of the properties of enzymes
isolated from the system. Steady state ﬂuxes and metabolite
concentrations are systemic properties. Enzyme rates, by contrast,
747P. de Atauri et al. / Biochimica et Biophysica Acta 1807 (2011) 746–754are properties of the isolated enzymes, and depend on the speciﬁc
mechanism and parameters governing the enzyme kinetics. Under
MCA, an elasticity εqk is the parameter sensitivity of the rate vq of an
isolated reaction—at steady state conditions—with respect to changes
in the concentration xk of one of its substrate, inhibitor or any other
kinetic effectors of the isolated reaction [3,4]:
εqk =
∂ ln vq
∂ ln xk
ð1Þ
Similarly, a control coefﬁcient is a system property deﬁned as the
sensitivity of a metabolite concentration xg or a ﬂux Jq with respect to
changes in some parameter p—usually the enzyme concentration—
whichwill in principle be proportional to the rate vkwhen the enzyme
is isolated, and then associated to the enzyme activity [3,4]:
Cgk =
∂ ln xg
∂ln p
,
∂ ln vk
∂ ln p =
∂ ln xg
∂ ln vk
ð2Þ
Cqk =
∂ ln Jq
∂ ln p
,
∂ ln vk
∂ ln p =
∂ ln Jq
∂ ln vk
ð3Þ
Different approaches have been proposed for describing the
control coefﬁcients, including methods based on matrices [6–10]
and those based on graph theoretical procedures [11,12]. These
methods allow the derivation of large expressions describing the
control coefﬁcients, whose sign and magnitude are a function of
the pathway stoichiometry, the elasticities, and the ratios of ﬂuxes
in branched pathways. In systems with moiety conservations,
concentrations are also required [8,10]. The sign of a control
coefﬁcient—positive or negative—is sufﬁcient to predict whether a
ﬂux or concentration will increase or decrease when an enzyme
activity is changed. Positive control coefﬁcient indicates that changes
in xg or Jqwill follow the same pattern as changes in vk. This means an
increase of vk will induce an increase of xg or Jq, while decreasing vk
will also decrease the value of xg or Jq.Negative control coefﬁcient, on
the contrary, indicates that changes in vkwill induce an inverse effect
on the changes in xg or Jq.
Some control coefﬁcients have ﬁxed signs, irrespective of the
magnitudes of the elasticities and ﬂuxes, and then they are either
always positive or always negative [13,14]. Other control coefﬁcients are
sign-indeterminate, meaning they can be positive or negative, and
some control coefﬁcients are always zero. The classiﬁcation into these
types of control coefﬁcients requires the only knowledge of the
metabolic network structure and the direction of regulatory depen-
dencies of the network,which basically refers to the positive or negative
sign of the elasticities: i) elasticities with respect to substrates or
activators are always positive; ii) elasticities with respect to inhibitors—
or products in reversible reactions—are always negative. The ﬁxed sign
will be maintained while both structure and qualitative regulatory
dependencies are maintained. Each control coefﬁcient predicts changes
in ﬂuxes and concentrations resulting from the change of one enzyme
activity. In general, the predictive value of this normalized derivative is
accurate for inﬁnitesimal changes of the enzyme activity and decays for
larger changes due to the redistribution of the elasticities and ﬂuxes. The
prediction of the sign of a sign-ﬁxed control coefﬁcient is a positive or
negative direction that is not modiﬁed for large changes.
In the present work, we take advantage of sign-ﬁxed control
coefﬁcients to derive hypotheses about the enzyme activities
which are modiﬁed in order to achieve speciﬁc changes in glycolytic
and pentose phosphate pathway (PPP) ﬂuxes and concentrations. As a
case study of metabolic reprogramming, we have analyzed the
transformation with mutated K-ras oncogenes of a mouse embryonic
ﬁbroblast cell line NIH-3T3. Oncogenic Ras-transformed NIH-3T3 cells
have been used as a model system to explore characteristics associatedwith cell transformation, such as a higher aerobic glycolysis and
changes of enzyme activities [15–18]. Ras proteins are a family of small
GTPases activated in response to extracellular stimuli and leading to the
activation of several signalling cascades [19–21]. Among the different
isoforms, K-Ras is the Ras protein which plays a major role in cancer.
NIH-3T3 cells stably transfected with constitutively active K-ras
mutated at codon 12 or codon 13 (K12- and K13-transformed
cells) induce tumours with distinct survival strategies, associated
with distinct transforming capabilities and aggressiveness [22,23].
Previously, we measured signiﬁcant changes in carbon metabolism
of K12- and K13-transformed cells based on stable-isotope (13C)
tracer-based technologies [24]. Interestingly, both mutants showed an
increased utilization of the oxidative branch of the PPP, higher for
K13 cells, compared with non-transformed NIH-3T3 cells.
In order to derive hypotheses about the enzyme activities that
contribute to the reprogramming of carbon metabolism: 1) we
characterized metabolic adaptations in non-transformed and K12-
and K13-transformed cells by means of experimentally measured
external and internal metabolite concentrations; and 2) we computed
the network ﬂux distribution using a constraint based approach and
the data obtained of external metabolite variations; 3) we identiﬁed
control coefﬁcients with ﬁxed signs in order to predict the pattern of
changes in enzyme activities which can explain the observed
increases or decreases in ﬂuxes and concentrations; and 4) ﬁnally,
wemeasured speciﬁc activities of key enzymes in order to validate the
predictions on the enzyme activity increases or decreases compatible
with the observed ﬂux and concentration changes.2. Materials and methods
A combination of experimental and mathematical–computational
methods was applied including the measurement of glucose uptake
(JA), lactate production (JT), and glutamate–glutamine uptake (JU)
together with measurements of sugar phosphate concentrations and
enzyme speciﬁc activities. All measures were replicated in inde-
pendent experiments. Mathematical–computational methods were
performed using Mathematica [25].2.1. Cell lines and culture
NIH-3T3 cells were obtained from the American Type Cell Culture
(ATCC). The transfectants contained a K-rasminigene with a G:C→A:
Tmutation at the ﬁrst position of codon 12 (K12 cells) and a G:C→A:T
mutation at the second position of codon 13 (K13). All lines were
maintained in Dulbecco's Modiﬁed Eagle Medium (DMEM) in the
presence of 10% FBS, 25 mM D-glucose and 4 mM L-glutamine, at 37 °C
in 95% air–5% CO2. Geneticin© Selective Antibiotic (GIBCO) was used
as a selective antibiotic in K12 and K13 cells.
For biochemical and enzyme activity measurements, cells were
seeded in p100 dishes at different densities between 0.8·106 and
1.2·106cells/cm2. 24 h after seeding, incubation medium was
removed and cells were incubated for 72 h with DMEM containing
10% FBS, 25 mM D-glucose and 4 mML-glutamine. At the end of the
incubations, media for biochemical analysis were removed and frozen
at−20 °C until processing. Cells for sugar phosphates determination
were immediately frozen in liquid nitrogen and kept at −80 °C until
processing. Cells for activity measurements were washed with PBS
and scrapped in a lysis buffer as detailed below. Cell counting was
performed with a haemocytometer.2.2. Protein concentration
Protein concentration of cell extracts was determined using the
BCA Protein Assay (Pierce Biotechnology, Rockford, IL).
Fig. 1. Network scheme. Each arrow indicates a reversible or irreversible reaction step
catalyzed by an enzyme (or transporter) or one block of enzymes. Grey dashed lines
account for the regulatory circuits (inhibitions and activations).
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Glucose, lactate, glutamate, and glutamine concentrations were
determined from frozen medium samples as previously described [26–
28] using a Cobas Mira Plus chemistry analyzer (ABX). The rates of the
medium metabolites consumption/production—glucose consumption
( JA), lactate production ( JT) and glutamate from glutamine consumption
( JU)—are derived from the total measured consumptions/production of
metabolites and corrected according to the measured cell proliferation,
assuming exponential growth and constant consumption or production.
The rate of glutamate from glutamine consumption is derived from the
measured rates of glutamine consumption and glutamate accumulation.
All the values are expressed in micromol of metabolite consumed or
produced per milligram of protein and hour (μmol mg prot−1 h−1).
2.4. Sugar phosphates determination
Hexose, pentose and triose phosphates were determined in cell
monolayers frozen in liquid nitrogen using addition curve methods as
described [29]. The MRM (multiple reaction monitoring) transitions
were 339/97 for fructose-1,6-bisphosphate (F16BP), 259/97 for
glucose-6-phosphate (G6P) and fructose-6-phosphate (F6P) (hexose
phosphates) (HexP), 229/97 for ribose-5-phosphate (R5P) and
xylulose-5-phosphate (pentose-phosphates) (PenP), 169/97 for
glyceraldehyde-3-phosphate (GAP) and dihydroxyacetone phos-
phate (triose phosphates) (TrisP) and 167/79 for phosphoenol
pyruvate (PEP). Sugar phosphate concentrations are expressed as
nanomol per milligram of protein (nmol mg prot−1).
2.5. Enzyme activity determinations
Activities of the glycolytic enzymes hexokinase (HK), pyruvate
kinase (PK), and lactate dehydrogenase (LDH), and PPP enzymes
glucose-6-phosphate dehydrogenase (G6PD) and transketolase (TKT),
were determined from cell culture extracts. Enzyme activities are
expressed as milliunits per milligram of protein (mUmg prot−1).
Preparationof cell extracts for enzymeactivity determination. Cell cultures
were washed with PBS and scrapped in lysis buffer (20mM Tris–HCl, pH
7.5, 1 mM dithiothreitol, 1 mM EDTA, 0.02% Triton X-100, 0.02% sodium
deoxycholate) supplemented with protease and phosphatase inhibition
cocktails. Cell lysates were disrupted by sonication (3 cycles of 5 s) and
immediatelyultracentrifugedat105,000 ×g for1 hat4 °C. Thesupernatant
was separated and used for the determination of enzyme activities using a
CobasMiraPlus chemistry analyzer (HORIBAABX,Montpellier, France). All
enzymatic activities were determined by monitoring NADH/NADPH
increment or decrement at a wavelength of 340 nm.
A strong decrease of the mitochondrial Complex I activity has been
recently reported inK-ras transformed cells [30]. The conditions of extract
preparation using a soft lysis buffer as well as soft sonication have been
optimised tominimise the extraction of mitochondrial Complex I activity
and other membrane-bound enzymes. The absence of unspeciﬁc
coenzyme (NADHorNADPH) consumption/production has been checked
before the addition of the reaction substrate for all the enzyme activities
measured.
Glucose-6-phosphate dehydrogenase (G6PD, EC 1.1.1.49) activity
was measured as described in Tian et al. [31]. Brieﬂy, samples were
added to a cuvette containing 0.5 mM NADP+ in 50 mM Tris–HCl, pH
7.6 at 37 °C. Reactions were initiated by the addition of G6P up to a
ﬁnal concentration of 2 mM.
Hexokinase (HK, EC 2.7.1.1) activity was determined by coupling
HK reaction to G6PD enzyme in the following conditions: 3.3 mM
NADP+, 14.8 mM ATP, 14.8 mM MgCl2, 2.8 U/mL G6PD and 50 mM
Tris–HCl, pH 7.6 at 37 °C. Reactions were initiated by the addition of
glucose to a ﬁnal concentration of 10 mM.
Transketolase (TKT, EC 2.2.1.1) activity was determined using the
enzyme linked method described by Smeets and colleagues [32]. Brieﬂy,samples were added to a cuvette containing 5 mMMgCl2, 0.2 U/ml triose
phosphate isomerase, 0.2 mMNADH, 0.1 mM thiamine pyrophosphate in
50 mM Tris–HCl, and pH 7.6 at 37 °C. The reaction was initiated by the
addition of a substratemixture in 1:2 proportion (substratemixture :ﬁnal
volume) prepared by dissolving 50 mM R5P in 50 mM Tris–HCl, pH 7.6
with 0.1 U/ml ribulose-5-phosphate-3-epimerase and 1.7 mU/ml phos-
phoriboisomerase. The substrate mixture was continuously stirred and
heated for 1 h at 37 °C and then kept at−20 °C until use.
Pyruvate kinase (PK, EC 2.7.1.40) activity was determined by coupling
the PK reaction to the LDH enzyme in the following conditions: 0.8 mM
NADH, 1.6 mM ADP, 12.1 mM MgCl2, 36.8 mM KCl, 5.2 U/mL LDH in
20 mM phosphate buffer, pH 7.2 at 37 °C. Reactions were initiated by the
addition of PEP up to a ﬁnal concentration of 3.5 mM.
LactateDehydrogenase (LDH, EC1.1.1.27) activitywasmeasuredat 37 °C
by adding sample extracts to a cuvette containing 0.2 mM of NADH and
100mMphosphatebuffer, pH7.4. Reactionwas initiatedby the additionof
pyruvate (Pyr) up to a ﬁnal concentration of 0.2 mM.2.6. Isotopomer abundances
13C labelled substrates generate for eachmetabolic product a set of
different labelled molecules—isotopomers—that differ only in the
labelling state of their individual carbon atoms. In a previous paper
[24] 50% [1,2-13C]-D-glucose was used as tracer and the generation of
13C labeled products was measured retaining for each product the
relative abundances of the non-labelled isotopomer form (m0), and
Fig. 2. Comparison of ﬂuxes. Non-transformed NIH-3T3 cells (white); K12-transformed
cells (light gray); and K13-transformed cells (dark gray). ▲) Increased ﬂux in
transformed cells with respect to non-transformed cells; and ▼) Decreased ﬂux in
transformed cells with respect to non-transformed cells. Some dependent ﬂuxes are
grouped together: JC and JE (JC,E); JF and JK (JF,K); JG, JH and JI (JG,H,I) ; JL, JM and JN (JL,M,N);
and JO and JP (JO,P).
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The isotopomer abundances of lactate are here applied to describe the
ratio of ﬂuxes through oxidative PPP (JB) with respect to the entry of
glucose ( JA) [33]: f1=JB/JA=3×(m1/m2)/(3+(m1/m2)).
2.7. Statistical analysis
Two-tailed Student's t-test was performed in order to compare
metabolite concentrations and activities of non-transfected against K12-
and K13-transfected cells. Differences were considered signiﬁcant for
pb0.1.
3. Results
3.1. Metabolic adaptations in K12- and K13-transformed NIH-3T3 cells
3.1.1. System description
The scheme of the whole network under study is depicted in Fig. 1.
Fluxes are represented with letter J, where Ji refers to the steady state
metabolic ﬂux through the ith step; concentrations are represented with
letter x, where xi refers to the concentration of the ith metabolic
intermediary; and activities are represented with letter v, where vi refers
to the rate of the isolated reaction of the ith step. Solid arrows (Fig. 1)—
reaction steps A to Z—refer to the principal carbonmetabolism, including
glycolysis, the PPP, the tricarboxylic acid cycle and the main inputs and
outputs. Some reactions were neglected and grouped into blocks—e.g.
reaction step F refers to the block from glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) to enolase—and others were assumed to be
involved in rapid equilibriums—e.g. glucose-6-phosphate isomerase.
Metabolites were combined into different pools: the pool x1 for HexP
refers to G6P and F6P; the pool x2 for PenP refers to R5P; ribulose-5-
phosphate and xylulose-5-phosphate; the pool x4 for TrisP refers to
dihydroxyacetone-phosphate (DHAP) and GAP; and the pool x13 refers to
oxaloacetate (Oaa) andmalate (Mal). The rest ofmetabolic intermediaries
are F16BP (x3), sedoheptulose-7-phosphate (x6; S7P), erythrose-4-
phosphate (x5; E4P), PEP (x7), Pyr (x8), acetyl-CoA (x9; ACoA), citrate
(x10; Cit),α-ketoglutarate (x11;αKG) and succinate-CoA (x12; SucCoA). In
our system, the main ﬂuxes in or out of the deﬁned metabolic network
correspond to experimentally measured glucose consumption ( JA),
glutamate from glutamine consumption ( JU), and lactate production
( JT). Additional output exchanges connected to biosynthetic processes
were not associated with a measured value ( JD, JX, JY, JZ).
3.1.2. Flux distributions
Under steady-state conditions, the ﬂux balance associatedwith the
stoichiometry constrains the dependences among ﬂuxes [34–36]. In
order to estimate the different ﬂux distributions of non-transformed,
K12- and K13-transformed cells, the ﬂuxes for internal reactions can
be expressed as dependent on a subset of ﬂuxes including all output
and input ﬂuxes, e.g.:
JC = JE = JA–
1
=3 JB + 2 × JDð Þ;
JF = JK = 2 × JA–
1
=3 JB + 5 × JDð Þ;
JGf =
1
=3 JB–JDð Þ + JGb;
JHf =
1
=3 JB–JDð Þ + JHb;
JIf =
1
=3 JB–JDð Þ + JIb;
JL = JM = 2 × JA–
1
=3 JB + 5 × JDð Þ–JT + JU–JX–JY–JZ ;
JN = 2 × JA–
1
=3 JB + 5 × JDð Þ–JT + JU–JX–2 × JY–JZ ;
JO = JP = 2 × JA–
1
=3 JB + 5 × JDð Þ–JT + 2 × JU–JX–2 × JY–JZ ;
JR = JU–JY–JZ ;
ð4Þwhere JGf, JHf, JIf and JGb, JHb, JIb are the forward (Jif) and backward (Jib)
ﬂuxes through the reversible reactions JG= JGf− JGb, JH= JHf− JHb,
and JI= JIf− JIb. An additional constraint was imposed based in our
previous isotopomer-based analysis of non-transformed NIH-3T3
cells and K12- and K13-transformed cells [24] (see Section 2.6):
JB = f1 × JA ð5Þ
where factor f1 relates the oxidative branch of PPP (JB) with the
entry of glucose (JA). This factor was set according to the measured
ratios [24]: 0.063±0.004 for non-transformed cells; 0.076±0.012
for K12-transformed cells; and 0.153±0.016 for K13-transformed
cells. Thus, the ﬂux through the oxidative branch of PPP was
signiﬁcantly lower than that descending through the glycolysis, and
there was a signiﬁcant increase of the ﬂux through the PPP in
transformed cells compared to non-transformed NIH-3T3 cells.
Between transformed cells, K13 mutants routed more glucose to
the oxidative branch of PPP than K12 mutants.
All these assumptions and measures are constraints limiting the
space of solutions for the internal metabolic ﬂuxes. Unfortunately, the
complete system cannot be determined with the available measure-
ments. Uncertainty is associated with the measured exchange ﬂuxes
( JA, JT, JU) and, specially, with those not measured ( JX, JY, JZ, JD). An
interval constraint satisfaction approach was applied as suggested by
Llaneras and Picó [37] for cases where available measurements are
insufﬁcient and the complete ﬂux distribution cannot be uniquely
calculated. The feasible range of solutions satisfying all constraints
was estimated for each reaction step. Initial lower and upper bounds
for intervals were assigned to the ﬂux through all reaction steps: 1)
lower and upper bounds were assigned as the mean value±
1.5×standard deviation for measured ﬂuxes JA, JT, and JU,; 2) a lower
bound of zero was assumed for the irreversible ﬂuxes JB, JD, JK, JL, JM, JN,
JO, JR, JS, JX, JY, JZ, which were assumed to have positive values (0b Ji).
For each cell type, the lower and upper bounds were constrained to
satisfy the stoichiometric description of the system Eq. (4) and the
isotopomer-based constraint in Eq. (5). These intervals of ﬂuxes
satisfying all constraints were calculated by two independent
procedures: 1) iterative interval propagation, or 2) solving each
minimum and maximum bound through linear programming, taking
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distributions for non-transformed cells, K12- and K13-transformed
cells are shown in Fig. 2, which graphically depicts the interval
ranges of ﬂux values which satisfy all the constraints. As an example,
for non-transformed cells, the initial intervals were 2.04b JAb3.41,
0b JBb∞, −∞b JCb∞, 0b JDb∞, −∞b JEb∞, −∞b JFb∞, 0b JGb∞, …,
6.63b JTb9.56, 0.20b JUb0.84,…, and the ﬁnal intervals satisfying all
constraints (solution space) computed with both iterative interval
propagation and linear programming were 2.93 b JA b3.41,
0 .18 b J B b0 .21 , 2 .86 b J C b3.34 , 0 b J D b0.57 , 2 .86 b J E b3.34 ,
5.80b JFb6.75, −0.11b JGb0.07, …, 6.63b JTb7.59, 0.20b JUb0.84, ….
Even with the propagated uncertainty, substantial changes in ﬂux
distribution are detected in transformed cells with respect non-
transformed cells, in particular for the ﬂux pattern in glycolysis and
the oxidative branch of the PPP.
3.1.3. Metabolite concentrations
Changes in ﬂuxes were coupled with additional experimental
measurement of key sugar phosphate concentrations. Thus, the
concentrations of HexP (x1), PenP (x2), F16BP (x3), TrisP (x4), and
PEP (x7) were measured for non-transformed and transformed cells
(K12 and K13) and are compared in Fig. 3. All concentrations were
found to be slightly decreased in transformed cells.
3.2. Predicted changes in ﬂuxes and concentrations
3.2.1. The sign of control coefﬁcients
In order to identify control coefﬁcients with ﬁxed signs, all regulatory
dependences were considered. The matrix approach proposed by
Cascante et al. [9,10] was applied and is depicted in Fig. 4. A matrixM−1
withall concentration control coefﬁcients andall independentﬂuxcontrol
coefﬁcients can be derived from the inverse of a matrixM containing all
elasticities and ﬂux dependences. The sign of the elasticities is taken in
order to derive the sign of the control coefﬁcients. For example, the
dependence of G6PD (reaction step B) on its substrate (HexP, x1)
corresponds to a positive elasticity εB1. In Fig. 1, grey dashed lines account
for the regulatory circuits—i.e. product (G6P, x1) inhibition ofHK (reaction
step A) [38], inhibition of phosphofructokinase (PFK, reaction step C) by
Cit (x10) [39] and activation of PK (reaction step K) by F16BP (x3) [40,41],
whichareassociatedwithnegative (εA1), negative (εC10) andpositive (εK3)Fig. 3. Comparison of measured concentrations. Values for concentrations are
proportional to the bar height for each chemical specie and error bars correspond to
standard deviations. See legend of Fig. 2 for meaning of colours and triangles. As a
reference for sugar phosphate concentrations, [F16BP]=3.229 nmolmg prot−1, [HexP]=
1.799 nmol mg prot−1, [PenP]=0.726 nmolmg prot−1, [TrisP]=2.710 nmolmg prot−1 and
[PEP]=0.457 nmolmg prot−1 for non-transformed NIH-3T3 cells. P-values using two-tailed
Student's t-test: *: pb0.1, **: pb0.05; ***: pb0.01.elasticities, respectively. Reversibility is associated with negative elastic-
ities with respect to products. Finally, reaction steps D, X, Y and Z
describing the demand of synthetic processes were assumed to be
saturated with respect to their respective substrates and then controlled
by thedemand; so, theelasticities εD2, εX8, εY10, and εZ13were set tobezero.
The sign of each control coefﬁcient was analyzed by checking the
positivity or negativity of the determinant |M| and the adjoint
matrices in Adj(M) used for the derivation of the inverse:
M−1 =
1
Mj j Adj Mð Þð Þ
T ð6Þ
Since the determinant |M| was positive, the sign depended on the
adjointmatrices. ThematrixM−1 in Fig. 4b shows all control coefﬁcients
for independent ﬂuxes and concentrations derived from this analysis.
Control coefﬁcients for the dependent ﬂuxes can be derived by
considering the dependences among ﬂuxes in Eq. (4) and the control
coefﬁcients of independent ﬂuxes [9,10], as demonstrated in the
example provided in Fig. 4c. A subset of control coefﬁcients signs are
presented in Fig. 4d in a table of dependences between the ﬂuxes and
concentrations and the main enzyme activities. Positive and negative
symbols correspond to control coefﬁcients with positive and negative
signs, respectively. The signs in Fig. 4d collectively give a complete
systemic predictive tool which can be used to evaluate the expected
impact of changes in enzyme activities. Thus, the speciﬁc pattern of
observed changes in ﬂuxes and concentrations can be associated with
increases or decreases of enzyme activities through analysis of the signs
of control coefﬁcients. For example, the observed decrease in the
concentration of PEP (x7) could correspond to an increase of PK activity
(vK), but never due to a decrease.
3.2.2. The magnitude of the control coefﬁcients
The analysis of the signs of metabolic control coefﬁcients is
sufﬁcient if the aim is to predict the direction of changes in
concentrations and ﬂuxes. However, this previous analysis does not
sufﬁce if the objectives are to predict the magnitudes of these
changes, and then the magnitude of the control coefﬁcients is
required. Unknown elasticities can be randomly sampled in order
to derive feasible magnitudes for control coefﬁcients [42]. We have
applied sampling procedures based on those described by Wang et
al. [42] in order to have an additional independent evaluation of
the sign and mean magnitude of the control coefﬁcients (results
exactly match the computed signs). This analysis identiﬁed a
subset of control coefﬁcients which are always associated with
small magnitudes. In the system considered (Fig. 1) the PPP is a
sub-network characterized by a ﬂux which is much smaller than
the main ﬂuxes through the rest of the network ( JB⋘ JC). The
effect of changes in the activity throughout this sub-network will
have minimal effect on the rest of the system, but these changes
can have a signiﬁcant effect on the concentrations and reaction
steps inside the sub-network. The dependence of control coefﬁ-
cients on particular ﬂuxes, such as JB, can be easily identiﬁed by
inspecting the adjoint matrices. Control coefﬁcients identiﬁed with
black circles in Fig. 4d are directly proportional to the value of JB,
which implies very small magnitudes due to the small ﬂux through
the oxidative branch of the PPP.
3.3. Testing and validation of hypotheses based on variations in enzyme
activities
3.3.1. Speciﬁc activities
The speciﬁc activities of HK (vA), G6PD (vB), TKT (vG, vH), PK (vK), and
LDH(vT)weremeasured fornon-transformedandtransformed(K12and
K13) cells and compared in Fig. 5a. Increases or decreases in speciﬁc
activities observed during the metabolic adaptation associated with the
K-ras transformation were analysed. Clear changes were observed for
Fig. 4.Matrix estimation of the sign of control coefﬁcients. For details about themethod see [9,10]. Elasticities with a magnitude of zero appear as 0, while those positives are represented
with a letter α (αki=εkiN0), and those negatives with a letter β (βki=εkib0); control coefﬁcients with a magnitude of zero appear as 0, while these positives are represented with the
letterA (Aki=CkiN0) or a symbol "+", and these negativeswith the letter B (Bki=Ckib0) or a symbol "−"; Those control coefﬁcients with indeterminate signs are representedwith a letter
G (Gki=CkiN0 or Ckib0) or a symbol "±". A matrix M (a) with the information containing both the stoichiometry and the regulatory properties of the analysed system (elasticities and
ratios among ﬂuxes), is inverted to obtain the matrix of control coefﬁcientsM−1 (b) for independent ﬂuxes and concentrations. (c) An example of estimation of a control coefﬁcient of
dependent ﬂuxes from the previously estimated control coefﬁcients of independent ﬂuxes. (d) Table of dependences connecting changes in ﬂuxes and concentrations with changes in
enzyme activities for a subset of analyzed control coefﬁcients. Superscripts "f" and "b" refers to net direction of reversible reactions of the non-oxidative branch of PPP (G,H,I) following the
forward or the backward directions, respectively. The net ﬂuxes for the remaining reversible reactions are set to follow only the forward direction according to Fig. 2. Symbols
("+","−","±") identiﬁed with a black circle refer to control coefﬁcients of very low magnitude in comparison with the other ones (see Section 3.2.2).
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changesalsoforTKTwithbothK12andK13transformedcellsandalsofor
PKwith K13 transformed cells. There were no signiﬁcant changes in the
observed HK activities.3.3.2. Do changes in measured activities satisfy the predictions for
concentrations and ﬂuxes?
The table of dependences in Fig. 5b identiﬁes both satisﬁed and
non-satisﬁed predictions of the sign of control coefﬁcients for those
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predictions, which are those where the direction of the changes in a
concentration or ﬂux is explained by the direction of the change in an
enzyme activity, are marked in green. Otherwise, if the prediction is
not satisﬁed, the sign of the control coefﬁcients is marked in red. For
example, the increase in LDH activity (vT) could help to explain the
measured increase in JA, but not the increase in JB, which is satisﬁed by
the increased G6PD activity (vB). Predictions regarding TKT are more
complicated because the slight decrease of TKT activity could
contribute to a predicted decrease of PenP levels (x2), but only if the
net ﬂux through the non-oxidative branch of PPP is following the
backward direction to PenP as is shown in Fig. 5b.
Indeterminate signs (±) identify control coefﬁcients that can be
positive or negative, depending on the relative values of the
elasticities and ratios between ﬂuxes. For a set of such sign-
indeterminate control coefﬁcients, only a limited combination of
positive and negative signs is possible. Indeterminate signs (±)
marked in green were used in Fig. 5b to highlight that a speciﬁc and
feasible combination of elasticities and ﬂuxes can result in a
combination of signs which satisfy the changes in ﬂuxes andFig. 5. Speciﬁc activities and satisﬁed predictions. (a) Comparison of speciﬁc activities.
See legend of Figs. 2 and 3 formeaning of bar height, error bars, colours and triangles. As
a reference for speciﬁc activities, HK=130.17 mU mg prot−1, LDH=2.83 Umg prot−1,
G6PD=215.02 mU mg prot−1, TKT=35.72 mU mg prot−1 and PK=6.98 Umg prot−1
for non-transformed NIH-3T3 cells. P-values using two-tailed Student's t-test: *: pb0.1,
**: pb0.05; ***: pb0.01. (b) Satisﬁed predictions represented in the table of
dependences connecting changes in ﬂuxes and concentrations with changes in enzyme
activities. See legend of Fig. 4 for meaning of superscripts "f" and "b", and positive-
negative symbols ("+","−","±"). Symbols marked in green or red refers to control
coefﬁcients that can explain or cannot explain, respectively, the observed directions of a
change in a ﬂux or a concentration with respect to the direction of ameasured change in
an enzyme activity (see Section 3.3.2).concentrations. For example, the measured decreases in x2, x4, and
x7 can be predicted by an increase in vT activity, which is possible
because the negative control coefﬁcients for C2T, C4T, and C7T can be
obtained by selecting the appropriate elasticities.4. Discussion
The existence of control coefﬁcients with ﬁxed or indeterminate
signs is dependent on the topology of the metabolic pathway and
location of regulatory loops (feedback, feed-forward), branches, etc.
[13]. The signs of the control coefﬁcients estimated above (Fig. 4)
were obtained by assuming a model adapted to the available data,
where the relevant topology and regulation are considered. Analysis
of the signs of control coefﬁcients in Fig. 5b provides a complete
picture of the potential effect that any change in enzyme activities
would have on systemic properties such as ﬂuxes and metabolite
concentrations. This picture conﬁrms that the increased ﬂuxes from
glucose to lactate ( JA, JC, JE, JF, JK, JT) and through the oxidative part of
the PPP (JB) (Fig. 2), and the decreased concentrations of sugar
phosphates (x1, x2, x3, x4, x7) (Fig. 3), observed in transformed cells,
can be explained in part by the increased speciﬁc activities for G6PD
(vB), PK (vK), LDH (vT), and decreased activity of TKT (vG,vH) (Fig. 5a).
Interestingly, the differences between the phenotypes of K12 and K13
tranformed cells [22–24] are reﬂected by the magnitude of the
changes in ﬂuxes and not by the sign of these changes. Changes in
enzyme activities are also in the same direction (with the same sign of
change) for both transformed cells with the exception of PK activity
which is only increased signiﬁcantly in the K13 cell line.
The measured changes in speciﬁc enzyme activities accounts for
changes in the enzyme concentrations. It should be noted that in vivo,
changes affecting an enzyme activity can be as a result of the changes
on its expression but also due to a variety of events including: changes
in cofactors, post-transductional modiﬁcation or changes in oligo-
merization state among others. One example of this is the case of PK.
Among the different PK isoforms, the M2-PK isoenzyme is expressed
in all proliferating cells, including embryonic, tumour and NIH-3T3
cells [41]. The M2-PK isoenzyme occurs in a highly active tetrameric
form and in a dimeric formwith low afﬁnity for PEP [40]. The tetramer
to dimer ratio of M2-PK is not static and depends on F16BP levels in
addition to any effects due to other external mechanisms [40].
The measured changes of the speciﬁc activities for G6PD (vB), PK
(vK), and LDH (vT) satisfy the predictions based on the sign of the
control coefﬁcients. Interestingly, Fig. 5b shows that the set of
observed changes in ﬂuxes and concentrations accompanying K12-
and K13-transformation cannot be attributed to the perturbation of a
single enzyme activity. According to results depicted in Fig. 5b,
simultaneous activation of G6PD and some of the glycolytic enzymes
is required in order to fully explain the observed pattern of changes in
ﬂuxes and metabolite concentrations. The experimentally measured
increase in G6PD and in some glycolytic enzymes (LDH (vT) and PK
(vK)) conﬁrms this prediction and helps to explain qualitatively
almost all observed increases in ﬂuxes and decreases in concentra-
tions, although it is likely that other glycolytic enzyme activities could
also be increased. The predictions of Fig. 5b are also in agreement with
the available literature on tumour metabolism that suggests the
action of transcription factors, as c-myc and the hypoxia-inducible
transcription factor 1 (HIF-1), which are associated with the
activation of oncogenes including transforming ras. This leads to the
reprogramming of different components of the cell metabolism,
including higher expression for most of the genes encoding
glycolytic enzymes [38,43–48]. Among the enhanced enzymes are
mammalian isoforms of HK (HK1 and 2), PK (M2-PK) and LDH
(LDH-A). We have also observed changes in LDH for both K12 and
K13 cells in addition to changes in PK for K13 cells. However, HK
activity is not signiﬁcantly altered by either of the two transformed cell
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the same K12- and K13-transformed NIH-3T3 cells used in the present
study, they showed an increased expression of GAPDH for both
transformed cell lineswith respect to the non-transformed ones. From
Fig. 5b we can predict that this increase of GAPDH (vF) can also
contribute to the observed metabolic phenotype of transformed cells.
Taking into account that control is distributed among the enzymes
of glycolysis, it is not surprising that simultaneously increasing a
number of different glycolytic enzymes is required in order to achieve
a large increase in glycolytic ﬂux. Thus, in a linear pathway, all the
control coefﬁcients are positive and their sum is equal to one [3],
which means that, if the control is shared between several enzymes,
then the magnitude of each individual control coefﬁcient is expected
to be quite low. A very low control coefﬁcient indicates that in order to
alter the ﬂux signiﬁcantly by using modiﬁcations of a single enzyme, a
very large change in the enzyme concentration is required. However,
a simultaneously balanced change in all glycolytic enzyme concentra-
tions should result in both a directly proportional change in the
glycolytic ﬂux and also the absence of change in intermediate
metabolites [49]. The observed slight decrease in all measured
metabolites could be the consequence of increased external demands.
However, it is also interesting to notice that according to Fig. 5b
the observed increase in the ﬂux through the oxidative part of PPP is
not predicted by an increase in measured glycolytic activities, but is
clearly satisﬁed by an increase in G6PD activity. Comparing K12 and
K13 cells, there is a perfect agreement between the higher G6PD
activity and the higher ﬂux through the oxidative part of the PPP.
Regulation of the expression of G6PD is altered in many tumours,
resulting in a signiﬁcant increase in G6PD activity, and it has been
suggested that G6PD may act as a potential oncogene [50]. Increased
G6PD activity in NIH-3T3 cells, transfected with human G6PD cDNA,
leads to tumorogenic transformations, dividing more quickly and
inducing tumors in nude mice [50]. The decreased levels of PenP (x2)
are not compatible with the increased activity of G6PD, but are
compatible with an increased demand of ribose (reaction step D).
Also, the decreased levels of PenP can be at least in part a
consequence of the slight decrease in the TKT activity. The two key
enzymes of the PPP, G6PD and TKT, were both previously identiﬁed
as potential targets in cancer therapy [51–54], and recently, the
increased G6PD/TKT ratio was proposed as a tumour metabolome
feature [55]. The observed notorious increase of G6PD resulted in a
higher G6PD/TKT ratio in both transformed cell lines with respect to
non-transformed cells in agreement with the results of Montoya et
al. [55]. Here, we have also found that this ratio is higher in K13 than
in K12.
Finally, it is interesting to note the fact that metabolic adaptations
observed in transformed cells require changes in more than one
enzyme, which suggests that a multi-hit strategywould be required to
counteract metabolic adaptations in transformed cells. These results
support the suggestions of Moreno-Sanchez et al. [56] who proposed
that a "multi-targeted MCA advised therapy" would be required to
design efﬁcient treatments in cancer based on the fact that control is
shared among several steps in metabolic networks.
5. Conclusion
An interesting advantage of control coefﬁcients with ﬁxed signs is
that they confer robustness to the system [14]. Consistently,
predictions based on ﬁxed signs of control coefﬁcients are also very
robust. The structure of the metabolic network and the regulatory
dependences affecting most of the metabolic processes, speciﬁcally
those associated with the carbon metabolism, are available and
sufﬁcient to predict the sign ofmetabolic control coefﬁcients.We have
proposed and veriﬁed the use of ﬁxed signs of metabolic control
coefﬁcients as a useful tool to evaluate the key enzyme activities
underlying metabolic adaptations associated with K-ras oncogenictransformation in NIH-3T3 cells. The predicted changes of G6PD, TKT,
PK, and LDH activities give very good agreement with the observed
pattern of changes in ﬂuxes and concentrations. Thus, with a limited
knowledge of themetabolic network structure and regulatory circuits,
the proposed analysis arises as a tool which can provide a complete
picture of predictable effects based on systemic properties—changes
in ﬂuxes and metabolite concentrations—with respect to changes in
enzyme activities.
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Abstract
Metabolite concentrations and ﬂuxes are the system variables that characterize metabolism. The systematic
study of metabolite proﬁles is known as metabolomics; however, knowledge of the complete set of
metabolites may not be enough to predict distinct phenotypes. A complete understanding of metabolic
processes requires detailed knowledge of enzyme-controlled intracellular ﬂuxes. These can be estimated
through quantitative measurements of metabolites at different times or by analysing the stable isotope
patterns obtained after incubation with labelled substrates. We have identiﬁed distinct intracellular ﬂuxes
associated with metabolic adaptations accompanying cancer. The maintenance of an imbalance between
ﬂuxes for the oxidative and non-oxidative PPP (pentose phosphate pathway) has been shown to be critical
for angiogenesis and cancer cell survival. Mouse NIH 3T3 cells transformed by different mutated K-ras
oncogenes have differential routing of glucose to anaerobic glycolysis, the PPP and the Krebs cycle. These
results indicate that knowledge of metabolic ﬁngerprints associated with an altered genetic proﬁle could be
exploited in the rational design of new therapies. We conclude that the understanding of the multifactorial
nature of metabolic adaptations in cancer may open new ways to develop novel multi-hit antitumoral
therapies.
The systematic study of the metabolism
Current high-throughput technologies are applied to examine
the whole components of a cell. However, understanding the
crucial cellular events such as differentiation, cell-cycle
progression or apoptosis requires detailed knowledge not
only of the components, but also of how they interact in
systems [1]. Moreover, high-throughput technologies cannot
be designed for the analysis of all cellular components. In
the case of the genome, the physicochemical homogeneity
of its components has facilitated its analysis, resulting in the
spectacular advance of genomics. This homogeneity contrasts
with the high heterogeneity that characterizes metabolism.
The systematic study of the metabolic compounds is known
as metabolomics, where the metabolome is defined as
the set of all low-molecular-mass compounds present in
a biological system [2]. The large number of different
metabolites, differences in their relative concentrations and
variability in their physicochemical properties (polarity,
hydrophobicity,molecularmass or chemical stability) require
the application of different technologies and a huge range
of experimental conditions. Thus specific methodologies are
Key words: antitumoral therapy, cancer, ﬂux analysis, metabolomics, systems biology, tumour
metabolism.
Abbreviations used: G6PDH, glucose-6-phosphate dehydrogenase; HIF-1, hypoxia-inducible
transcription factor-1; LDH, lactacte dehydrogenase; PDH, pyruvate dehydrogenase; PK, pyruvate
kinase; PPP, pentose phosphate pathway; ROS, reactive oxygen species; TKT, transketolase;
TKTL1, TKT-like-1.
1To whom correspondence should be addressed (email martacascante@ub.edu).
2Present address: Laboratory of Developmental Signalling, Cancer Research UK London Research
Institute, London WC2A 3PX, U.K.
being developed for the various groups ofmetabolites, such as
lipids (lipidomics) or sugars (glycomics). Interestingly, such
methods could be applied to the study of the metabolome
and its importance in the development and progression of
tumours [3].
Differential ﬂux distribution
Metabolite concentrations and fluxes are the interdependent
system variables that characterize metabolism. A com-
prehensive characterization of metabolic operation can be
obtained from quantitative knowledge of intracellular fluxes,
which are intimately associated with the corresponding
enzyme activities. Moreover, the metabolic profile of a
specific cell represents the integrated end point of many
growth-signalling events, and it consists of the simultan-
eous assessment of fluxes in major metabolic pathways
under various physiological conditions, growth phases and
substrate environments [4]. Quantitative measurements of
metabolites at different times are applied for themeasurement
of metabolic fluxes. In particular, tracer-based metabolomics
is a useful approach for the analysis of the propagation
of labelled molecules to metabolic products by NMR or
chromatography coupled to MS [GC–MS and LC (liquid
chromatography)–MS]. Thus the analysis of the stable
isotope patterns obtained after incubation with labelled
substrates is applied for the measurement of the fluxes
throughout the steps of the metabolic pathways. For
example, labelling with [1,2–13C2]glucose and the subsequent
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analyses of its propagation to ribose (RNA), lactate and
glutamate has been widely used to simultaneously determine
carbon flow towards the PPP (pentose phosphate pathway),
glycolysis, direct glucose oxidation, tricarboxylic acid cycle
and fatty acid synthesis [4–7]. The use of these analytical
methods has demonstrated that there are specific metabolic
adaptations in response to cell-transforming agents or cancer-
growth-controlling factors [8,9]. In recent years, several
computational tools have been developed for the quantitative
estimationof fluxes inmetabolic networks from isotopomeric
distributions (see [10,11] and references therein).
Tumour metabolism and the design of new
antitumoral strategies
The first energy metabolism alteration described in cancer
cells was the increase in the conversion of glucose into
lactate even in the presence of oxygen [12]. The energetic
inefficiency of this process, compared with mitochondrial
respiration, increases glucose consumption in tumour cells, a
difference that has been exploited in the clinical detection
of neoplasies by PET (positron emission tomography)
imaging [13]. The molecular mechanism underlying this
high glycolytic capacity has been extensively analysed and
some of the key factors have been identified [14–21].
Since many solid tumours provoke hypoxic conditions,
the transcription factor HIF-1 (hypoxia-inducible factor-1)
has emerged as a key player in this process. Thus HIF-
1, which is modulated by oncogenes such as Ras or Her-
2, increases the expression of several glycolytic enzymes
[22–24]. Other molecular mechanisms have been proposed
to link tumour progression and glycolytic phenotype, e.g.
the oncogenic transcription factor Myc has been related
to the expression of several glycolytic enzymes such as
LDH (lactate dehydrogenase) [25]. The regulation of glucose
metabolism has also been reported to be mediated by the
PI3K (phosphoinositide 3-kinase)/Akt/mTOR (mammalian
target of rapamycin) pathway [20,26], which is commonly
activated in tumour cells. Taken together, these observations
reveal that distinct molecular mechanisms cause alterations
in the tumour metabolic network. Great efforts to elucidate
these mechanisms are expected to be made in the near future.
There is evidence that the up-regulationof genes expressing
glycolytic enzymes is associated with the metabolic repro-
gramming of tumour cells, but the role of mitochondria
is less clear. A reduction in the mitochondrial content and
differences in its activity has been reported in tumours [26].
Certainly, mitochondrial metabolism is closely related to
tumour progression, not only at the energetic level, but also
through the generation of ROS (reactive oxygen species).
The role of ROS in tumour progression is controversial.
On the one hand, mitochondrial malfunction and subsequent
production of ROS have been reported in cancer cells [27].
This increase in ROS production could increase the rate of
mutagenesis, thus exacerbating malignancy [27,28]. On the
other hand, the generation of ROS has been proposed for
treatment of cancer [29], following the observation that the
generation of oxidative stress leads to apoptosis [30].
Proliferating cells strongly rely on the availability of
glycolytic intermediates as precursors of a large number of
essential biomolecules. In this way, several anabolic routes
are also regulated differentially in tumour cells, for example
lipid synthesis [31]. Another example is the synthesis through
the PPP of the sugar component of nucleic acids: ribose 5-
phosphate.Nucleotide reservoirs are not sufficient to support
cell duplication and, therefore, biosynthetic pathways are up-
regulated during the cell cycle. Previously, we have shown
that the PPP is enhanced in several tumour-derived cell lines
[32,33], and we have identified the two key enzymes of this
pathway,G6PDH (glucose-6-phosphate dehydrogenase) and
TKT (transketolase), as potential targets in cancer therapy
[34–38]. These two enzymes belong to the oxidative and non-
oxidative branches respectively, of the PPP (see Figure 1). We
hypothesized that the balance between oxidative and non-
oxidative branches is a requirement tomaintain the metabolic
efficiency of cancer cells for growth and proliferation. We
validated this hypothesis by showing that the perturbation
of this balance using a multiple-hit drug strategy results
in metabolic inefficiency and cell death [38]. Recently, we
have correlated enhanced enzyme activities of G6PDH
and TKT with an increased pentose monophosphate/hexose
monophosphate ratio in late G1- and S-phases of cell cycle,
suggesting a regulation of these key enzymes during cell-
cycle progression [39]. This distinctive modulation of these
enzymesmay represent a new strategy to inhibit proliferation
in anticancer treatments. Moreover, we have shown that
growth factor induction of endothelial cells (a common step
during angiogenesis) can be reduced by direct inhibition of
key enzymes of glycogen metabolism and PPPs [9].
An additional feature of tumour metabolism is the
differential expression of isoenzymes, which have been
postulated as interesting targets for cancer treatment. The
glycolytic isoenzyme M2-PK (pyruvate kinase) is one of the
most interesting examples. This isoenzyme can shift between
a dimeric and a tetrameric form, depending on the energetic or
biosynthetic requirements of the cells [40,41]. Likewise, Coy
et al. [42] have described a new isoenzyme of TKT called
TKTL-1 (TKT-like-1). The mRNA levels of this isoenzyme
are overexpressed in urothelial, ovarian, colon and gastric
cancers [43–45]. It has been suggested that TKTL-1 could
have distinct kinetic properties and that its overexpression
could raise the concentration of G3P (glyceraldehyde 3-
phosphate) available for glycolysis, thus contributing to the
Warburg effect [42,44].
Most of the research on tumour cell metabolism has
focused on glucose utilization, and consistent evidence
supports the finding that cancer cells have enhanced glucose
consumption.However, an important controversy surrounds
the dependence of cancer cells on anaerobic glycolysis.
On the one hand, when glucose is no longer available, as
is expected in solid tumours, tumour cells are forced to
catabolize alternative substrates such as glutamine.Glutamine
catabolism represents a valuable energy source and provides
C©The Authors Journal compilation C©2010 Biochemical Society
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Figure 1 Schematic representation of the central carbon metabolism
The potential antitumoral targets of the PPP are marked in red. A hypothetical distinct reaction mode of action
proposed for TKTL1 is shown with a broken line. Abbreviations: HK, hexokinase; PGI, phosphoglucose isomerase;
PFK1, phosphofructokinase 1; F1,6Bpase, fructose-1,6-bisphosphatase; ALD, aldolase; GAPDH, glyceraldehyde-3-phosphate
dehydrogenase; TPI, triose-phosphate isomerase; PC, pyruvate carboxylase; CS, citrate synthase, AC, aconitase; IDH, isocitrate
dehydrogenase; α-KGDH, α-ketoglutarate dehydrogenase; SCS, succinyl-CoA synthetase; SDH, succinate dehydrogenase;
FH, fumarate hydratase; MDH, malate dehydrogenase; GDH, glutamate dehydrogenase; GS, glutaminase; GLS, glutamine
synthase; LAC, lactonase; 6-PGDH, 6-phosphogluconate dehydrogenase; TALD, transaldolase; P, phosphate.
cells with glutamate and aspartate, which are precursors of
nucleic acid and serine synthesis. Enhanced glutaminolysis
has been associated with neoplastic transformation and
its inhibition has been shown to decrease tumour cell
proliferation and to correlate with the phenotypic and
functional differentiation of these cells [46,47]. On the
other hand, it is unclear whether there is a unique suitable
phenotype for energetic metabolism in cancer cells [48]. Our
results showed that different codon-specific mutations in K-
ras lead to differentmetabolic phenotypes inNIH3T3mouse
fibroblasts [8]. Significant changes in fluxes were observed,
taking advantage of [1,2–13C2]glucose tracer labelling, when
non-transfected NIH 3T3 cells were stably transfected with
a mutated K-ras minigene, either at codon 12 (K12) or at
codon 13 (K13). These differences support the evidence that
the re-routing of glucose carbons towards either anaerobic
glycolysis (K12) or PDH (pyruvate dehydrogenase) and the
oxidative branch of the PPP (K13) is associated with distinct
strategies of proliferation: higher resistance to apoptosis
(K12) compared with enhanced mitotic capacity (K13).
The fact that cancer cells have distinctivemetabolic profiles
compared with normal counterparts offers the exciting
possibility of designing new complementary strategies based
on the specific reversal of these metabolic adaptations.
Moreover, the overexpression of specific isoenzymes in
cancer cells is an emerging opportunity to develop novel
therapies. It is expected that this specific inhibition will
result in the disruption of the necessary metabolic adaptation
of cancer cells without affecting the metabolism of non-
tumoral cells. In this way, tools such as metabolic control
analysis provide the opportunity to systematically analyse
the distribution of flux control among the different enzymes
of the metabolic network [49,50] and permit researchers to
identify those enzymes whose inhibition or overexpression
will affect tumour tissue more than normal tissues. These
enzymes and tumour-overexpressed isoenzymes are potential
C©The Authors Journal compilation C©2010 Biochemical Society
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targets for chemotherapy, since their inhibition is expected to
have a strong effect on tumour cell metabolism.
In summary, a better comprehension of metabolic
adaptations underlying hypoxia, oncogene transformation,
cell differentiation, apoptosis and cell-cycle progression can
reveal clues to identify complementary targets in the design
of rational combinational treatments in chemotherapy. Thus
a better understanding of tumour metabolism may open new
avenues in drug discovery aswell as the possibility to combine
drugs that inhibit well-established antitumoral targets, such
as proteins controlling cell-cycle progression, with specific
inhibitors of cancer cell metabolic adaptations.
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